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Patients with long-term oestrogen-deprived (LTED) breast cancer (BC), after resistance to 
tamoxifen or aromatase inhibitors develops, can experience tumour regression when treated 
with oestrogens. Oestrogen’s anti-tumour effect is attributed to apoptosis via the oestrogen 
receptor (ER). Oestrogen treatment can have unpleasant gynecological, as well as non-
gynecological adverse events, and thus the development of safer oestrogenic agents remains a 
clinical priority. Here, we study synthetic selective oestrogen mimics (SEMs) BMI-135 and 
TTC-352, and the naturally-occurring oestrogen oestetrol (E4), which are proposed as safer 
oestrogenic agents compared to 17β-oestradiol (E2), for the treatment of endocrine-resistant 
BC. TTC-352 and E4 are being evaluated in advanced BC clinical trials. Cell viability assays, 
real-time polymerase chain reaction, luciferase reporter assays, chromatin 
immunoprecipitation, immunoblotting, ERE DNA pull downs, mass spectrometry, X-ray 
crystallography, docking and molecular dynamics simulations, live cell microscopic imaging 
and analysis, and annexin V staining, were conducted in 11 biologically-different patient-
derived BC models and a human endometrial cancer model. Results were compared with the 
potent full agonist E2, less potent full agonists oestrone and oestriol, the benchmark partial 
agonist triphenylethylene bisphenol (BPTPE), antagonists or Selective ER modulators 4-
hydroxytamoxifen, endoxifen, and raloxifene, and Selective ER Downregulator fulvestrant. 
This work reports ERα’s regulation and coregulators’ binding profiles with SEMs and E4. It 
also describes SEMs and E4’s pharmacology as weak full agonists, and anti-tumour 
molecular mechanisms through the unfolded protein response (UPR) and apoptosis. These 
studies highlight the phenolic OH of TTC-352’s benzothiophene scaffold and E4’s A ring that 
yield an H-bond with Glu353, which allows Asp351-to-helix 12 (H12) interaction; sealing 
ERα’s ligand binding domain (LBD), recruiting E2-enriched coactivators, and triggering 
rapid ERα-induced UPR and apoptosis, as the basis of its anti-cancer properties. By contrast, 
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BPTPE’s phenolic OH yields an H-Bond with Thr347, which disrupts Asp351-to-H12 
interaction; not sealing ERα’s LBD properly, not recruiting many E2-enriched coactivators, 
and triggering delayed ERα-induced UPR and apoptosis. Such delay might increase the risk 
of metastasis, clonal evolution, and acquired resistance. Overall, this work concludes the 
structural, pharmacological, and mechanistic constituents of an effective oestrogen for the 
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I. Introduction  
IA. Historical background    
In 1944, Scottish pathologist Sir Alexander Haddow used high-dose synthetic 
oestrogen (diethylstilbestrol (DES) and triphenylchloroethylene) therapy to treat metastatic 
breast cancer (BC) (MBC) (Haddow et al., 1944). Women can achieve oestrogen deprivation 
either naturally after menopause (average age of menopause in the U.S. and UK is 51 years 
old), or through long-term adjuvant endocrine therapy with tamoxifen (TAM) or aromatase 
inhibitors (AIs). Tamoxifen blocks oestrogen action at the level of the breast oestrogen 
receptor (ER), whereas, AIs inhibit oestrogen synthesis at the level of the breast aromatase 
enzyme system (Jordan and Brodie, 2007). In Haddow’s study, women were long-term 
oestrogen-deprived (LTED) (≥5 years past menopause), and had a 30% response rate on 
receipt of the treatment (Haddow, 1970).    
  High-dose oestrogen therapy was, subsequently, used for 30 years prior to the 
successful introduction of TAM (Jordan, 2003) (Figure. 1). Tamoxifen was used rather than 
oestrogen therapy because of the lower incidence of adverse events (AEs) such as those 
gynecological (i.e., vaginal bleeding and endometrial hypertrophy) and non-gynecological 
(i.e., hot flashes and thromboembolism-related) (Cole et al., 1971, Ingle et al., 1981). In the 
1970s, adjuvant endocrine therapy was successfully advanced with the proposal of long over 
short-term adjuvant TAM therapy (Jordan and Allen, 1980, Jordan et al., 1979) (Figure. 1). 
This translational research strategy helped establish TAM as the agent of choice for adjuvant 
anti-hormone therapy (Early Breast Cancer Trialists’ Collaborative Group, 1998).  
Beforehand in 1941, Canadian-American physiologist and Nobel Laureate Charles 
Huggins, and American physician Clarence Hodges, used androgen therapy to treat 
metastatic prostate cancer (PC) (Huggins and Hodges, 1941). Men were androgen-deprived 
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either through surgical castration (bilateral orchiectomy), or medical castration with high-
dose synthetic oestrogen therapy (DES) that suppresses testosterone levels to the castrate 
range (Huggins and Hodges, 1972, Huggins and Hodges, 1941). A 50% response rate has 
been reported on receipt of the treatment (Schweizer et al., 2015, Huggins and Hodges, 1972, 
Huggins and Hodges, 1941). Huggins and Hodges’s work marked the first successful 
chemical therapy, and awarded Huggins his Nobel Prize for Physiology or Medicine in 1966. 
Huggins, Hodges, and Haddow’s work marked the first successful use of hormones to treat 
cancer.        
Androgen therapy was, subsequently, used for 45 years until the successful 
introduction of the first luteinizing hormone (LH) releasing hormone (LHRH) analogue, 
leuprolide, in the 1980s (Garnick, 1984). Leuprolide was used rather than androgen therapy 
because of the lower incidence of AEs such as gynecomastia and serious cardiovascular-
related AEs (Cox and Crawford, 1995, Blackard et al., 1970). Other successful treatment 
modalities followed such as: anti-androgens (e.g., bicalutamide) that block androgen action at 
the level of the testes androgen receptor (AR) (Chen et al., 2009), and inhibitors of the testes 
CYP17 enzymes (e.g., abiraterone acetate) that block androgen synthesis (Reid et al., 2008) 




Figure 1 | Schematic representation of the treatment paradigms used clinically for breast and 
prostate cancers. (Panel above) early-stage prostate cancer (PC) is usually approached with active 
surveillance, and local treatments such as: surgery and radiation therapy. Hormone therapy can be 
given for early-stage PC men at high-risk, or if they cannot undergo surgery or radiation therapy. The 
newer treatments for early-stage PC are: Intensity-Modulated Radiation Therapy, Proton beam 
therapy, and Cryosurgery. If early-stage PC progresses to metastatic PC (MPC), or what is known as 
castration-sensitive PC (CSPC), it will be treated with androgen deprivation therapy (ADT); using 
GnRH agonists, or complete androgen blockade (CAB) with a GnRH agonist plus flutamide as one 
example, or secondary hormone therapy (SHT) using abiraterone, or enzalutamide as an another 
example. If CSPC progresses to castration-resistant PC (CRPC), it will be treated with ADT or SHT. 
About 60% of PC is diagnosed in men >65, with 97% in men age >=50. The median age at the time of 
diagnosis in the U.S. is about 66. (Below panel) early-stage BC can be treated with local treatments 
such as: surgery and radiotherapy, or systemic treatments such as: hormone therapy. What sets early-
stage BC treatment apart from prostate cancer treatment is adjuvant therapy with tamoxifen or AIs for 
5–10 years. If early-stage BC progresses to metastatic BC (MBC), one therapeutic option is 
fulvestrant. Breast cancer rates increase after age 40 and are highest in women >70. The median age 
of diagnosis of BC for women in the U.S. is 62. 
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IB. Breast and prostate cancer epidemiology     
Breast cancer is the most common cancer in women, and the second leading cause of 
cancer death in females, in the United States and United Kingdom (Siegel et al., 2020, Cancer 
Research UK, 2014) (Figure. 2). In 2014 in Great Britain, 31 women died every day from BC 
(Cancer Research UK, 2014). In 2012 in Europe, more than 131,000 women died from BC 
(Cancer Research UK, 2014). England ranks 14th in Europe in regards to the highest BC 
related-mortality rates (Cancer Research UK, 2014). Whereas, by 2019 in the United States, 
an estimate of 41,760 women were expected to die from BC (2019b). Rosenberg and 
colleagues projected BC cases to double between 2011 and 2030 in the United States 
(Rosenberg et al., 2015). In this projection, the majority of BC cases will be ER-positive 
(Rosenberg et al., 2015), which has a high risk of recurrence and residual relapse even with 
clinically low-risk disease (T1N0) (Schroeder et al., 2017).  
 
Figure 2 | Schematic representation of the epidemiology of breast cancer in the United States 
and United Kingdom. 
Prostate cancer is the most common solid-organ malignancy in men in the United 
States and the United Kingdom, and the second most common worldwide (Siegel et al., 2015, 
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Ferlay et al., 2015, Cancer Research UK, Siegel et al., 2020). It is also the second leading 
cause of cancer death in males in the United States and the United Kingdom (American 
Cancer Society, Cancer Research UK, Siegel et al., 2020). Between 2014-2016 in Great 
Britain, 31 men died every day from PC (Cancer Research UK). Whereas, in 2019 in the 
United States, approximately 91 men died every day from PC (2019a).   
IC. Oestrogen and androgen receptor signal transduction pathways  
The ER has two subtypes (Thomas and Gustafsson, 2011): ERα which was discovered 
in the late 1950s, and ERβ identified in 1996. ERα is a product of the gene ESR1, and ERβ is 
a product of ESR2 on a different chromosome (Thomas and Gustafsson, 2011). The ER has 
several structural and functional domains (Thomas and Gustafsson, 2011) (Figure. 3): the 
amino-terminal A/B region contains a transactivation domain (AF-1), which is pivotal to the 
transcriptional activity of ERα through a ligand-independent function, and a co-regulatory 
domain responsible for co-activators and co-repressors recruitment. ERβ is truncated and 
lacks AF-1. The C region represents the DNA-binding domain (DBD), which is the most 
conserved region among ERα and ERβ. This region is crucial for binding to specific 
oestrogen response elements (EREs) in the proximal promoter region or at distal regulatory 
elements of ERE. The D region (or the hinge region) is part of the ligand-dependent 
activating domain and the nuclear localization signal. The regions E and F, contain the 
ligand-binding domain (LBD), a coregulatory binding surface, the dimerization domain, 
second nuclear localization signal, and activation function 2 (AF-2).   
Both AF-1 and AF-2 act together at the promoter region for a full oestrogen-like 
activity in ERα, but ERβ does not have an active AF-1 site (Figure. 3). As there is no AF-1 in 
ERβ, heterodimerization of ERα and ERβ causes anti-oestrogenic effects. The amino acids 
Leu384 and Met421 in the LBD regions of ERα are replaced by Met336 and Ile373 in ERβ, 
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respectively. This similarity in the LBD of ERα and ERβ created problems for targeting 
ligands to a specific ER. Human ERα and ERβ isoforms are expressed differently in 
malignant tissues, which impacts cancer biology, and exerts opposite effects on cellular 
proliferation and apoptosis. Isoform ERα- 36 (Wang and Yin, 2015) (Figure. 3), also known 
as the “dwarf or truncated ER”, lacks both trans-activation domains. ERα- 36 maintains a 
“nongenomic” signaling pathway through mitogen-activated protein kinase, and is resistant to 
TAM treatment. 
 
Figure 3 | Schematic representation of structural and functional domains of the nuclear steroid 
receptor (NSR) super family, including: ERα, ERβ, ERα-36, and AR. The structural domains of 
ERα and ERβ are depicted A–F, with the amino acid numbers indicated above. The percentage amino 
acid homologies between wild-type oestrogen receptor-α (ERα) and ERβ are also shown. The 
structural domains for hAR, and hPR are depicted A–F, with the amino acid numbers indicated above. 
The diagram demonstrates the molecular weight of all receptors.  
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The expression level and stability of ER is modulated by oestrogens and anti-
oestrogens. Two regulatory mechanisms that govern the steady-state of ER messenger 
RNA (mRNA) and protein levels in BC cells were reported (Pink and Jordan, 1996) (Figure. 
4). Model I ER regulation reflects the rapid down-regulation of the steady-state of ER mRNA 
and protein levels upon oestrogen exposure, and is exemplified in MCF-7:WS8 BC cell line, 
ovarian carcinoma line (PEO4) (Langdon et al., 1993), and the mouse and rat uterus 
(Medlock et al., 1991). Model II ER regulation reflects the up-regulation of the steady-state 
level of ER mRNA, alongside the maintenance of the ER protein level upon oestrogen 
exposure, and is exemplified in T47D:A18 BC cell line (Pink and Jordan, 1996).  
 
Figure 4 | Schematic representation of Model I and Model II of ERα regulation with ligands. 
In basic terms, once the ligand binds to the ER in the cytoplasm, ER dissociates from 
heat shock proteins (HSPs), dimerizes, gets phosphorylated and relocates within nucleus 
(Thomas and Gustafsson, 2011) (Figure. 5). The ligand-ER complex then binds to a gene 
specific ERE, and recruits corresponding co-activators or co-repressors. This, in turn, initiates 
or inhibits a cascade of transcription and translation (Figure. 5).   
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ERα’s transcriptional control of diverse downstream gene expression (Feng and 
O'Malley, 2014) is dictated by its ability to properly recruit and assemble (Heery et al., 1997, 
Shiau et al., 1998a, Brzozowski et al., 1997) primary steroid receptor coactivators (e.g., p160 
family proteins like steroid receptor coactivator -3 (SRC-3); also known as nuclear receptor 
co-activator-3 [NCOA3] or A1B1), followed by secondary coactivators (e.g., histone 
acetyltransferases like p300/E1A binding protein p300 [EP300]), in what’s known as minimal 
receptor-coactivator complex (Yi et al., 2015). This facilitates chromatin remodeling and 
transcriptional activation. A model was proposed for the assembly mechanism of the 
quaternary complex (of ERE-bound ERα, SRC-3, and p300/EP300): the two ligand-bound 
ERα monomers each, independently, recruits one SRC-3 protein through the transactivation 
domain of ERα, and the two SRC-3s, subsequently, bind to different regions of one p300 
protein via multiple contacts (Yi et al., 2015).   
Resistance to endocrine therapies can be attributed to ample factors, such as: 
increased activity of downstream kinase pathways (Jordan et al., 2004), or overexpression of 
growth factor receptors (Schiff et al., 2005), or increased phosphorylation of ER, or 
mutations at the level of ER (Roodi et al., 1995).  
Androgen synthesis is finely regulated by the hypothalamic–pituitary–gonadal axis. 
Upon the stimulation of the hypothalamus, LHRH is produced. This hormone works in a 
pulsatile fashion to stimulate the release of LH by the anterior pituitary. This, in turn, induces 
the synthesis of androgen at the testicular level. Moreover, LHRH also stimulates the 
production of adrenocorticotropic hormone by the anterior pituitary, which augments overall 
androgen production, but at the adrenal gland level.   
Testosterone is metabolically converted to dihydrotestosterone by enzyme 5α 
reductase, which then binds to AR causing the dissociation of corresponding HSPs, and 
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subsequent dimerization and phosphorylation of the AR (Figure. 5). The AR has three 
distinctive functional domains: N-terminal domain, the DBD and the LBD (Wong et al., 
2014) (Figure. 5). In the nucleus, the androgen-AR complex (Edwards and Bartlett, 2005) 
binds to androgen response elements/genes including TMPRSS2:ERG and prostate-specific 
antigen. This, in turn, recruits the DNA transcriptional machinery to initiate gene 
transcription (Edwards and Bartlett, 2005). Although the AR is the essential mediator to 
regulate normal growth, it also participates in promoting the oncogenic fusion genes 
especially E-twenty-six family (Wang et al., 2009).  
 
Figure 5 | Schematic representation of the ER and AR structural and functional domains, their 
corresponding signal transduction pathways, commonly used therapeutic agents, and target 
tissues. The DBD is most conserved among ERα and ERβ with a homology of 96%. Oestrone is 
converted to androstenedione, and testosterone is converted to oestradiol through the aromatase 
enzyme system, which is inhibited by AIs. Androstenedione, in turn, is converted to oestradiol 
through 17-hydroxysteroid dehydrogenase. Tamoxifen/SERMs competitively inhibit oestrogen 
binding to the ER, while SERDs destroy the ER through the ubiquitin proteasome system. Oestrogen 
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binding to the ER initiates a cascade of events throughout the ER signal transduction pathway. 
Similarly, the binding of DHT to the AR, after it’s synthesis from testosterone by 5α-reductase, 
initiates a cascade of events throughout the AR signal transduction pathway. Finasteride inhibits 5α-
reductase, and AR antagonists competitively inhibit the binging of androgens to the AR.    
Mechanisms of maintained AR signaling in castration-resistant prostate cancer 
(CRPC) have been identified (Ryan and Tindall, 2011, Attard et al., 2011), such as: increased 
AR signaling whether it was increased AR expression or gene amplification, point mutations 
in AR LBD, expression of active AR splice variants, cross-talk with other pathways, presence 
of residual androgens, and changes in co-regulator proteins.   
A unique transcription factor termed forkhead-box A1 (FOXA1), plays a critical role 
in chromatin remodeling and decompaction (Yang and Yu, 2015). This allows the genomic 
access by the nuclear hormone receptors such as the AR and ER. The complex of FOXA1-
AR remains in equilibrium states in the nucleus, and defines the prostatic AR binding profile. 
In prostate cancer, this equilibrium is disturbed with FOXA1 and/or AR de-regulation (Yang 
and Yu, 2015). A recent meta-analysis (Shou et al., 2016) showed that higher levels of 
FOXA1 expression is associated with a better prognosis in BC.  
ID. Oestrogen synthesis and metabolism   
 There are four naturally-occurring forms of oestrogen: oestrone (E1), E2, oestriol (E3), 
and oestetrol (E4) (Figure. 6). 17β-oestradiol is the most potent and biologically-active 
oestrogen, which is primarily secreted by the ovarian granulosa cells (positioned next to theca 
cells), under the influence of the follicle-stimulating hormone (FSH) (Cui et al., 2013). 
Oestriol is the major oestrogen in pregnant women given its production in large quantities by 
the placenta, is the most abundant oestrogen in the urine of all women, and is not used in 
long-term oral oestrogen therapy as it has a very short oral elimination half-life. Oestetrol is 
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exclusively produced by the fetal liver during pregnancy, and reaches maternal circulation 
through the placenta (Holinka et al., 2008). Overall, E1 is generally 12 times weaker than E2, 
and E3 is generally 80 times weaker than E2.  
Oestrone is reversibly converted to E2 through the enzyme 17β-hydroxysteroid 
dehydrogenase (Ryan, 1959) (Figure. 6). Androstenedione, produced in the theca cells during 
the follicular phase of the menstrual cycle, acts as a precursor for E1 and testosterone in the 
ovaries and peripheral tissues (Cui et al., 2013). Testosterone is then converted to E2 through 
the aromatase enzyme in the peripheral tissues (Figure. 6). Aromatase (CYP19; encoded by 
the CYP19A1 gene) is the rate-limiting enzyme in converting androgens to oestrogens 
(Tsuchiya et al., 2005). Oestriol is produced by the hydroxylation of E2 or 16α-
hydroxyoestrone, while E4 is produced from E2, E3, and other precursors from the fetal liver 
and adrenal gland (Figure. 6). In premenopausal women, E2 is synthesized in the ovaries, and 
is considered the dominant oestrogen. In postmenopausal women, oestrone is synthesized in 
peripheral tissues, and is considered the dominant oestrogen.  
17β-oestradiol is metabolized by three competitive pathways involving irreversible 
hydroxylations by the NADPH-dependent cytochrome P450 (CYP) enzymes (CYP1A1, 
CYP1B1, and CYP1A2) (Samavat and Kurzer, 2015). Catechol oestrogens are further 
metabolized to methoxyestrogens (2-methoxyestrone, 4-methoxyestrone, 2-methoxyestradiol 





Figure 6 | Schematic representation depicting the synthesis of different oestrogens. 
Other than methylation, parent oestrogens and catechol oestrogens are conjugated 
with glucuronic acid and sulfate by hepatic phase II enzymes (UDP-glucuronosyltransferases 
and sulfotransferases, respectively). Such conjugation makes oestrogens become either water 
soluble to be excreted in the urine or feces, or turn them into a more lipophilic moiety with 
prolonged half-lives (Lakhani et al., 2003).  
Sulfation remains the main pathway for oestrogen metabolism, and is involved in the 
inactivation of oestrogens in target tissues; through converting oestrogens to 17b-estra-1,3,5-
trien-3,17-diol 3-sulfateno, which cannot interact with the oestrogen receptors (Kotov et al., 
1999). In specific, SULT1E1 and PAPSS (PAPSS1 and PAPSS2) are responsible for 
the oestrogen sulfation, through providing the catalyzing enzyme and universal sulfate donor. 
Dietary flavonoids were shown to influence the bioavailability of endogenous oestrogens 
through inhibiting steroid sulfatase (Harris et al., 2004).  
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Overall, the ratio of circulating oestrogens could be indicative of the woman’s 
dynamic metabolism, in terms of the balance between oestrogen synthesis and deactivation 
(through metabolism of E2 to the less-potent forms E1 or E3, and sulfation of E2 by oestrogen 
sulfotransferase).    
IE. Breast and prostate cancer therapeutics  
More than 70% of BC is ER– positive (Clark et al., 1984), which is effectively 
targeted with endocrine therapies (Abderrahman and Jordan, 2016e), such as: Selective ER 
Modulators (SERMs) (e.g., TAM) (Maximov et al., 2013), or AIs (e.g., anastrozole, 
exemestane, and letrozole) (Jordan and Brodie, 2007).    
Tamoxifen (Figure. 7) is a competitive inhibitor of oestrogen at the level of the ER, 
and causes a G1 blockade in BC cell cycle (Sutherland et al., 1983, Osborne et al., 1983). On 
the other hand, AIs inhibit the BC aromatase enzyme system CYP19, blocking the conversion 
of androstenedione or testosterone to oestrogens in peripheral tissues (Jordan and Brodie, 
2007). Neither TAM nor AIs are cytotoxic and, therefore, do not cause cellular apoptosis 
(Jordan, 2015a, Bhattacharya et al., 2017). Tamoxifen is used to treat all stages of ER-
positive BC, for long-term adjuvant therapy, and chemoprevention (Abderrahman and 
Jordan, 2015, Abderrahman and Jordan, 2016c, Abderrahman and Jordan, 2016a). It can be 
administered to pre-and-post-menopausal women, and has serious but rare AEs such as: 
endometrial cancer and thromboembolic events. Such AEs were observed particularly in 
postmenopausal women (Vogel et al., 2010).  
Aromatase inhibitors (Figure. 7) are now the treatment of choice in BC, because there 
are fewer AEs compared to TAM, but are used only to treat post-menopausal women, except 
those who are at risk of osteoporosis. Nevertheless, AIs can have unpleasant musculoskeletal 
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symptoms (Khan et al., 2010), cause osteoporotic fractures (Hadji et al., 2017), and lead to 
significant urogenital atrophy including vaginal atrophy (Melisko et al., 2017).  
Pure anti-oestrogens, or Selective ER Downregulators (SERDs) (e.g., ICI 182,780 
fulvestrant [ICI]) (Figure. 7), exert a proteasomal degradation of the ERα protein through the 
ubiquitin proteasome system (McDonnell et al., 2015). Fulvestrant is used in post-
menopausal women with MBC, but given its route of administration being intramuscular 
injections (Robertson, 2007, Ellis et al., 2015, Robertson et al., 2016), it has an unfavorable 
AE of pain and swelling at the injection site.    
 
                        Figure 7 | Schematic representation of the signal transduction pathways in ER-positive breast 
cancer cells and their targeted therapeutics. At the adrenal level, adrenal androgen de 
novo steroidogenesis occurs. Cholesterol is produced and converted to Pregnenolone with the aid of 
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CYP11A1 enzyme. Pregnenolone is converted to dehydroepiandrosterone (DHEA) with the aid of 
CYP17A1. Finally, DHEA is converted to androstenedione (AD) with the aid of 3-β hydroxysteroid 
dehydrogenase enzyme. Then, AD is converted to testosterone via 17-β hydroxysteroid 
dehydrogenase. At the adipose tissue level, both androstenedione and testosterone are converted with 
the aid of the aromatase enzyme system to oestrone (predominant in postmenopausal women), and 
oestradiol (predominant in premenopausal women), sequentially. Oestrogen normally binds to the ER 
in the cytoplasm, the oestrogen:ER complex translocates to the nucleus, gets phosphorylated, and 
binds to oestrogen responsive elements (EREs) with the recruitment of coactivators. This creates a 
transcription complex (TC). This in turn, will initiate a cascade of protein synthesis and subsequent 
tumour proliferation through the activation of oestrogen-sensitive genes. Whereas, SERMs:ER 
follows a similar pattern, but recruits corepressors and inhibits protein synthesis; causing tumour 
regression. For SERDs, they bind to the ER causing an alien conformation, which leads to the 
destruction of the ER through the ubiquitin proteasome system; subsequently tumour regression.  
Patients with MBC, who have failed prior endocrine therapy with TAM, AIs, or ICI, 
can be treated with mammalian target of rapamycin (mTOR) inhibitors (e.g., everolimus) 
(Vicier et al., 2014), or Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors (e.g., palbociclib) 
(O'Leary et al., 2016, Xu et al., 2017). Both mTOR and CDK4/6 inhibitors are expensive 
(Abderrahman and Jordan, 2016e), costing patients ~$10,000-11,000 per month out-of-
pocket expense. In addition, they have undesirable toxicity profiles with grade 1/2 AEs (e.g., 
stomatitis) for mTOR inhibitors (Paplomata and O'Regan, 2014), and grade 3/4 AEs (e.g., 
non febrile neutropenia) for CDK4/6 inhibitors (Finn et al., 2016). Endocrine therapies often 
fail to achieve their therapeutic targets because of acquired resistance (Musgrove and 
Sutherland, 2009, Jeselsohn et al., 2015), or patients’ non-adherence from toxicity and/ or 
other factors (Osterberg and Blaschke, 2005, Abderrahman, 2017a, Abderrahman, 2017b).  
Prostate cancer has followed a similar treatment strategy to that of BC, in essentially 
exploiting the clues and principles established for BC treatment. Androgen deprivation can 
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still be achieved by gonadectomy and high-dose oestrogen therapy, however, they are now 
replaced by the use of sustained release of an LHRH superagonist. This effectively 
suppresses the release of gonadotropins, which, in turn, suppresses androgen synthesis in the 
testes. Anti-androgens (Figure. 8) that bind to and block the AR, have been refined and 
improved over the past three decades, based on the experiences with the modulation of the 
ER. The next generation “anti-androgenic” blocking agents (abiraterone acetate and 
enzalutamide), have significantly prolonged survival in patients with CRPC (Wong et al., 
2014). Abiraterone acetate is considered a first-in-class inhibitor of cytochrome P-450c 17 
(Figure. 8), which is responsible for androgen synthesis at the testicular and extragonadal 
level, and has shown to improve overall survival, and delay the initiation of chemotherapy in 
metastatic CRPC (Ryan et al., 2013). The combination of abiraterone acetate and prednisone 




Figure 8 | Schematic representation of the signal transduction pathways in prostate cancer cells 
and their targeted therapeutics. At the adrenal level, adrenal androgen de novo steroidogenesis 
occurs. Cholesterol is produced and converted to Pregnenolone with the aid of CYP11A1 enzyme. 
Pregnenolone is converted to dehydroepiandrosterone with the aid of CYP17A1. Finally, DHEA is 
converted to DHEA-S with the aid of following enzymes: steryl-sulfatase (STS) and bile salt 
sulfotransferase. At the prostae level, DHEA-S in Leydig cells is converted back to DHEA via STS, 
and then DHEA is converted to AD via enzyme 3β-HSD. Then, AD is converted to testosterone via 
enzyme AKR1C3, and finally to DHT via steroid 5α-reductase. Dihydrotestosterone normally binds to 
the AR in the cytoplasm, the DHT:ER complex translocates to the nucleus, gets phosphorylated, binds 
to androgen responsive elements (AREs) with the recruitment of coactivators. This creates a 
transcription complex (TC), which initiates a cascade of protein synthesis and subsequent tumour 
proliferation; through the activation of androgen-sensitive genes. Whereas, AR inhibitors:AR 
complex follows a similar pattern, but recruits corepressors and inhibits protein synthesis; causing 
tumour regression. For SARDs, they bind to the AR causing the degradation of the receptor; 
subsequently tumour regression. Androgen receptor inhibitors vary in their mechanisms of action. For 
example, enzalutamide competitively inhibits the AR binding to DHT, inhibits nuclear translocation 
of AR, and DNA and cofactor binding. Whereas, bicalutamide is a highly selective,  competitive and a 
silent antagonist of the AR, which was also found to accelerate AR degradation. Abiraterone inhibits 
CYP17A1 and subsequently adrenal androgen de novo steroidogenesis. Dutasteride is a 5α-reductase 
inhibitor that blocks testosterone conversion into DHT.  
IF. Long vs. short-term adjuvant tamoxifen therapy  
The use of adjuvant TAM therapy was initially short-term; limited to 1-2 years 
(Jordan, 1990). This cautious approach by the clinical community was based upon their 
experience with TAM being effective for 2-3 years in the treatment of 30% of MBC, and that 
resistance might develop with long-term treatment. The first question was: what would 
happen if TAM treatment is extended beyond 2 years? The Swedish Breast Cancer 
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Cooperative Group trial catered to answering this question (1996). It showed that 5 years of 
TAM is more beneficial than 2 in the treatment of postmenopausal women with ER-positive, 
early stage, invasive BC (1996).  
The second question was: what is the duration of therapy necessary to maintain the 
maximum benefit, and what is the nature and severity of AEs from prolonged treatment? The 
National Surgical Adjuvant Breast and Bowel Project (NSABP) filled in these gaps by 
evaluating the outcomes of patients in the NSABP B-14 trial through 10 years of follow-up, 
and evaluating the effects of 5 years versus more than 5 years of TAM therapy in ER-positive 
lymph node-negative BC patients (Fisher et al., 1996).  The trial concluded that the 5-year-
benefits from TAM treatment persisted through 10 years of follow-up, and that the TAM-
extended arm had a higher incidence of thromboembolic AEs, but not endometrial cancer.  
The third question was: if 5-year-TAM treatment is better than 2, would 10 years be 
better than 5, especially when at least 50% of BC recurrences occur more than 5 years after 
diagnosis, according to the Oxford overview analyses (Early Breast Cancer Trialists' 
Collaborative et al., 2011)? The Adjuvant Tamoxifen Longer Against Shorter (ATLAS) trial 
demonstrated both a reduction in BC recurrence and mortality, when TAM treatment is 
continued to 10 years in ER-positive BC women (Davies et al., 2013). These effects were 
more pronounced after 10 years (Davies et al., 2013). The ATLAS trial alongside other 
previous trials, suggested that 10 years of TAM treatment can halve BC mortality during the 
second decade after diagnosis (Davies et al., 2013) (Figure. 10). A similar trial but UK-based, 
referred to as adjuvant Tamoxifen Treatment offers more (aTTom) (Gray et al., 2013) 
(Figure. 10), has reaffirmed ATLAS’s conclusions. Pooled data from the ATLAS and aTTom 
trials accentuated the tremendous clinical benefit of long-term adjuvant TAM treatment up to 
10 years (Schiavon and Smith, 2014). These findings changed clinical practice. The 
American Society of Clinical Oncology guidelines now recommend that women with ER-
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positive BC should consider 10 years of TAM treatment (Abderrahman and Jordan, 2018). 
Investigators, subsequently, provided a guide (Sgroi et al., 2013) to improve the risk-benefit 
of long-term adjuvant endocrine therapy in concordance with the patient’s individualized risk 
for early- versus late-distant recurrence.     
Earlier scientific studies dovetailed with clinical trials in demonstrating that TAM can 
reduce the risk of BC, whereby TAM in animal models was capable of preventing chemical 
carcinogenesis in rats, and spontaneous mammary carcinogenesis in high-risk strains of mice 
(Jordan, 1976, Jordan et al., 1991). They also showed that TAM treatment might yield occult 
endometrial cancer, which warrants gynecological screening (Gottardis et al., 1988).    
The fourth and last question was: can AIs replace TAM in short or long-term adjuvant 
endocrine therapy for BC? Several clinical trials (Baum et al., 2002, Howell et al., 2005, 
Breast International Group 1-98 Collaborative et al., 2005, Coates et al., 2007, Coombes, 
2004, Boccardo et al., 2005, Goss et al., 2003b, Goss et al., 2005) (Figure. 10) answered this 
question with a “yes”; showing equal clinical benefits to TAM, if not superior in certain 
patient populations. However, there seems to be a general outlook that 3 years of TAM 
followed by 2 years or more of AIs is cost-effective, well-tolerated, and improves event-free 
and recurrence-free survival in postmenopausal patients with early BC (Boccardo et al., 
2005).   
IG. Acquired resistance to endocrine therapy in breast cancer  
Laboratory studies demonstrated the unique properties of acquired resistance to anti-
oestrogen therapy in vivo in ER-positive BC. Acquired resistance to TAM therapy initially 
involves the growth of BC populations, within 1 to 2 years, which are TAM and oestrogen-
dependent (Gottardis and Jordan, 1988, Gottardis et al., 1989b) (Figure. 10). Further studies 
of resistance in vivo demonstrated that >5 years of TAM treatment (mimicking the period of 
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the standard of care at the time), leads to cell selection pressure during oestrogen deprivation 
(Figure. 9), of new BC populations that grow with TAM, but now die with physiologic levels 
of oestrogen (Yao et al., 2000, Wolf and Jordan, 1993). This discovery provided an 
explanation of why high-dose oestrogen therapy was only effective ≥5 years past menopause 
in Haddow’s studies (Haddow, 1970).     
 
Figure 9 | Schematic representation of the oestrogen deprivation therapy in pre- and 
postmenopausal women with breast cancer. (Left) The hypothalamic–pituitary–gonadal axis in 
premenopausal women with breast cancer and their therapeutic targets. The hypothalamus produces 
gonadotropin-releasing hormone (GnRH), which stimulates the adenohypophysis of the pituitary to 
produce luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This in turn, stimulates 
the granulosa cells in the ovarian follicles to produce oestrogen. However, FSH in particular 
stimulates the granulosa cells to produce inhibin, which suppresses FSH in a feedback loop and 
activin; a peripherally produced hormone that stimulates GnRH cells. Oestrogen stimulates the growth 
of breast cancer cells, and exerts a negative feedback loop onwards to the hypothalamus and pituitary. 
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Ovarian suppression can be achieved with LHRH superagonists such as goserelin, which is an 
analogue of LHRH, and a GnRH or LHRH agonist. Goserelin initiates a flare of LH production and 
ultimately leads to receptor downregulation. Anti-oestrogens can be oestrogen receptor (ER) 
competitive blockers such as the Selective ER Modulators (SERMs, i.e., tamoxifen), or pure anti-
oestrogens or what is known as a Selective ER Downregulators (SERDs, i.e. , fulvestrant). Third-
generation aromatase inhibitors (i.e., anastrozole, letrozole, exemestane) selectively block the 
aromatase enzyme system at the breast cancer level and, therefore, suppress oestrogen synthesis. 
(Right) The hypothalamic–pituitary–gonadal axis in postmenopausal women with breast cancer and 
their therapeutic targets. The differences from premenopausal women is that the ovarian follicles are 
depleted, therefore, there is no active production of oestrogen and progesterone. This leads to a 
dramatic increase in GnRH, and an increase in FSH serum level relatively to that of LH through the 
feedback loops. Ovarian suppression is not used as a treatment option anymore. 
The effect of physiologic oestrogen on LTED BC in vitro, was shown to trigger a 
cellular stress response, named the unfolded protein response (UPR), and, subsequently, 
induce mitochondrial apoptosis (Ariazi et al., 2011, Lewis et al., 2005a, Song et al., 2001) 
(Figure. 10). Hosford and colleagues (Hosford et al., 2019) confirmed the involvement of the 
UPR and apoptosis in patient-derived oestrogen-deprived ER-positive xenografts when 
treated with 17β‐ oestradiol (E2). This UPR-and-apoptosis-paired biology, underlining 
oestrogen-induced tumour regression in LTED BC, not only explains the earlier observational 
clinical science (Haddow, 1970), but also forms the pillar of oestrogen’s therapeutic potential 




Figure 10 | Schematic representation of the in vitro and in vivo studies of tamoxifen resistance 
alongside the landmark clinical trials that evaluated tamoxifen versus AIs (over 5 and 10 years).   
IH. Acquired resistance to endocrine therapy through ER mutations  
Under normal physiologic conditions, the planar steroid oestradiol is positioned in the 
LBD of the WT ERα by Glu353, Arg394, and His524 (Figure 11B). This allows H12 to seal 
the LBD (Figure 11B). The amino acids Tyr537, which gets phosphorylated to ensure an 
efficient oestrogenic action of the ligand:ERα complex and was shown to influence the 
turnover and activation of ERα, as well as Asp538 have become of interest. ESR1 somatic 
mutations, Y537S and D538G, stabilize ERα in the agonist state, and are linked to acquired 
resistance to endocrine therapies (Fanning et al., 2016) (Figure. 11A). Mutations Tyr537Ser 
and Asp538Gly were most prevalent in BC metastases (Toy et al., 2013b), especially AI-
resistant BC patients, and contribute to roughly 25% of overall resistance to endocrine 
therapies. These mutations improve the closure of H12 over ERα’s LBD, through interacting 
with Asp351, and recruiting coactivators in the absence of oestrogen, which increases the 
estrogen-like properties of the complex (Toy et al., 2013b, Jordan et al., 2015). These 
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mutations are positioned on the external view of the E2:ERα complex, and are closely aligned 
with Asp351 in the LBD (Jordan et al., 2015) (Figure. 11C and E).  
The prognostic and predictive value of circulating ESR1 mutation, and its kinetics 
before and after progression on AI treatment, was evaluated. ESR1 circulating D538G and 
Y537S/N/C mutations were shown to be independent risk factors for poor outcome after AI 
failure, and were frequently detectable before clinical progression (Clatot et al., 2016).  
 
Figure 11 | Schematic representation of ERα’s mutations and the molecular interactions of the 
oestradiol (E2)–oestrogen receptor (ER) complex. A) Schematic representation of the wild-type 
human ER cDNA. The position initially known for the natural single-point mutations, such as 
Asp351Tyr is indicated. The activating function (AF) – 2 region, and various mutant receptors 
generated by random chemical or site-directed mutagenesis are shown, which either cause loss of AF-
2 activity (i.e., 537, 538), or an increase in oestrogenic activity if the receptor is unliganded or 
liganded with an anti-oestrogen (other mutations). The orange line connecting 537, and 538 to the 
anchor Asp351 illustrates the current finding of Toy et al. (Toy et al., 2013a) that D538G interacts and 
closes the empty ER pocket. The most common and important mutations in the LBD are highlighted 
in red. B) The interaction of E2 (blue) in the ligand-binding domain (LBD) with relevant amino acids 
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and the associated amino acids in the vicinity from helix 12 (Brzozowski et al., 1997). C) A space 
filled model from the top of the E2 LBD showing the closed helix 12 (yellow) securing E2 within. 
Three amino acids of relevance are indicated on the surface of the LBD complex: Asp(D)351, 
Tyr(Y)537, and Asp(D)538. D) The selective ER modulators 4-hydroxytamoxifen (4-OHT) and 
raloxifene (Ral) secured within the LBD of the ER by the same two amino acids, Glu353 and Arg394, 
via a phenolic hydroxyl on both 4-OHT and Ral, as noted with the 3 phenolic hydroxyl on ring A of 
E2 (B). E) A space filler model from the top of the Ral LBD showing helix 12 pushed back (yellow), 
and the piperidine ring of Ral-neutralizing Asp(D)351.  
II. Oestrogen-induced BC regression in clinical trials  
In 2001, Lonning and colleagues (Lonning et al., 2001) successfully used high-dose 
oestrogen therapy in postmenopausal women with advanced endocrine-resistant BC, who 
were exhaustively treated with multiple endocrine therapies (median of deprivation 4 years). 
In 2004, the conjugated equine oestrogen arm in the Women’s Health Initiative (WHI) trial 
(Anderson et al., 2004), and its long-term follow-up (Chlebowski et al., 2019, Jordan, 2020), 
unwittingly, revealed the tremendous clinical benefit of oestrogen-induced tumour regression 
(Abderrahman and Jordan, 2016d). The WHI trial had more than 75% of the postmenopausal 
women (aged 50 to70 years) LTED (i.e., 10 years past menopause). When given oestrogen 
hormone replacement therapy (HRT), there were significant decreases in both BC incidence 
and mortality (Roehm, 2015, Anderson et al., 2004). In 2009, Ellis and colleagues (Ellis et 
al., 2009), compared and contrasted high-and-low-dose oestrogen therapy in postmenopausal 
women with advanced adjuvant AIs-resistant BC (deprivation ≥ 2 years). These clinical trials 
combined (Lonning et al., 2001, Ellis et al., 2009) demonstrated a 30% response rate on 
receipt of the treatment, and reaffirm the earlier laboratory findings that oestrogen treatment 
after LTED leads to BC regression (Yao et al., 2000). Iwase and colleagues (Iwase et al., 
2013) using ethinyloestradiol in MBC patients (median age 63 years), had a 50% response 
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rate, a 56% clinical benefit rate, and reported no severe AEs. Chalasani and colleagues 
(Chalasani et al., 2014) using low-dose E2 during 3-month exemestane breaks in MBC 
patients, had measurable clinical activity with minimal toxicity.     
Taken together, these in vivo, in vitro studies, and clinical trials, support the clinical 
benefit of using oestrogen alone, or potentially in combination with growth inhibitors and/ or 
apoptosis promoters, for the treatment of endocrine-resistant BC. Nonetheless, concerns 
regarding AEs require the research and development of safer oestrogens or oestrogen mimics.  
IJ. Hormones causing regression of other cancers   
Chuu and colleagues (Chuu et al., 2011) showed that CRPC (e.g., LNCaP, ARCaP, 
and PC-3 cells over-expressing AR), becomes vulnerable to androgens, and dies with 
androgen-induced apoptosis, after long-term androgen deprivation (Chuu et al., 2011) 
(Figure. 12). In androgen-induced tumour regression, the response rate was 50% (Salonen et 
al., 2008, Schweizer et al., 2015) on receipt of the treatment. Laboratory studies in vitro and 
in vivo confirm this phenomenon, however, additional clinical trials are underway (Michaud 
et al., 2015, Schweizer et al., 2015).  
In a retrospective study of epithelial ovarian cancer patients over 20 years, Eeles and 
colleagues (Eeles et al., 2015) showed that women, who were put on oestrogen-containing 
preparations to treat postmenopausal symptoms, had a doubled survival rate, compared to 
those who did not (Figure. 12). The survival benefits even continued after oestrogen was 
stopped (Abderrahman and Jordan, 2016b). Syed and colleagues (Syed and Ho, 2003) 
demonstrated that progesterone induces apoptosis in immortalized normal, and malignant 
human ovarian surface epithelia cells, by enhancing the expression of FasL (i.e., extrinsic 
pathway of apoptosis). 
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IK. Hormones causing apoptosis in developmental biology   
The UPR is involved in many processes that are part of developmental biology. Song 
and colleagues (Song et al., 2002) demonstrated that hormonal withdrawal of oestrogen and 
progesterone, after the proliferative and secretory phases in a woman’s menstrual cycle, leads 
to the observed shedding in the uterine wall, through the extrinsic pathway of apoptosis 
(Figure. 12). The study also showed that the dysregulation of the Fas/FasL could be involved 
in endometrial cancer (Song et al., 2002).     
Krum and colleagues (Krum et al., 2008) demonstrated in vivo and in vitro that bone-
resorbing osteoclasts undergo oestrogen-induced apoptosis. This explains how oestrogen 
maintains bone health in women through fueling the survival and proliferation of osteoblasts, 
which build bone, and killing off extra osteoclasts, which destroy bone. Several studies 
supported this notion, and showed that oestrogen specifically kills pre-osteoclasts before they 
evolve into mature osteoclasts (Nakamura et al., 2007, Kameda et al., 1997, Imai et al., 2009, 
Xing and Boyce, 2005, Wang et al., 2015) (Figure. 12).    
Patel and colleagues (Patel et al., 2015) demonstrated in vitro that cytotrophoblasts 
undergo oestrogen-induced apoptosis to maintain the balance of normal placental 
development, remodeling, and implantation of the fertilized ovum (Figure. 12). This occurs 
specifically when oestrogen levels are elevated during a narrow window in the first trimester 
of pregnancy. This also explains why premature or abnormal elevation in oestrogen 
concentration leads to abnormal placentation and preeclampsia (Patel et al., 2015). Matsuura 
and colleagues (Matsuura et al., 2004) demonstrated in vivo that oestradiol benzoate at 
physiological doses in pregnant rats, leads to fetoplacental growth retardation via 
trophoblastic apoptosis, and degeneration of placental labyrinth (i.e., the branching layer of 
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placental trophoblasts, which is situated between the maternal and fetal blood vessels) 
(Figure. 12). 
 
Figure 12 | Schematic representation of sex-storied induced-apoptosis in cancer and non-cancer 
tissues.    
Rijhsinghani and colleagues (Rijhsinghani et al., 1996) showed in vivo that CD4 and 
CD8 thymocyte T cells, specifically CD4+/CD8+, undergo oestrogen-induced apoptosis to 
maintain the balance of the immune system cells, at the level of the thymus gland. This 
explains why oestrogen causes a dramatic decrease in thymic size and cellularity. Oestrogen 
specifically kills double positive T cells (CD4+/CD8+) before they evolve into single positive 
T cells (CD4+/CD8- or CD4-/CD8+). Other studies in vivo (Lee et al., 2013, Do et al., 2002, 
Staples et al., 1999) reaffirm this conclusion (Figure. 12).    
The phenomenon of oestrogen-induced apoptosis is prevalent in normal cells, as part 
of developmental biology, but appears to be an acquired vulnerability in 30% of LTED BC 
and 50% of androgen-deprived PC. Understanding the molecular mechanisms that underline 
sex-steroid-induced apoptosis, and leveraging that understanding to identify switch 
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mechanisms to cancer cell death, can lead to novel therapeutic advances applied to treating a 
wide range of cancers.  
 IL. Endoplasmic reticulum stress: a prelude to apoptosis   
Under normal or disease conditions, cells face environmental or intracellular stress. 
Initially, cells respond with instigating a protective endoplasmic reticulum (EnR) stress 
regulation (i.e., integrated stress response [ISR], and UPR), in an attempt to defend 
themselves against the insult and eventually recover (Fulda et al., 2010, Pakos-Zebrucka et 
al., 2016) (Figure. 13). However, if the insult creates a maximum or a prolonged and 
unresolved EnR stress, then organisms choose to sacrifice these irreparable cells, through 
triggering a terminal ISR or UPR regulation, and, subsequently, proceeding into irreversible 
programmed cell death (apoptosis) (Fulda et al., 2010, Hetz, 2012) (Figure. 13). The ISR and 
UPR are part of the cellular stress responses. Whereas, apoptosis is part of cellular stress-
induced death (Fulda et al., 2010). The UPR usually leads to the activation of intrinsic 
apoptosis in the mitochondria (Walter and Ron, 2011). The nature and duration of the stress 
alongside the cell type were shown to be key to this decision-making; for cells to either 
persist with a protective ISR or UPR, or flip to a pro-apoptotic one (Hetz, 2012, Pakos-
Zebrucka et al., 2016). This survival response against stress is highly conserved throughout 
evolution, and is embedded in the EnR of all organisms (Maly and Papa, 2014).  
The ISR and UPR are involved in the development, differentiation, function, and 
survival of immune cells (Pierre, 2019), and ample diseases, such as: cancers, 
neurodegenerative diseases, cardiovascular diseases, ocular disorders, and diabetes type 1, 
among others (Cybulsky, 2017, Hetz and Saxena, 2017b, Grootjans et al., 2016, Walter and 
Ron, 2011). The UPR is also involved in many inflammatory diseases. Jing and colleagues 
(Jing et al., 2012) demonstrated that glaucoma, diabetic retinopathy, and age-related macular 
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degeneration create an EnR stress that leads to the activation UPR, and eventually apoptosis 
of retinal vascular and neuronal cells (Shimazawa et al., 2007, Ryoo et al., 2007, Yang et al., 
2008). This was observed in both cultured retinal cells (i.e., vascular endothelial cells, 
pericytes, ganglion cells, Muller cells, and RPE cells), and in the retina from animal models 
of various diseases. In retinitis pigmentosa, the role of EnR stress and UPR were central to 
photoreceptor cell death, and retinal degeneration (Rebello et al., 2004, Yang et al., 2008).  
 
Figure 13 | Schematic representation of the UPR and its connection to survival or apoptosis in 






Figure 14 | Schematic representation of the UPR in breast cancer.    
In addition, a chronic EnR stress was found to repress the synthesis of synaptic 
proteins, and result in neuronal loss, with implications on cognition, memory, and autism 
spectrum disorder (Hetz and Saxena, 2017a). The UPR was shown to be at the center of 
Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, Huntington’s disease, 
prion-related disorders, and some myelin-related disorders.    
The UPR is activated when cells are exposed to a stress stimuli, such as: glucose 
starvation, inhibition of protein glycosylation, Ca2+ depletion as one form of Ca2+ 
disequilibrium, oxygen deprivation, DNA damage, and cytokine deprivation, among others. 
The EnR is considered the chief site for generating and tailoring mature proteins in all cells 
(Walter and Ron, 2011). This protein synthesis process is guarded by the ISR and UPR. 
Under normal circumstances, proteins within the EnR undergo posttranslational processing 
(i.e., glycosylation, disulfide bond formation, correct folding, and oligomerization) (Walter 
and Ron, 2011). If cells are under extrinsic or intrinsic stress insults, proteins will not 
undergo this process efficiently and, therefore, a buildup of misfolded or unfolded proteins 
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will follow (Walter and Ron, 2011). These defective proteins will be sensed by the 4 
transducers of the ISR: PERK, PKR, GCN2, and HRI (Pakos-Zebrucka et al., 2016), or the 3 
transducers of the UPR: PERK, IRE1α, and ATF6 (Schroder and Kaufman, 2005, Ron and 
Walter, 2007, Walter and Ron, 2011).   
During the UPR activation, PERK is activated rapidly, followed by ATF6, and lastly 
IRE1α (Figures. 13 and 14). Studies suggest that IRE1α could be the “switch transmitter”, 
whereby the “time” of IRE1α activation is hypothesized to be a switch mechanism to flipping 
the UPR trajectory from pro-survival to pro-apoptotic (Lin et al., 2007). The potential 
mechanisms include: IRE1 inducing p58IPK (Szegezdi et al., 2006), and IRE1α-dependent 
activation of ASK1, and its downstream target JNK. Many studies show that an EnR stress 
that leads to a tonic or a maximum activation of the UPR sensors is credited with the UPR 
switching from a protective to a terminal UPR regulation. This naturally begs the question: 
how can we leverage the molecular switch mechanisms to cell death, in this stress-death 
associated biology, to enhance the clinical responses seen in anti-hormone resistant BC and 
PC patients, when treated with the stress-inducing sex-storied hormones?         
IM. New promising oestrogenic agents for endocrine-resistant BC treatment     
Oestetrol is proposed as a promising oestrogen for the treatment of advanced BC 
(Bennink et al., 2017, Singer et al., 2014, Verhoeven et al., 2018, Schmidt, 2020), advanced 
PC (Dutman et al., 2017), and for use in HRT (Coelingh Bennink et al., 2016, Donesta 
Bioscience, 2016, Gerard et al., 2015) as well as oral contraception (Apter et al., 2017) 
(Figures. 15 and 16). The combination of E4 and progestin drospirenone is subject to FDA 
approval, with the possibility of E4 becoming the first natural oestrogen approved in a 
contraceptive product in the US, and the first new oestrogen introduced in the U.S. in 50 
years. Oestetrol is devoid of ERα Membrane Initiated Steroid Signaling in the endothelium, 
44 
 
which conveys an atheroprotective effect in an ERα-dependent manner (Abot et al., 2014). 
It’s also associated with a low risk of drug-drug interactions (CYP450 family) as well as a 
neutral impact on risk markers of venous thromboembolism. In preclinical models, E4 
selectively activates the nuclear ERα, which plays a prominent role in the vasculoprotective 
action of oestrogens (Abot et al., 2014). An ongoing phase I/IIA clinical trial of E4 (Schmidt, 
2020), to treat advanced BC, shows that the majority of patients experienced favorable 
subjective effects on wellbeing. One patient of such completed both the phase 1/IIA with 
stable disease after 24 weeks of treatment. The 20 mg dose E4 allowed dose escalation to 40 
mg per day.   
 
Figure 15 | Schematic representation of the new generations of oestrogenic therapies, their 
clinical trials, and superior AEs’ profile compared to E2.    
Three Selective Human ER Partial Agonists (ShERPAs; including pilot BMI-135 and 
clinically-tested TTC-352) were shown not to cause significant uterine growth in certain 
TAM-resistant BC models, and are proposed as safer oestrogen mimics for the treatment of 
endocrine-resistant BC (Molloy et al., 2014, Xiong et al., 2016) (Figures. 15 and 16). TTC-
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352, an orally-bioavailable ShERPA, caused growth inhibition in 3 TAM-resistant ER-
positive BC cultures (Molloy et al., 2014, Xiong et al., 2016). Moreover, preclinical 7-day 
repeated dose studies conducted in 2-gender Sprague-Dawley rats and in dogs, demonstrated 
TTC-352’s efficacy, tolerability, and rapid absorption (Tonetti et al., 2017). A phase 1 
clinical trial using TTC-352 in metastatic hormone receptor-positive BC patients, who had 
progressed on at least two lines of endocrine therapy (with one that included a CDK 4/6 
inhibitor), has been completed (Dudek et al., 2020). It shows that TTC-352 has manageable 
safety and early clinical evidence of activity in patients with MBC progressing on endocrine 
therapy. The 180 mg BID dose is recommended for further testing. Both compounds have 
further clinical trials planned.    
 
Figure 16 | Schematic representation of the chemical structures of planar oestrogens, angular 
oestrogens, SERMS, and ShERPAs. The box (in green) highlights the benzothiophene scaffold 
embedded in raloxifene and arzoxifene structures, of which the ShERPAs’ structures were based 
upon. The continuous box (in yellow) highlights the phenyl ring bearing OH of triphenylethylenes 
(TPEs): trihydroxytriphenylethylene (3OHTPE) and BPTPE (Maximov et al., 2020), which makes 
them angular oestrogens/partial agonists. The dashed box (in brown) highlights the absence of OH on 
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the phenyl ring of the Z-isomer of dihydroxytriphenylethylene (Z2OHTPE), which makes it an 
angular oestrogen/full agonist like E2 and diethylstilbestrol (DES) (Maximov et al., 2020). 
IN. Rationale for research  
Given the unpleasant gynecological and non-gynecological AEs of oestrogen 
treatment, the development of safer oestrogens for the treatment of endocrine-resistant BC, or 
for use in HRT, remains a priority. The naturally-occurring oestrogen E4 and synthetic 
oestrogen mimic TTC-352 are being put forward as such, and are currently being evaluated in 
endocrine-resistant MBC patients. The rationale for this research (i.e., two peer-reviewed 
publications) lies in the fact that ShERPAs and E4 currently lack: (i) thorough structural 
studies, (ii) molecular mechanistic studies on how they cause tumour regression in LTED BC 
patients, and (iii) thorough pharmacological studies in a wide range of patient-representative 
BC models, as previous studies used either 1-2 models or an engineered model that does not 
necessarily reflect patients’ tumour heterogeneity. This evaluation is necessary to guide the 
future clinical trials of ShERPAs and E4, and provide accurate structural, pharmacological, 
and mechanistic insights into what an “effective and safer oestrogenic agent to treat advanced 
drug-resistant BC” looks like.  
To fill in these specific gaps, cell viability and proliferation assays, real-time 
polymerase chain reaction, luciferase reporter assays, chromatin immunoprecipitation, 
docking and molecular dynamics simulations, X-ray crystallography, human UPR RT2 PCR 
profiler arrays, live cell microscopic imaging and analysis, annexin V staining assays, 
immunoblotting, ERE DNA pull downs, and mass spectrometry were conducted in 11 
biologically-different BC models, including those endocrine-resistant. Results were compared 
with the benchmark potent full oestrogen agonist E2, less potent full oestrogen agonists E1 
and E3, the benchmark partial agonist triphenylethylene bisphenol (BPTPE), the classical 
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antagonists (or SERMs) 4-hydroxyTAM (4OHT), endoxifen, and raloxifene, and the 
benchmark SERD ICI.         
IO. Hypothesis of research  
The first part of this research’s hypothesis is that TTC-352 is classified as a weak full 
oestrogen agonist not a partial oestrogen agonist (as originally classified by the group of 
investigators that synthesized it). This stemmed from the observation that at least one BC 
patient developed occult endometrial hypertrophy after TTC-352 treatment (i.e., full 
oestrogen agonist AE). If TTC-352 was, indeed, a full oestrogen agonist, then the hypothesis 
would extend to include the following junctures: i) TTC-352 would improve helix 12 (H12)-
to-Asp351 interaction of ERα, and the closure of H12 over the LBD; conferring an agonist 
conformation of the ligand-ERα complex (based on our earlier structural studies), and 
recruiting E2-enriched coactivators; and ii) TTC-352 and E4 would lead to a rapid activation 
of ERα-mediated UPR and apoptosis (based on our earlier biological studies of oestrogens in 
LTED BC), which, in turn, constitutes their molecular mechanisms of tumour regression in 
LTED endocrine-resistant MBC patients.       
IP. Novelty and contribution of research  
The novelty and contribution of this research lies in providing: (i) the first structural 
studies of ShERPAs including the X-ray crystallography of TTC-352:mutant ER with clinical 
implications given that the majority of MBC patients harbor ER mutations  (Niu et al., 2015, 
Pejerrey et al., 2018, Toy et al., 2013b), (ii) the first report on the molecular mechanisms of 
TTC-352 and E4’s anti-cancer properties in LTED BC patients, (iii) the first comprehensive 
pharmacological studies of ShERPAs and E4 in numerous patient-representative BC models, 
and (iv) the key interactions at the molecular and atomic levels of the benchmark partial 
agonist BPTPE:WT ER, involving Asp351 and H12, which explains the delayed ERα-
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induced UPR and apoptosis compared to TTC-352. This sets the structure-function model of 
TTC-352 apart from BPTPE, and clearly demonstrates that TTC-352 is not a partial agonist, 
as originally classified by the group that synthesized it.   
II. Materials and Methods    
IIA. Reagents.   
E1, E2, E3, E4, and 4OHT were purchased from Sigma-Aldrich (St. Louis, MO). 
Endoxifen (Endox) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA), 
raloxifene (Ralox) from Sigma-Aldrich, and ICI from Tocris Bioscience/FisherScientific 
(Bristol, United Kingdom). BPTPE was originally synthesized at the Organic Synthesis 
Facility, Fox Chase Cancer Center (Philadelphia, PA) (Maximov et al., 2010). The ShERPAs 
BMI-135 and TTC-352 were a gift from Drs Debra Tonetti and Gregory R. J. Thatcher 
(University of Chicago, IL). The PERK inhibitor GSK G797800 was purchased from Toronto 
Research Chemicals (Toronto, Ontario, Canada). The IRE1α Inhibitor MKC-3946 was 
purchased from Calbiochem (San Diego, CA). Thioflavin T (ThT) was purchased from 
Sigma-Aldrich. For the ChIP assays, the antibodies used for pull-downs are: anti-ERα clone 
F-10X mouse monoclonal (2 μg/μl; 5 μg per reaction) (Santa Cruz Biotechnology), anti-SRC-
3 clone AX15.3 mouse monoclonal (1 μg/μl; 5 μg per reaction) (Abcam, Cambridge, United 
Kingdom), and normal mouse IgG as IP negative control (2 μg/μl; 5 μg per reaction) (Santa 
Cruz Biotechnology). For Western blotting, anti-ERα (sc-544), anti-eIF2α (D-3), and anti-β-
actin (C-4), were purchased from Santa Cruz Biotechnology. Anti-phospho-eIF2α (Ser51) 
(#9721), anti-ATF4 (D4B8), anti-CHOP (L63F7), and anti-cleaved PARP (Asp214) (19F4), 
were purchased from Cell Signaling Technology. Anti-XBP1 (isoforms non-spliced and 




IIB. Cell culture .  
Wild type (WT) oestrogen-dependent BC cell line MCF-7:WS8 (Jiang et al., 1992); 
mutant p53 oestrogen-dependent BC cell line T47D:A18 (Murphy et al., 1990); the first in 
vitro cellular model recapitulating acquired-TAM resistance developed in athymic mice in 
vivo MCF-7:PF (Fan et al., 2014); oestrogen-responsive, ER-positive, progesterone receptor 
(PgR)-positive, and human epidermal growth factor receptor 2 (HER2)-positive luminal B 
BC cell line BT-474 (Kraus et al., 1987); oestrogen-responsive, ER-positive, PgR-positive, 
and androgen receptor-positive luminal A BC cell line ZR-75-1 (Engel et al., 1978); anti-
hormone-resistant oestrogen-independent BC cell line MCF-7:5C (Lewis et al., 2005b); anti-
hormone-sensitive oestrogen-independent BC cell line MCF-7:2A (Pink et al., 1995); and 
anti-hormone (Ralox)-resistant oestrogen-independent BC cell line MCF-7:RAL (Liu et al., 
2003); TAM-sensitive, oestrogen-independent, ER-positive BC cell line LCC1 (Clarke et al., 
1989, Brunner et al., 1993a); TAM-resistant and ICI-sensitive, oestrogen-independent, ER-
positive BC cell line LCC2 (Brunner et al., 1993b); and TAM-and-ICI-cross resistant, ER-
positive BC cell line LCC9 (Brunner et al., 1997), were cultured as described previously. 
Human endometrial adenocarcinoma cell line Ishikawa was cultured as described previously 
(Nishida et al., 1985). All cell cultures were done in T75 and T175 culture flasks (Thermo 
Fisher Scientific, Waltham, MA), passaged twice a week at 1:3 ratio, and grown in 5% CO2 
at 37°C. All cell lines were validated according to their short tandem repeat (STR) profiles at 
The University of Texas MD Anderson Cancer Center Characterized Cell Line Core (CCLC). 
The STR patterns of all cell lines were consistent with those from the CCLC standard cells 





IIC. Cell viability and proliferation assays .  
The biological properties of compounds (E1, E2, E3, E4, BMI-135, TTC-352, BPTPE, 
4OHT, endoxifen, raloxifene, and ICI) in cells lines (MCF-7:WS8, T47D:A18, BT-474, ZR-
75-1, MCF-7:PF, MCF-7:5C, MCF-7:2A, and MCF-7:RAL), were evaluated by assessing the 
DNA content of the cells, as a measure of cell viability and proliferation. MCF-7:WS8 and 
T47D:A18 cells were starved in oestrogen-free medium for 3 days, and then seeded into 24-
well plates at a density of 8,000 cells/well for one-week treatment. MCF-7:PF, BT-474, and 
ZR-75-1 cells were starved in oestrogen-free medium for 3 days, and seeded into 24-well 
plates at a density of 10,000 cells/well for one-week treatment. MCF-7:5C cells were seeded 
into 24-well plates at a density of 10,000 cells/well for one-week treatment. MCF-7:2A cells 
were seeded into 24-well plates at a density of 3,000 cells/well for two-week treatment. 
MCF-7:RAL cells were seeded into 24-well plates at a density of 4,000 cells/well for three-
week treatment. After 24 hours, cells were treated with compounds over the aforementioned 
periods of time, in oestrogen-free medium (MCF-7:WS8, T47D:A18, MCF-7:PF, BT-474, 
and ZR-75-1, MCF-7:5C, and MCF-7:2A), and in oestrogen-and-raloxifene-free medium 
(MCF-7:RAL). The medium was changed every 48 hours. On the last day of treatment, cells 
were harvested by medium aspiration, washed once with ice-cold Dulbecco’s PBS (DPBS) 
(Life Technologies, Carlsbad, CA), and analyzed using the DNA Quantification Kit (Bio-
Rad, Hercules, CA) according to manufacturer’s instructions. Samples were then quantitated 
on a Synergy H1 plate reader (BioTek Instruments Inc., Winooski, VT) in black wall 96-well 
plates (Nalge Nunc International, Rochester, NY). All treatments were performed in 
triplicate. The calculated half maximal effective concentrations (EC50)s of all compounds in 
different human BC and human endometrial cancer cell lines are summarized (Table. 1 




IID. Quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR). 
MCF-7:WS8 (after 3-day starvation in oestrogen-free medium) and MCF-7:5C cells 
were seeded into 24-well plates at a density of 100,000 cells/well. After 24 hours, cells were 
treated with E2 [1 nM], BMI-135 [1 μM], TTC-352 [1 μM], BPTPE [1 μM], and endoxifen [1 
μM]. After 24-hour-treatment, cells were harvested, RNA was isolated using MagMAX-96 
Total RNA Isolation Kit (Applied Biosystems, Carlsbad, CA), and processed using 
Kingfisher Duo Prime magnetic particle processor (Thermo Fisher Scientific) according to 
manufacturer’s instructions. The cDNA was synthesized, utilizing 1µg of purified RNA, and 
using High Capacity cDNA Reverse transcription kit (Applied Bioscience) according to 
manufacturer’s instructions. Synthesized cDNA diluted in nuclease-free water and Power 
SYBR green PCR master mix, was used for RT-PCR (Applied Bioscience) according to 
manufacturer’s instructions. The RT-PCR was run using a QuantStudio 6 Flex Real Time 
PCR thermocycler (Applied Bioscience). All primers were obtained from Integrated DNA 
Technologies Inc. (IDT, Coralville, IA), and validated by melt curve analysis that revealed 
single peaks for all primer pairs. The primer sequences used for human TFF1 cDNA 
amplification are: 5’-CATCGACGTCCCTCCAGAAGA-3’ sense, 5’-
CTCTGGGACTAATCACCGTGCTG-3’ anti-sense; human GREB1 gene: 5’-
CAAAGAATAACCTGTTGGCCCTGC-3’sense, 5’-
GACATGCCTGCGCTCTCATACTTA-3’ anti-sense; and the reference gene 36B4: 5′-
GTGTCCGACAATGGCAGCAT-3′ sense, 5′-GACACCCTCCAGGAAGCGA-3′ anti-sense. 
The fold changes of mRNA after treatment with compounds vs. vehicle control were 





IIE. Transient transfection and dual luciferase reporter assays .  
Ishikawa cells were seeded into 24-well plates at a density of 100,000 cells/well. 
After 24 hours, cells were transfected with 28.8 μg of pERE(5X)TA-ffLuc, and 9.6 μg of 
pTA-srLuc reporter plasmids, using 3 μl of TransIT-LT1 transfection reagent (Mirus Biolabs, 
Madison, WI) per 1 μg of plasmid DNA, in 52.5 mL of OPTI-MEM serum-free media 
(Invitrogen, Carlsbad, CA). Transfection mix was added to cells in growth media to a final 
concentration of 0.3 μg pERE(5X)TA-ffLuc, and 0.1 μg of pTA-srLuc reporter plasmids per 
well. After 18 hours, transfection mix was removed and fresh media was added instead. After 
24 hours post transfection, cells were treated with compounds (E2, E4, BMI-135, BPTPE, and 
endoxifen) for 24 hours. After 24-hour-treatment, cells were washed once with cold DPBS 
(Invitrogen), lysed, and the ERE luciferase activity was determined using Dual-Luciferase 
Reporter Assay System (Promega, Madison, WI) according to manufacturer’s instructions. 
Samples were quantitated on a Synergy H1 plate reader (BioTek Instruments Inc.) in white 
wall 96-well plates (Nalge Nunc International). All treatments were performed in triplicate.  
IIF. Chromatin immunoprecipitation (ChIP) assays .  
The ChIP assay was performed as described previously (Sengupta et al., 2010, 
Obiorah et al., 2014). MCF-7:5C cells were grown in 15-cm Petri dishes to approximately 
80% confluency, and treated for 45 minutes with compounds (E2 [1 nM], E4 [1 μM], BMI-
135 [1 μM], BPTPE [1 μM], 4OHT [1 μM], and endoxifen [1 μM]) in growth media. After 
45-minute-treatment, cells were washed once with warm DPBS, and then crosslinked with 
1% formaldehyde in DPBS for 10 minutes at room temperature (73.4° F, or 23 °C). The 
crosslinking reactions were quenched with 0.125 M glycine, and cells were, subsequently, 
washed twice with ice-cold DPBS. Cells were scraped and collected into DPBS with Halt 
protease and phosphatase inhibitor cocktail (Thermo Fisher Scientific). Cells were pelleted by 
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centrifugation, and chromatin was isolated using Pierce Magnetic ChIP Kit (Thermo Fisher 
Scientific) according to manufacturer’s instructions. The washing of the magnetic beads used 
for the pull-downs was processed using Kingfisher Duo Prime Magnetic Particle Processor 
(Thermo Fisher Scientific) according to manufacturer’s instructions. The DNA fragments 
were purified using Qiaquick PCR purification kit (Qiagen, Germantown, MD). Then, 2 μl of 
eluted DNA was used for RT-PCR analysis. The sequences of used primer are: GREB1 
proximal ERE enhancer site amplification: 5’-GTGGCAACTGGGTCATTCTGA-3’ sense, 
5’-CGACCCACAGAAATGAAAAGG-3’ anti-sense (Integrated DNA Technologies). The 
data are expressed as percent input of starting chromatin material, after subtracting the 
percent input pull down of the IP negative control. The assays were performed in triplicate.   
IIG. Immunoblotting.  
MCF-7:WS8, MCF-7 ATCC, T47D:A18, BT-474, and ZR-75-1, were starved for 3 
days in oestrogen-free medium. MCF-7:WS8, MCF-7 ATCC, T47D:A18, BT-474, ZR-75-1, 
MCF-7:5C, MCF-7:2A, MCF-7:RAL, LCC1, LCC2, and LCC9 BC cells, were seeded into 5-
cm Petri dishes at a density of 2 million cells/dish for the 24-and-48-hour-time points, and at 
a density of 1.5 million cells/dish for the 72-hour-time point. After 24 hours, cells were 
treated with compounds (E2 [1 nM], E4 [1 μM], BMI-135 [1 μM], TTC-352 [1 μM], BPTPE 
[1 μM], 4OHT [1 μM], endoxifen [1 μM], raloxifene [1 μM], ICI [1 μM], thapsigargin [1 
μM], GSK G797800 [10 μM], and MKC-3946 [20 μM]) for different periods. After 
treatments, cells were harvested in cell lysis buffer (Cell Signaling Technology, Danvers, 
MA) supplemented with Protease Inhibitor Cocktail Set I and Phosphatase Inhibitor Cocktail 
Set II (Calbiochem). Total protein content of the lysate was determined by a standard BCA 
assay (Bio-Rad Laboratories). Fifty micrograms of total protein were separated on 10% SDS 
polyacrylamide gel, and transferred to a nitrocellulose membrane. The membranes were 
probed overnight at 4°C with primary antibodies; diluted in 5% dry nonfat milk in Tris-
54 
 
buffered saline/Tween 20 blocking buffer at ratios recommended by the supplier. This was 
followed by 1-hour incubation at room temperature with secondary antibodies conjugated 
with HRP. The signals were visualized using Western Lighting™ plus-ECL enhanced 
chemiluminescent substrate (PerkinElmer Inc., Waltham MA), and exposure of membranes 
to X-ray film. All treatments were performed in triplicate. Analysis was validated by 
densitometry using Image J (National Institutes of Health, Bethesda, MD). Densitometry data 
is presented in Supplementary Tables. S3-4 PAP2.  
IIH. Human UPR RT2 PCR Profiler PCR Arrays (Real-Time Profiler Assays).  
MCF-7:5C cells were seeded into 6-well plates at a density of 200,000 cells/well for 
the 48-and-72-hour-time points, and 45,000 cells/well for day 7-time point. After 24 hours, 
cells were treated with compounds (E2 [1 nM], E4 [1 μM], BMI-135 [1 μM], and BPTPE [1 
μM]). Cells were harvested using Qiazol reagent (Qiagen), and total RNA was isolated using 
an miRNeasy Mini Kit (Qiagen) according to manufacturer’s instructions. During the RNA 
purification process, samples were treated with DNAse using the RNase-Free DNase Set 
(Qiagen) according to manufacturer’s instructions. The cDNA was reverse transcribed using 
2 μg of isolated RNA and the High Capacity cDNA Reverse Transcription Kit (Applied 
Bioscience) according to manufacturer’s instructions. The cDNA was diluted 1:50, and a 2x 
RT2 SYBR Green Mastermix (Qiagen) was used to prepare the reactions. The plates were 
loaded and run on a QuantStudio 6 Flex Real Time PCR thermocycler (Applied Bioscience) 
according to manufacturer’s instructions. The Ct values were exported at the end of each run, 
compiled, and uploaded to the Qiagen’s Data Analysis Center, for analysis. All treatments 





III. Live cell microscopic imaging and analysis .  
MCF-7:5C cells were seeded into 15 μ-slide 2-well chambered coverslip slides (Ibidi, 
Martinsried, Germany) at a density of 300,000 cells/well for the 48-hour-time point, and at 
200,000 cells/well for the 72-hour-time point. After 24 hours, cells were treated with 
compounds (E2 [1 nM], E4 [1 μM], BMI-135 [1 μM], TTC-352 [1 μM], 4OHT [1 μM], 
control [0.1% DMSO], and positive control thapsigargin [1 μM]). On the day of live cell 
imaging, the green fluorescent dye ThT (UPR-indicative dye) (Sigma-Aldrich) was freshly 
prepared at a final concertation of 5 μM as described previously (Beriault and Werstuck, 
2013), and the blue fluorescent live cell nuclear dye Hoechst 33342 (counterstaining dye) 
(Thermo Fisher Scientific) was freshly prepared at a final concertation of 5 μg/mL. 
Thioflavin T solution was prepared by dissolving ThT in 70% ethanol, then diluting it in 
culture media to a concentration of 5 mM, and finally adding it to culture media containing 
test compounds; reaching a final concentration of 5 μM. The staining with ThT was for 1 
hour, followed by substituting the culture media (containing test compounds and ThT) with 
PBS containing Hoechst 33342 for 15 minutes in a CO2 incubator. Fluorescent images of 
MCF-7:5C live cells were taken at a 38 ms exposure under a 20X/0.7 objective with ZEISS 
Celldiscoverer 7 (Carl Zeiss AG, Oberkochen, Germany). Images were converted to 12-bit 
before being quantified by the ZEISS Zen Software Module-Image Analysis. Cells from each 
image were manually counted to normalize the fluorescent data per cell. Relative intensity 
per cell =ThT intensity/cell count, was generated for each treatment per image. An mean of 
the relative intensity per cell (using 3 images per treatment) was then calculated to give a 
final quantification alongside the standard deviation (SD). The excitation and emission 
settings were: Hoechst 33342 (Ex. 348 nm, Em. 455 nm), and ThT (Ex. 433 nm, Em. 475 




IIJ. Annexin V staining assays .  
MCF-7:5C cells were seeded into 10-cm Petri dishes at a density of 800,000 cells/dish 
for the 72-and-96-hour-time points. MCF-7:2A cells were seeded into 10-cm Petri dishes at a 
density of 400,000 cells/dish for day 9-time point, and at 100,000 cells/dish for day 13-time 
point. MCF-7:RAL cells were seeded into 10-cm Petri dishes at a density of 150,000 
cells/dish for the day 14, day 17, and day 21-time points. After 24 hours, cells were treated 
with compounds (E2 [1 nM], E4 [1 μM], BMI-135 [1 μM], TTC-352 [1 μM], 4OHT [1 μM], 
raloxifene [1 μM] (with MCF7:RAL), ICI [1 μM] (with MCF7:RAL), GSK G797800 [10 
μM] (with MCF7:5C), and MKC-3946 [20 μM] (with MCF7:5C), over the aforementioned 
time points. Cells were harvested by aspirating the media, washing them twice with warm 
DPBS, and treating them with accutase (Sigma-Aldrich), or trypsin solution (Life 
Technologies), at 5% CO2 37°C incubator. After the addition of warm DPBS to either 
accutase or trypsin, cells were harvested by pipetting, transferred to centrifuge tubes, and 
precipitated. Harvested cells were suspended in 1x binding buffer, and 1*105 cells were 
simultaneously stained with FITC-labeled Annexin V and propidium iodide (PI) for 15 
minutes at 37°C, using the FITC Annexin V Apoptosis Detection Kit I (BD Pharmingen, San 
Diego, CA) according to the manufacturer’s instructions. The cells were analyzed using a BD 
Accuri C6 plus flow cytometer. The assay was performed in triplicates.   
IIK. Statistical analyses .  
All data are mean ± SD of three different fields, for each condition, from three 
independent biological experiments performed in technical duplicates. One-way ANOVA 
was used with a follow-up Tukey’s test to determine the statistical significance of the 
treatments. For the cell viability and proliferation assays, EC50 was calculated using the 
formula: Y=Bottom + (Top-Bottom)/(1+10 (̂(LogEC50-X)*HillSlope)). For the volcano 
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plots, the fold-Change (2  ̂ (- Delta Delta CT)) is the normalized gene expression (2 (̂- Delta 
CT)) in the Test Sample divided the normalized gene expression (2  ̂(- Delta CT)) in the 
Control Sample. Fold-Regulation represents fold-change results. Fold-change values greater 
than one indicates a positive- or an up-regulation, and the fold-regulation is equal to the fold-
change. Fold-change values less than one indicate a negative or down-regulation, and the 
fold-regulation is the negative inverse of the fold-change. The p values of the volcano plots 
were calculated using a Student’s t-test of the replicate 2  ̂(- Delta CT) values, for each gene 
in the control group and treatment groups. 
III. Results  
IIIA. Effects of ShERPAs and E4 on cell viability in numerous BC models . 
Cell viability assays were used to test the biological properties of compounds. TTC-
352, BMI-135, and E4 exhibit a full agonist action, similar to E2, across eight BC cell lines 
that are oestrogen-dependent (MCF-7:WS8, T47D:A18, BT-474, ZR-75-1, and MCF-7:PF), 
oestrogen-independent (MCF-7:5C, MCF-7:2A, and MCF-7:RAL), endocrine-sensitive 
(MCF-7:2A), endocrine-resistant (MCF-7:PF, MCF-7:5C, and MCF-7:RAL), mutant p53 
(T47D:A18), HER2-positive (BT-474), luminal A (ZR-75-1), and luminal B (BT-474).   
The concentration 1 μM for TTC-352, BMI-135, and E4 achieved either the maximal 
cellular growth (P-value < 0.05 compared to vehicle control) (Fig. 2A-E, and Supplementary 
Fig. 1A-C PAP1, and Supplementary Fig. S1A-E PAP2), or the maximal cellular death (P < 
0.05 compared to vehicle control) (Fig. 2F-H, and Supplementary Fig. 1D-F PAP1, and 
Supplementary Fig. S1F-H PAP2). TTC-352, BMI-135, and E4 were shown to be a less 
potent full agonist compared to E2 (Fig. 2 and Table 1 PAP1, and Supplementary Fig. S1 and 
Supplementary Table S2 PAP2). The calculated EC50s are summarized in Table 1 (PAP1) 
and Supplementary Table S2 (PAP2).  
58 
 
In MCF-7:5C, E4 and BMI-135 completely reduced the amount of viable MCF-7:5C 
cells after one week of treatment, in a dose-dependent manner, with a maximum reduction of 
cells by an average of 58% for E4 and 46% for BMI-135, at their highest concentration of 10-6 
M (P < 0.05 compared to vehicle) (Fig. 2F PAP1). Reduction in the amount of viable MCF-
7:5C cells by E2 at 10-9 M was by an average of 58% (Fig. 2F PAP1). TTC-352 completely 
reduced the amount of viable MCF-7:5C cells after one-week of treatment, in a dose-
dependent manner, with a maximum reduction of cells by an average of 50.12% at its highest 
concentration of 10-6 M (p-value < 0.05 compared to vehicle control) (Supplementary Fig. 
S1F PAP2). Reduction in the amount of viable MCF-7:5C cells by E2 at 10-9 M was by an 
average of 76.93% (Supplementary Fig. S1F PAP2). 
In MCF-7:2A, E4 and BMI-135 completely reduced the amount of viable MCF-7:2A 
cells after a 2-week treatment, in a dose-dependent manner, with a maximum reduction of 
cells by an average of 57% for E4 and 50% for BMI-135, at their highest concentration of 10-6 
M (P < 0.05 compared to vehicle) (Fig. 2G PAP1). Reduction in the amount of viable MCF-
7:2A cells by E2 at 10-9 M was by an average of 67% (Fig. 2G PAP1). TTC-352 completely 
reduced the amount of viable MCF-7:2A cells after a 2-week treatment, in a dose-dependent 
manner, with a maximum reduction of cells by an average of 40% at its highest concentration 
of 10-6 M (p-value < 0.05 compared to vehicle control) (Supplementary Fig. S1G PAP2). 
Reduction in the amount of viable MCF-7:2A cells by E2 at 10-9 M was by an average of 
50.18% (Supplementary Fig. S1G PAP2).  
In MCF-7:RAL, E4 and BMI-135 completely reduced the amount of viable MCF-
7:RAL cells after a 3-week treatment, in a dose-dependent manner, with a maximum 
reduction of cells by an average of 45% for E4 and 43% for BMI-135, at their highest 
concentration of 10-6 M (P < 0.05 compared to vehicle) (Fig. 2H PAP1). Reduction in the 
amount of viable MCF-7:RAL cells by E2 at 10-9 M was by an average of 45% (Fig. 2H 
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PAP1). TTC-352 completely reduced the amount of viable MCF-7:RAL cells after a 3-week 
treatment, in a dose-dependent manner, with a maximum reduction of cells by an average of 
45% at its highest concentration of 10-6 M (p-value < 0.05 compared to vehicle control) 
(Supplementary Fig. S1H PAP2). Reduction in the amount of viable MCF-7:RAL cells by E2 
at 10-9 M was by an average of 45.32% (Supplementary Fig. S1H PAP2).  
IIIB. ShERPAs TTC-352 and BMI-135 induce the transcriptional activity of ER similar 
to E2 in WT BC MCF-7:WS8 and apoptotic-type BC MCF-7:5C. 
qRT-PCR was used to assess the transcriptional activity of ERα on oestrogen-
responsive genes (TFF1 and GREB1) with TTC-352 and BMI-135. After 24-hour-treatment 
in MCF-7:WS8, TTC-352 and BMI-135 significantly (P < 0.05) increased the levels of TFF1 
and GREB1 mRNAs compared to vehicle controls (Fig. 3A-B PAP1, and Fig. 2A-B PAP2). 
On the other hand, BPTPE induced a partial increase in the levels of TFF1 and GREB1 
mRNAs, significantly (P < 0.05) less than that of E2, TTC-352 and BMI-135 (Fig. 3A-B 
PAP1, and Fig. 2A-B PAP2). The minimal concentration that produced a complete increase 
in the levels of TFF1 and GREB1 was at 10-6 M for TTC-352 and BMI-135 (P < 0.05 
compared to vehicle control).    
After 24-hour-treatment in MCF-7:5C, TTC-352 and BMI-135 significantly (P < 
0.05) increased the levels of TFF1 and GREB1 mRNAs compared to vehicle controls (Fig. 
3C-D PAP1, and Fig. 2C-D PAP2). On the other hand, BPTPE induced a partial increase in 
the levels of TFF1 and GREB1 mRNAs, significantly (P < 0.05) less than that of E2, TTC-
352, and BMI-135 (Fig. 3C-D PAP1, and Fig. 2C-D PAP2). The minimal concentration that 
produced a complete increase in the levels of TFF1 and GREB1 was at 10-6 M for TTC-352 
and BMI-135 (P < 0.05 compared to vehicle control).   
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The ERE-dependent transcriptional activity with E4 was done by Abot and colleagues 
(Abot et al., 2014), and showed an induction similar to E2, only with a lower potency.  
Overall, the induction of the levels of TFF1 and GREB1 mRNAs by TTC-352 and 
BMI-135 in MCF-7:WS8 and MCF-7:5C is similar to that by full agonist E2, only at a higher 
concentration. 
IIIC. Effects of ShERPAs and E4 are mediated via ERα. 
MCF-7:5C, MCF-7:2A, and MCF-7:RAL representing LTED oestrogen-independent 
BC, were treated with 1 μM E4, 1 μM BMI-135, and a combination of these with 1 μM 4OHT 
and 1 μM endoxifen, to investigate if E4 and BMI-135 exert their function via ERα. In MCF-
7:5C, full oestrogen agonists should cause cellular death within 1 week, antagonists should 
not (i.e., MCF-7:5C is endocrine-resistant), and the agonists’ pairing with the antagonists 
should block the death effect. Indeed, E2, E4, and BMI-135 killed the cells within 1 week (P < 
0.05 compared to vehicle) (Supplementary Fig. 2A PAP1), whereas, 4OHT and endoxifen did 
not (P < 0.05 compared to vehicle) (Supplementary Fig. 2A PAP1). The combination of E2, 
E4, and BMI-135 with 4OHT and endoxifen blocked the death effect (Supplementary Fig. 2A 
PAP1). 
In MCF-7:2A, full agonists should cause cellular death within 2 weeks, antagonists 
should cause growth inhibition (i.e., MCF-7:2A is endocrine-sensitive), and the agonists’ 
pairing with the antagonists should block the death effect. Indeed, E2, E4, and BMI-135 killed 
the cells within 2 weeks (P < 0.05 compared to vehicle) (Supplementary Fig. 2B PAP1), 
whereas, 4OHT and endoxifen caused growth inhibition (P < 0.05 compared to vehicle) 
(Supplementary Fig. 2B PAP1). The combination of E2, E4, and BMI-135 with 4OHT and 
endoxifen blocked the death effect (Supplementary Fig. 2B PAP1).   
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In MCF-7:RAL cells, full agonists should cause cellular death within 2-3 weeks in 
vitro, antagonists, especially the SERM raloxifene (positive control), should cause cellular 
growth, and the agonists’ pairing with antagonists should block the death effect. Indeed, E2, 
E4, and BMI-135 killed the cells within 3 weeks (P < 0.05 compared to vehicle) 
(Supplementary Fig. 2C PAP1), whereas, the SERMs 4OHT, endoxifen and especially 
raloxifene, caused cellular growth (P < 0.05 compared to vehicle) (Supplementary Fig. 2C 
PAP1). The combination of E2, E4, and BMI-135 with 4OHT and endoxifen blocked the 
death effect (Supplementary Fig. 2C PAP1). Interestingly, the SERD ICI caused a decrease in 
cell DNA amount in MCF-7:RAL cells after a 3-week treatment (P < 0.05 compared to 
vehicle) (Supplementary Fig. 1F, and Supplementary Fig. 2C PAP1).     
Endoxifen, the major biologically-active metabolite of TAM, was used as an anti-
oestrogenic control alongside 4OHT, and neither induced a significant increase or decrease in 
viable cells, compared to vehicle control (Supplementary Fig. 2A PAP1). Only in MCF-7:2A 
cells, 4OHT and endoxifen caused growth inhibition (Supplementary Fig. 2B PAP1), and in 
MCF-7:RAL cells, both caused growth stimulation (Supplementary Fig. 2C PAP1), as 
predicted.   
The transcriptional-translational, UPR, and apoptotic effects of TTC-352 were shown 
to be mediated via ERα. The combination of TTC-352 and 4OHT blocked SRC-3 recruitment 
compared to TTC-352 alone treatment (Fig. 9A PAP2); inhibited ERE activation compared to 
TTC-352 alone treatment (Fig. 9B PAP2); blocked the anti-proliferative effects of TTC-352 
alone treatment (Supplementary Fig. S8A-C PAP2); inhibited the PERK UPR pathway 





IIID. Effects of ShERPAs and E4 on ERα regulation in numerous BC models .  
Western blotting and densitometry were used to assess the regulation of ERα protein 
levels with compounds. In MCF-7:WS8, TTC-352 was able to down-regulate the protein 
levels of ERα after 72-hour-treatment, compared to vehicle control, and similar to E2 and E4 
(Model I) (Fig. 3A and Supplementary Table. S3 PAP2). Whereas, BMI-135 seems to have a 
different effect by slightly downregulating ERα’s protein levels by 72 hours, compared to 
vehicle control (Supplementary Fig. S2A and Supplementary Table. S4 PAP2). This down-
regulation is less than that with BPTPE, nonetheless, BMI-135 does not accumulate the 
receptor compared to 4OHT and endoxifen (Supplementary Fig. S2A and Supplementary 
Table. S4 PAP2). This regulation trend with TTC-352, BMI-135, and E4 in MCF-7:WS8 is 
replicated in MCF-7 ATCC (Supplementary Fig. S2B and Supplementary Table. S3 PAP2).  
In T47D:A18, TTC-352 and BMI-135 maintain the protein levels of ERα (Model II), 
compared to vehicle control, and similar to E2 and E4 (Fig. 3B, Supplementary Fig. S2C and 
Supplementary Tables. S3-S4 PAP2). BPTPE, 4OHT, and endoxifen accumulate the receptor 
by 72 hours (Supplementary Fig. S2C and Supplementary Table. S4 PAP2).    
In BT474, TTC-352 down-regulates the protein levels of ERα by 72 hours, compared 
to vehicle control, and similar to E2 and E4 (Model I) (Fig. 3C, Supplementary Fig. S2E, and 
Supplementary Tables. S3-S4 PAP2). Whereas, BMI-135 seems to have a similar trend 
except that the protein levels by 72 hours are similar to vehicle control (Supplementary Fig. 
S2E and Supplementary Table. S4 PAP2). The protein levels are up-regulated by 72 hours 
with BPTPE, and more so with endoxifen and 4OHT (Supplementary Fig. S2E and 
Supplementary Table. S4 PAP2).   
In ZR-75-1, TTC-352 slightly down-regulates the protein levels of ERα after 72-hour-
treatment, compared to vehicle control, and similar to E2 and E4 (Model I) (Fig. 3D, 
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Supplementary Fig. S2D, and Supplementary Tables. S3-S4 PAP2). Whereas, BMI-135 
seems to have a different trend whereby by 72 hours the protein levels become similar to 
vehicle control (Supplementary Fig. S2D and Supplementary Table. S4 PAP2). The protein 
levels are maintained by 72 hours with BPTPE, 4OHT, and endoxifen, compared to vehicle 
control (Supplementary Fig. S2D and Supplementary Table. S4 PAP2).    
In MCF-7:5C, MCF-7:2A, and MCF-7:RAL, TTC-352, BMI-135, and E4 down-
regulate the protein levels of ERα by 72 hours, compared to vehicle control, and similar to E2 
(Model I) (Fig. 3E-G, and Supplementary Fig. S3D-F PAP2). In MCF-7:2A, ER66 and ER77 
proteins levels with BMI-135, TTC-352, and E4 are similarly regulated over time (Model I) 
(Fig. 3F, and Supplementary Fig. S3E PAP2) (Pink et al., 1995). In these cell lines, the 
protein levels are slightly down-regulated with BPTPE, and maintained or accumulated with 
endoxifen, 4OHT, and raloxifene (in MCF-7:RAL) (Supplementary Fig. S3D-F PAP2).    
In LCC1, LCC2 and LCC9, TTC-352, BMI-135, and E4 down-regulate the protein 
levels of ERα by 72 hours, compared to vehicle control, and similar to E2 (Model I) (Fig. 3H-
J, Supplementary Fig. S3A-C, and Supplementary Table. S3 PAP2). In these cell lines, the 
protein levels are down-regulated with BPTPE, and maintained or accumulated with 
endoxifen and 4OHT (Supplementary Fig. S3A-C, and Supplementary Table. S3 PAP2).   
In eleven BC cell lines, TTC-352 regulated the protein levels of ERα in a similar 
manner to E2 (Fig. 3 and Supplementary Table. S3 PAP2), and different from that with 
BPTPE (Supplementary Figs. S2-3, and Supplementary Table. S4 PAP2), and ICI 
significantly down-regulated the protein levels of ERα (Fig. 3, and Supplementary Figs. S2-




IIIE. ShERPAs and E4 induce the transcriptional activity of ERα similar to E2 in human 
endometrial cancer model Ishikawa.  
Transient transfection and luciferase activity assays were used to determine the 
transcriptional activity of ERα on oestrogen-responsive genes (5xERE) with compounds, as 
ERE dual luciferase activity. After 24-hour-treatment of Ishikawa cells, E4 and BMI-135 
increased the levels of 5x-ERE luciferase activity compared to vehicle controls (P < 0.05) 
(Fig. 4A PAP1). On the other hand, the partial agonist BPTPE induced a partial increase in 
the levels of 5x-ERE luciferase activity, and less than that of full agonist E2, E4, and BMI-135 
(P < 0.05), at concentration range of 10-8-10-6 M (Fig. 4A PAP1). The minimal concentration 
that produced a complete increase in the levels of 5x-ERE luciferase activity was at 10-7 M 
for E4 and BMI-135 (P < 0.05 compared to vehicle) (Fig. 4A PAP1).   
To determine if the effects of E4 and BMI-135 are mediated via ERα in Ishikawa cells, 
transiently-transfected Ishikawa cells were treated with test compounds in combination with 
antagonist endoxifen for 24 hours, and luciferase activity assays were conducted (Fig. 4B 
PAP1). The increase in the levels of 5x-ERE luciferase activity with E4 and BMI-135 was 
blocked with endoxifen treatment at 10-6 M (P < 0.05 compared to vehicle) (Fig. 4B PAP1). 
This confirms that E4 and BMI-135 exert their function via Ishikawa’s ERα. In addition, 
endoxifen alone does not increase the levels of 5x-ERE luciferase activity in Ishikawa cells, 
acting as an antagonist in this uterine model (Fig. 4B PAP1).       
Overall, the induction of the levels of 5x-ERE luciferase activity by E4 and BMI-135 





IIIF. ShERPAs and E4 recruit ERα and SRC-3 to the GREB1 proximal enhancer region 
similar to E2 in MCF-7:5C BC model.  
ChIP assays were used to assess the recruitment of ERα and SRC-3 to the GREB1 
proximal enhancer region with test compounds. Oestetrol and BMI-135 treatments resulted in 
a very strong recruitment of ERα to the GREB1 proximal enhancer region similar to E2, and 
higher than that with the partial agonist BPTPE (P < 0.05) (Fig. 5A PAP1).   
Whereas, the recruitments of the coactivator SRC-3 to the GREB1 proximal enhancer 
region with E4 and BMI-135 treatments were higher than that with BPTPE (P < 0.05) (Fig. 
5B PAP1). SRC-3 recruitment with E2 was the highest. With E4, there was an 18.72% 
recruitment reduction compared to E2 ; with BMI-135, there was a 51.17% recruitment 
reduction compared to E2; with BPTPE, there was a 65.47% recruitment reduction compared 
to E2; and with endoxifen, there was a 98.14% recruitment reduction compared to E2 (Fig. 5B 
PAP1).     
Overall, the recruitment of ERα to the GREB1 proximal enhancer region with E4 and 
BMI-135 in MCF-7:5C cells is similar to that by full agonist E2, and the recruitment of SRC-
3 to the GREB1 proximal enhancer region with E4 and BMI-135 in MCF-7:5C cells is higher 
than that with the partial agonist BPTPE. Although SRC-3 recruitment with BMI-135 
treatment is lower than that with E2 (P < 0.05), it is higher than that with BPTPE (P < 0.05). 
TTC-352 treatment resulted in a very strong recruitment of SRC-3 to the GREB1 proximal 
enhancer region (Fig. 9A PAP2).  
IIIG. ShERPAs and E4 activate the UPR.   
Human UPR real-time profiler assays were used to assess the regulation of UPR genes 
with test compounds. Cell viability and proliferation assays showed a decline in MCF-7:5C 
cell DNA amount with E2 and E4 treatments at 72 hours (Fig. 7D PAP1). Furthermore, flow 
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cytometry showed apoptosis at 72 hours (annexin staining 14.8% with E2 and 12.6% with E4 
versus vehicle control 4.5%) (Fig. 7E PAP1). The time point 48 hours, was chosen to 
investigate the terminal (or pro-apoptotic) UPR gene regulation with E2 and E4 treatments in 
MCF-7:5C cells, which precedes apoptosis by 72 hours.     
After 48-hour-treatment with 1 nM E2 and 1 μM E4 (i.e., these concentrations were 
shown earlier to trigger maximal cellular death (Fig. 2 and Table 1 PAP1)), the endoplasmic 
reticulum associated degradation (ERAD) genes (downstream IRE1α/XBP1s and ATF6 p50): 
HTRA4 (p < 0.001), SYVN1 (p < 0.001), and HERPUD1 (p < 0.001), were down-regulated 
(Fig. 7B-C, and Supplementary Fig. 5A-B PAP1). The lipid or cholesterol metabolism genes 
(downstream IRE1α/XBP1s and ATF6 p50): MBTPS1 (p < 0.001) and SERP1 (p < 0.001), 
were down-regulated with E2 treatment, whereas, only MBTPS1 (p < 0.001) with E4 (Fig. 7B-
C, and Supplementary Fig. 5A-B PAP1). The chaperone (chaperones are usually downstream 
IRE1α/XBP1s, PERK/P-eIF2α:ATF4 and ATF6 p50) gene SIL1 (p < 0.001) was down-
regulated with E4 treatment (Fig. 7C, and Supplementary Fig. 5B PAP1). By contrast, the genes 
CEBPB (p < 0.001) and INHBE (p < 0.001), which reflect high UPR stress, were up-regulated 
(Fig. 7B-C, and Supplementary Fig. 5A-B PAP1).    
The heat map of MCF-7:5C cells with E2 and E4 treatments at 48 hours displays a 
general UPR gene downregulation (situated on the right side of the heat map) compared to 
vehicle control (situated on the left) (Fig. 7A PAP1). The majority of the profiler assays’ genes 
belong to the lipid metabolism, ERAD, and chaperone gene groups, which are considered pro-
survival mechanisms that help the cells cope with extrinsic or intrinsic cellular stress (Fig. 9 
PAP1). This general downregulation by 48 hours (Fig. 7B-C, and Supplementary Fig. 5A-B 
PAP1) highlights MCF-7:5C cells’ pro-apoptotic UPR phase and programming to undergo 
apoptosis by 72 hours (Fig. 7E PAP1).      
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Cell viability and proliferation assays showed a decline in MCF-7:5C cell DNA amount 
with BMI-135 treatment by 96 hours (Fig. 8D PAP1). Furthermore, flow cytometry showed 
apoptosis by 96 hours (annexin staining 17.1% with BMI-135 versus vehicle control 5.7%) 
(Fig. 8E PAP1). The time point 72 hours, was chosen to investigate the pro-apoptotic UPR 
gene regulation with BMI-135 treatment in MCF-7:5C cells, which precedes apoptosis by 96 
hours. Another time point 48 hours, was chosen to compare and contrast the UPR gene 
regulation with that by 72 hours, and show how this regulation is dynamic and culminates over 
time.  
After 48-hour-treatment with 1 μM BMI-135, the ERAD genes: EDEM1 (p < 0.001), 
HTRA4 (p < 0.001), SYVN1 (p < 0.001), and HERPUD1 (p < 0.001), were down-regulated 
(Fig. 8C, and Supplementary Fig. 5C PAP1). The lipid metabolism genes: MBTPS1 (p < 0.001) 
and SERP1 (p < 0.001), were down-regulated (Fig. 8C, and Supplementary Fig. 5C PAP1). By 
contrast, the genes CEBPB (p < 0.001) and INHBE (p < 0.001), were up-regulated (Fig. 8C, 
and Supplementary Fig. 5C PAP1). Interestingly, there was a 9.46 fold (p < 0.05) down-
regulation of EIF2AK3 (PERK) (Supplementary Fig. 5C PAP1), which might play a role in 
MCF-7:5C cells’ delayed course of apoptosis with BMI-135 treatment compared to E2 and E4. 
After a 72-hour-treatment with 1 μM BMI-135, there is an intensified (or terminal) UPR gene 
regulation compared to 48 hours, with an up-regulation of CEBPB (p < 0.001), INHBE (p < 
0.001), PPP1R15A (GADD34, p < 0.001), DDIT3 (CHOP, p < 0.001), and ERN1 (IRE1α, p < 
0.001). This is coupled with a down-regulation of the ERAD genes: HTRA4 (p < 0.001), 
SEL1L (p < 0.01), and HERPUD1 (p < 0.001), the chaperone gene HSPA2 (p < 0.001), and 
the lipid metabolism gene MBTPS1 (p < 0.001) (Fig. 8B, and Supplementary Fig. 5D PAP1).    
The heat map of MCF-7:5C cells with BMI-135 treatment at 72 hours (Fig. 8A PAP1) 
displays a general UPR gene downregulation (situated on the right side of the heat map) 
compared to vehicle control (situated on the left). This general downregulation by 72 hours 
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(Fig. 8B, and Supplementary Fig. 5D PAP1) highlights MCF-7:5C cells’ trajectory to undergo 
apoptosis by 96 hours (Fig. 8E PAP1).       
Cell viability and proliferation assays showed a decline in MCF-7:5C cell DNA amount 
with BPTPE treatment by day 8 (Supplementary Fig. 4D PAP1). Furthermore, flow cytometry 
showed apoptosis by day 8 (annexin staining 31.5% with BPTPE versus vehicle control 9.4%) 
(Supplementary Fig. 4E PAP1). The time point day 7, was chosen to investigate the pro-
apoptotic UPR gene regulation, which precedes apoptosis by day 8. Another time point day 3, 
was chosen to compare and contrast the UPR gene regulation with that by day 7, and show how 
this regulation is dynamic and culminates over time.    
After a 3-day-treatment with 1 μM BPTPE, there was a relatively minor UPR gene 
activation compared to the one seen by day 7 (Supplementary Fig. 4B-C, and Supplementary 
Fig. 5E-F PAP1). Interestingly, there was a 2.15 fold (p < 0.001) down-regulation of EIF2AK3 
with 3-day BPTPE treatment (Supplementary Fig. 5E PAP1), which might play a role in MCF-
7:5C cells’ delayed course of apoptosis with BPTPE treatment compared to E2 and E4. This is 
also observed with BMI-135’s early treatment time point (Supplementary Fig. 5C PAP1). After 
a 7-day-treatment with BPTPE, there was a down-regulation of the ERAD gene HERPUD1 (p 
< 0.001), the lipid metabolism genes: INSIG2 (p < 0.001) and MBTPS1 (p < 0.001), and the 
chaperone genes: HSPA2 (p < 0.001) and DNAJB9 (p < 0.001) (Supplementary Fig. 4B, and 
Supplementary Fig. 5F PAP1).    
The heat map of MCF-7:5C cells with BPTPE treatment at day 7 (Supplementary Fig. 
4A PAP1) displays a general UPR gene downregulation (situated on the left side of the heat 
map) compared to vehicle control (situated on the right). This general downregulation by day 
7 (Supplementary Fig. 4B, and Supplementary Fig. 5F PAP1) highlights MCF-7:5C cells’ 
programming to undergo apoptosis by day 8 (Supplementary Fig. 4E PAP1).     
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The statistically-significant regulated UPR genes, with test compounds are stated and 
grouped, at select time points (Fig. 9 PAP1) to show the similar terminal UPR regulation 
preceding apoptosis.   
PERK downstream targets p-eIF2α, ATF4, and CHOP, are up-regulated after 72-hour 
treatment with TTC-352 (Fig. 8B PAP2).   
IIIH. ShERPAs and E4 induce ThT fluorescence as a marker of UPR.  
Thioflavin T was used to detect and quantify the EnR stress or UPR in living cells, as 
it interacts directly with the accumulated misfolded protein amyloid during the UPR (Beriault 
and Werstuck, 2013). The “blue” Hoechst 33342 fluorescent dye was used as a nuclear 
counterstaining dye in MCF-7:5C living cells (channel A), the “green” ThT fluorescent dye 
was used as a UPR-indicative dye (channel B), and a co-localization of ThT and Hoechst 
33342 dyes is shown (channel C).  
17β-oestradiol and E4 were shown to induce ThT fluorescence by 48 hours, like the 
induction seen with positive control thapsigargin (i.e., triggers EnR stress by disrupting EnR 
Ca2 + homeostasis), and compared to vehicle control (Supplementary Fig. 6B PAP1). After 
48-hour treatment, E4 had the highest ThT relative intensity/cell of 1.244892, followed by 
thapsigargin of 0.875072; E2 of 0.741126; and BMI-135 of 0.497225, compared to vehicle 
control of 0.27594 (Table 2A PAP1).    
BMI-135 induces a stronger delayed ThT fluorescence by 72 hours (Fig. 10B and 
Table. 2B), compared to that seen by 48 hours (Supplementary Fig. 6B and Table 2A PAP1). 
The relative intensity/cell with 48-hour BMI-135 treatment was 0.497225, compared to 
vehicle control 0.27594 (Table 2A PAP1). Whereas, the relative intensity/cell with 72-hour 
BMI-135 treatment was 4.878173, compared to vehicle control 0.29573 (Table 2B PAP1). 
The relative intensity/cell over time is represented in Table 2 (PAP1).    
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TTC-352 induced ThT fluorescence by 72 hours compared to vehicle control, and 
somewhat similar to the induction seen with thapsigargin (Fig. 7B PAP2). ThT relative 
intensity/cell for thapsigargin was 3.320555, and 2.025762 for TTC-352, compared to 0.4725 
for vehicle control.     
IIII. ShERPAs and E4 trigger apoptosis in multiple oestrogen-independent and 
endocrine-resistant BC models . 
Flow cytometry was used to assess if the type of stress-induced cell death was 
actually apoptosis, when treated with 1 μM TTC-352, 1 μM BMI-135, and 1 μM E4.  
In MCF-7:5C, 1 μM E4 induces apoptosis (annexin staining 12.6% versus vehicle 
control 4.5%) similar to the time course of 1 nM E2 (annexin staining 14.8% versus vehicle 
control 4.5%) (Fig. 7E PAP1), which is by 72 hours. Whereas, MCF-7:5C’s apoptosis with 
BMI-135 treatment (annexin staining 17.1% versus vehicle control 5.7%) is delayed, by 96 
hours (Fig. 8E representing 96 hours, and Supplementary Fig. 8D representing 72 hours 
PAP1). The antagonist 4OHT (as a negative control), and its pairing with E2, E4 and BMI-
135, do not induce apoptosis by 72 or 96 hours, as predicted (data not shown). TTC-352 
induces apoptosis (annexin staining 22.9% versus vehicle control 6.9%) (Fig. 8A PAP2), 
similar to the time course of 1 nM E2 (annexin staining 23.4% versus control 6.7%) 
(Supplementary Fig. S7A PAP2), which is in 3 days.   
In MCF-7:2A, E4 induces apoptosis (annexin staining 6.7% versus vehicle control 
0.8%) similar to the time course of E2 (annexin staining 8% versus vehicle control 0.8%) 
(Supplementary Fig. 8A PAP1), which is by day 9. Whereas, MCF-7:2A’s apoptosis with 
BMI-135 treatment (annexin staining 7.3% versus vehicle control 2.2%) is delayed, by day 
13 (Supplementary Fig. 8B representing day 13, and Supplementary Fig. 8C representing day 
9 PAP1). The antagonist 4OHT (as a negative control), and its pairing with E2, E4, and BMI-
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135, do not induce apoptosis by day 9 or 13, as predicted (data not shown). TTC-352 induces 
apoptosis (annexin staining 21.2% versus control 2.7%), similar to the time course of E2 
(annexin staining 20.4% versus control 2.7%) (Supplementary Fig. S7B PAP2), which is in 9 
days.    
In MCF-7:RAL, E4 induces apoptosis (annexin staining 7.6% versus vehicle control 
5.3%) similar to the time course of E2 (annexin staining 9% versus control 5.3%) 
(Supplementary Fig. 9A PAP1), which is by day 14. Whereas, MCF-7:RAL’s apoptosis with 
BMI-135 (annexin staining 8% versus control 0.8%) is delayed, until day 17 (Supplementary 
Fig. 9B representing day 17, and Supplementary Fig. 9C representing day 14 PAP1). The 
antagonists 4OHT and raloxifene, and their pairing with E2, E4, and BMI-135, do not induce 
apoptosis by day 14 or 17, as predicted (Supplementary Fig. 9A PAP1). Interestingly, 
treatment of MCF-7:RAL cells with ICI for 3 weeks caused a significant decline in cell DNA 
amount (Supplementary Fig. 2C PAP1), however, this is not due to apoptosis (Supplementary 
Fig. 9D PAP1). Such observed effect of ICI in MCF-7:RAL could be attributed to growth 
inhibition by preventing cell replication. TTC-352 induces apoptosis (annexin staining 8.4% 
versus control 1.5%), similar to the time course of E2 (annexin staining 9.1% versus control 
1.5%) (Supplementary Fig. S7C PAP2), which is in 14 days.  
IIIJ. Inhibition of UPR PERK pathway blocks apoptosis in MCF-7:5C with ShERPAs 
and E4 treatments . 
Blocking the UPR transducer PERK with 10 μM GSK G797800 in combination with 
1 nM E2, and in combination with 1 μM E4 by 72 hours, inhibited apoptosis (annexin staining 
7.8% and 7.9%, respectively, versus vehicle control 7%) (Supplementary Fig. 7A PAP1), 
compared to E2 and E4 alone treatments that trigger apoptosis (Fig. 7E PAP1), and compared 
to the negative control GSK G797800 alone treatment that does not trigger apoptosis 
(annexin staining 5.7% versus vehicle control 7%) (Supplementary Fig. 7A PAP1).  
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Blocking PERK with 10 μM GSK G797800 in combination with 1 μM BMI-135 by 
96 hours, inhibited apoptosis (annexin staining 4% versus vehicle control 5.7%) (Fig. 11A 
PAP1), compared to BMI-135 alone treatment that triggers apoptosis (Fig. 11A PAP1), and 
compared to GSK G797800 alone treatment (annexin staining 5.5% versus control 5.7%) 
(Fig. 11A PAP1).  
Blocking PERK with 10 μM GSK G797800 in combination 1 μM TTC-352 by 72 
hours, inhibited apoptosis (annexin staining 6.9% versus control 6.9%) (Fig. 8A PAP2), 
compared to TTC-352 alone treatment (Fig. 8A PAP2) (annexin staining 22.9% versus 
vehicle control 6.9%), and compared to 10 μM GSK G797800 alone treatment (annexin 
staining 8.3% versus control 6.9%) (Fig. 8A PAP2).   
PERK downstream targets p-eIF2α, ATF4, and CHOP as well as apoptosis target 
cleaved PARP, are up-regulated after 72-hour treatment with TTC-352, whereas, the addition 
of GSK 797800 completely inhibits this UPR/apoptosis effect (Fig. 8B PAP2).   
IIIK. Inhibition of UPR IRE1α:XBP1s pathway enhances apoptosis in MCF-7:5C with 
ShERPAs and E4 treatments .   
Inhibiting the UPR transducer IRE1α, by inhibiting basal XBP1 splicing, with 20 μM 
MKC-3946 in combination with 1 μM E4 by 72 hours, induces more apoptosis (annexin 
staining 34.1% versus control 1.4%) (Supplementary Fig. 7B PAP1), compared to E4 alone 
treatment that triggers apoptosis (annexin staining 18.6% versus control 1.4%) 
(Supplementary Fig. 7B PAP1), and compared to MKC-3946 alone treatment that triggers 
apoptosis (annexin staining 8.8% versus control 1.4%) (Supplementary Fig. 7B PAP1). 
 Blocking IRE1α with 20 μM MKC-3946 in combination with 1 μM BMI-135 by 96 
hours, induces more apoptosis (annexin staining 33.3% versus control 1.4%) (Fig. 11B 
PAP1), compared to BMI-135 alone treatment (annexin staining 26.5% versus control 1.4%) 
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(Fig. 11B PAP1), and compared to MKC-3946 alone treatment (annexin staining 8.8% versus 
control 1.4%) (Fig. 11B PAP1).   
Blocking IRE1α with 20 μM MKC-3946 in combination with 1 μM TTC-352 by 72 
hours, enhanced apoptosis (annexin staining 35.5% versus vehicle control 1.4%) (Fig. 8C 
PAP2), compared to TTC-352 alone treatment (annexin staining 27.9% versus vehicle control 
1.4%) (Fig. 8C PAP2), and compared to 20 μM MKC-3946 alone treatment (annexin staining 
8.8% versus vehicle control 1.4%) (Fig. 8C PAP2).  
   IRE1α downstream target XBP1s (or spliced XBP1) is up-regulated after 72-hour 
treatment with TTC-352, whereas, the addition of MKC-3946 inhibits this splicing effect 
(Fig. 8D PAP2).   
IV. Discussion 
Oestetrol is a naturally-occurring fetal oestrogen, which is associated with a low risk 
of drug-drug interactions (CYP450 family), and a neutral impact on risk markers of venous 
thromboembolism unlike E2 (Bennink et al., 2017, Singer et al., 2014, Verhoeven et al., 
2018). TTC-352 and BMI-135 are members of a new class of oestrogen mimics, which did 
not cause significant uterine proliferation (Molloy et al., 2014, Xiong et al., 2016). Oestetrol 
and the ShERPA TTC-352 are currently being evaluated in endocrine-resistant MBC clinical 
trials (Dudek et al., 2020, Schmidt, 2020). This work reports: (i) the structural studies of E4 
and ShERPAs (Fig. 6 PAP1, and Figs. 5-6 PAP2), including the X-ray crystallography of 
TTC-352:mutant ER with clinical implications given that the majority of MBC patients 
harbor ER mutations  (Fig. 5G-I PAP2) (Niu et al., 2015, Pejerrey et al., 2018, Toy et al., 
2013b); (ii) the molecular mechanisms of E4 and TTC-352’s BC regression in LTED patients 
(Figs. 7-12, Supplementary Fig. 5B and 5D, and Supplementary Figs. 6-9 PAP1, and Figs. 7-
10 PAP2); and (iii) the key interactions at the molecular and atomic levels of the benchmark 
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partial agonist BPTPE:WT ER, involving Asp351 and H12 (Fig.6B-C PAP2), which explains 
the reduced E2-enriched coactivator binding (Fig. 5B PAP1, and Fig. 4A PAP2), and delayed 
ERα-induced UPR and apoptosis compared to TTC-352 (Supplementary Fig. 4 PAP1, and 
Figs. 7-8 PAP2).                 
Our earlier pharmacological studies classified ER binding ligands into agonists, 
partial agonists, and antagonists (Jordan and Lieberman, 1984), and complimented the 
subsequent X-ray crystallography studies of the agonist and antagonist ER complexes of the 
LBD (Brzozowski et al., 1997, Shiau et al., 1998b). Our earlier biological studies described 
E2-induced apoptosis (Jordan, 2015b). Current studies, in a wide range of biologically-
different human BC cell models as well as a human endometrial cancer cell model, shows 
TTC-352, BMI-135, and E4 to be weak full oestrogen agonists (Figs. 2-6, Supplementary Fig. 
S1, and Supplementary Table. S2 PAP2, and Figs. 2-5, and Fig. 6B and 6F PAP1), with the 
induction of terminal UPR and apoptosis as their anti-tumour mechanism of action (Figs. 7-
10, and Supplementary Fig. S7B-C PAP2, and Figs. 7-12, and Supplementary Figs. 5-9 
PAP1). Although BMI-135 exhibits a slightly delayed UPR-and-apoptosis biology compared 
to E2 and E4 (Figs. 7-8, Figs. 9-11, and Supplementary Figs. 6-9 PAP1), it is still distinct from 
the much delayed UPR-and-apoptosis biology of the benchmark partial agonist BPTPE 
(Supplementary Fig. 4 PAP1).        
This research area is of particular importance given that BC is projected to double by 
2030 than it was in 2011 (Rosenberg et al., 2015). The majority will be ER-positive with a 
high risk of recurrence, even with clinically low-risk disease (T1N0) (Schroeder et al., 2017). 
Moreover, treated metastases often harbor private ‘driver’ mutations, compared to untreated 
metastases (Hu et al., 2020). In the case of ER-positive HER2-negative BC, metastases 
treated with endocrine therapy, acquire somatic single-nucleotide variants (Toy et al., 2013b). 
This highlights the need to evaluate and develop new rapidly-acting BC therapeutics such as 
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oestrogens. The recent long-term follow-up results of the WHI Trials (Jordan, 2020) reaffirm 
the clinical potential of novel and safe oestrogenic therapy in significantly reducing BC 
incidence and mortality in LTED patients.   
 The application of long-term adjuvant endocrine therapy (Jordan et al., 1979), to treat 
ER-positive BC, is invaluable for patient care. As a result, women’s lives are extended or 
saved (Early Breast Cancer Trialists' Collaborative Group, 1998, Goss et al., 2003a, Goss et 
al., 2005). Nonetheless, recurrence of endocrine-resistant stage IV BC is common (Pisani et 
al., 2002), hence the discovery of new therapeutic options remains a clinical priority.   
Cell models (Liu et al., 2003, Pink et al., 1995, Ariazi et al., 2011, Fan et al., 2014, 
Lewis et al., 2005b), and athymic mice models (Gottardis and Jordan, 1988, Gottardis et al., 
1989b, Yao et al., 2000, Gottardis et al., 1989a), deciphered the evolution of acquired TAM 
resistance over years to eventually give rise to a vulnerability in BC: E2-induced apoptosis 
(Jordan, 2008, Jordan, 2015b). Although oestrogen is approved to treat BC, there is a 
reluctance to use oestradiol as a salvage therapy (in stage IV BC), because of AEs. As a 
result, safer oestrogenic alternatives are being considered.      
First, the actions of E4 and BMI-135 were compared and contrasted with those of the 
well-characterized partial agonist BPTPE. Current study shows that E4, and BMI-135:ERα 
complexes initiate and modulate the UPR (Figs. 7-12, and Supplementary Figs. 5-7 PAP1). 
This is an ERα-mediated (Supplementary Fig. 2 PAP1) activation of the unfolded proteins’ 
synthesis, and thus of cellular stress.       
  The intrinsic activity of the ER complex was evaluated by comparing and 
contrasting TFF1 and GREB1 oestrogen-regulated gene activation with E2, BMI-135, 
BPTPE, and endoxifen treatments in WT MCF-7 and LTED MCF-7:5C cells (Fig. 3 PAP1). 
The pharmacology of each ligand as a full agonist (E2, E4, and BMI-135), or a partial agonist 
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(BPTPE), or an antagonist with no intrinsic activity (endoxifen), mirrored the pharmacology 
in cells (Fig. 2 PAP1).      
Molecular modeling studies demonstrated that E4, BMI-135, and BPTPE bind to the 
classical agonist conformation of ERα, similar to E2 (Fig. 6A, 6C, and 6E PAP1). The 
flexible docking and MD simulations, performed for BMI-135:ERα complex, show the 
dynamic profile of the system to be similar to E2 (Supplementary Fig. 3A PAP1); with the 
ligand firmly bound to the active site (Supplementary Fig. 3B PAP1). Although BMI-135 is 
larger than E2, the same contacts have been observed, with the notable exception of the H-
bond to His524 (Fig. 6B PAP1). These H-bonds and hydrophobic contacts are stable for both 
ligands, with slightly larger frequencies of occurrence with E2 (Supplementary Fig. 11A-B 
PAP1), which indicates a stronger binding mode of E2. BPTPE exhibits equivalent binding 
contacts to E2 (Fig. 6C-D PAP1), but forms a distinctive robust H-bond with Thr347 
(Supplementary Fig. 11C PAP1), which induces the stability of the ligand binding, but 
increases the mobility of H12 and the loop connecting H11 and H12, which affects the 
overall stability of the system. This is most likely responsible for the partial agonist profile of 
BPTPE. These data support the molecular classification of E4 and BMI-135 as full agonists, 
and further explain their observed biological behavior.     
A comparison of E4, BMI-135, and BPTPE in multiple WT and LTED BC cell lines 
(Fig.2 and Supplementary Fig. 1 PAP1) demonstrates the partial agonist actions of BPTPE on 
both growth (Fig. 2A-E, Fig. 3A-B, and Supplementary Fig. 1A-C and 1F PAP1) and E2-
induced apoptosis (Fig. 2F-H, Fig. 3C-D, and Supplementary Fig. 4D-E PAP1). All 
experiments used BPTPE as a well-characterized partial agonist (Jordan and Lieberman, 
1984), which triggers delayed E2-induced apoptosis in LTED BC cells, compared to E2 
(Obiorah et al., 2014, Obiorah and Jordan, 2014) (Supplementary Fig. 4E PAP1). The 
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mechanism is shown here to be through a delay in the induction of the pro-apoptotic UPR 
signaling (Supplementary Fig. 4B-C, and Supplementary Fig. 5E-F PAP1).  
Delayed apoptosis with BPTPE (contains a free para-hydroxyl on the phenyl ring) 
mirrors the delayed apoptosis with the synthesized angular triphenylethylene (TPE) 
derivative 3OHTPE (contains the free para-hydroxyl) (Maximov et al., 2020). The other 
synthesized TPE derivative Z2OHTPE, does not contain the free para-hydroxyl, and causes 
early apoptosis, similar to E2 (Maximov et al., 2020). This free para-hydroxyl in BPTPE and 
3OHTPE, is part of the anti-oestrogenic side chain of endoxifen, which prevents the complete 
closure of ERα’s H12 over the ligand:LBD (Supplementary Fig. 11C PAP1). This delays the 
coactivators’ recruitment to the ER to form a transcriptionally-active complex (Fig. 5B 
PAP1), which delays the ligand:ERα–induced transcription and translation of the unfolded 
proteins, resulting in delayed apoptosis (Supplementary Fig. 4 PAP1).          
Although BMI-135 does not exhibit the pharmacology of BPTPE (Figs. 2-5, Fig. 6A-
B, and Table 1 PAP1), there is still a slight delay in the induction of the terminal UPR 
signaling and apoptosis, which is mediated by the BMI-135:ERα complex (Fig. 8B-C and 8E 
versus Supplementary Fig. 8D, Fig. 10B versus Supplementary Fig. 6B, Supplementary Fig. 




Figure 17 | Schematic representation of the first paper’s concluded anti-tumour molecular 
mechanisms of E4, BMI-135, and BPTPE in LTED endocrine-resistant BC MCF-7:5C. 
Oestetrol:ERα complex recruits the most co-activator SRC-3 and thus induces the most accumulation 
of unfolded proteins (highest threshold of stress), followed by BMI-135:ERα (BMI-135 is referred to 
as BMI in the illustration), and BPTPE:ERα (BPTPE is referred to as BP in the illustration). This 
differential ligand:ERα:coactivator-induced endoplasmic reticulum stress activates the transducers of 
the UPR, with a down-regulation of chaperons, ERAD, and lipid metabolism genes and proteins (P < 
0.05), which are considered pro-survival mechanisms. This down-regulation state constitutes the pro-
apoptotic UPR phase, which is reached quickly with E4, followed by BMI-135, and BPTPE, and 
eventually induces apoptosis.       
The ChIP assay (Fig. 5 PAP1) is valuable to understand the delayed apoptotic biology 
with BMI-135 and BPTPE. Earlier studies (Obiorah et al., 2014, Sengupta et al., 2013) 
demonstrated a reduction in the binding of the BPTPE:ERα:SRC-3 complex, using the ChIP 
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assay in MCF-7 cells, which is reproduced here (Fig. 5A-B PAP1). A reduced DNA binding 
of the partial agonist complex occurs, which correlates with a reduction in the efficacy of the 
complex to synthesize misfolded or unfolded proteins, hence with a delay in the induction of 
the terminal UPR and apoptosis, compared to E2 (Supplementary Fig. 4 PAP1). Although 
BMI-135 recruits equivalent quantities of ERα (Fig. 5A PAP1), there is a reduced recruitment 
of the coactivator SRC-3, compared to E2 and E4. Nonetheless, BMI-135:ERα’s recruitment 
of SRC-3 is significantly higher than that with BPTPE (Fig. 5B PAP1). This correlates with 
BMI-135’s slightly delayed induction of the terminal UPR and apoptosis (Fig. 8 PAP1).     
The significant down-regulation of the pro-survival mechanisms: chaperones, ERAD, 
and lipid metabolism genes, alongside the significant up-regulation of marker UPR stress 
proteins (INHBE and CEBPB), constitute the terminal/pro-apoptotic UPR phase, and 
underscores the anti-tumour mechanism of E2, E4, BMI-135, and BPTPE (Figs. 7-9, Fig.12, 
and  Supplementary Figs. 4-5 PAP1).   
Apoptosis with E4 and BMI-135 treatments was prevented by blocking the PERK 
pathway (Fig. 11A and Supplementary Fig. 7A PAP1). By contrast, blocking the 
IRE1α:XBP1s pathway, following E4 and BMI-135 treatments, enhanced apoptosis (Fig. 11B 
and Supplementary Fig. 7B PAP1). These data demonstrate the modulation of apoptosis with 
E4 and BMI-135 through the modulation of UPR’s subcellular sensors.   
The timing of UPR-indicative ThT fluorescence with E4 and BMI-135 is synchronic 
with that of their significant pro-apoptotic UPR gene regulation. The ThT fluorescence and 
terminal UPR gene regulation were shown to be by 48 hours with E2 and E4 (before apoptosis 
by 72 hours); by 72 hours with BMI-135 (before apoptosis by 96 hours), and by day 7 with 
BPTPE (before apoptosis by day 8) (Figs. 7-8, Fig. 10B, Supplementary Figs. 4-5, 
Supplementary Fig. 6B, and Table 2 PAP1).   
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Our earlier translational research (Gottardis et al., 1988) identified a potential link 
between TAM treatment and the occurrence of endometrial cancer in patients (Jordan and 
Assikis, 1995). Raloxifene does not have an increased risk of endometrial cancer in clinical 
trials (Cummings et al., 1999, Vogel et al., 2006). BMI-135 is a raloxifene derivative (Fig. 1 
PAP1) (Xiong et al., 2016), and was tested to determine whether the ShERPA BMI-
135:ER:coregulators complex is an agonist, in the human endometrial cancer cell line 
Ishikawa transfected with 5x-ERE (Fig. 4 PAP1). BPTPE exhibited a partial agonist activity 
(Fig. 4A PAP1), but both E4 and BMI-135 exhibited a weak full agonist activity compared to 
E2 (Fig. 4A PAP1). This effect is mediated via the Ishikawa ERα (Fig. 4B PAP1). Although 
BMI-135 was shown not induce uterine growth in a mouse xenograft model (Xiong et al., 
2016), based on this study’s observations, it would be wise to require an endometrial 
screening for BC patients receiving E4 or BMI-135.    
Raloxifene induces acquired resistance as evidenced by SERM-stimulated BC cell 
growth (Liu et al., 2003, Balaburski et al., 2010) (Fig. 2H, Supplementary Fig. 1F and 
Supplementary Fig. 2C PAP1). Such laboratory data has clinical significance, as a case report 
of an anti-oestrogen withdrawal effect with raloxifene, was reported (Lemmo, 2016). 
Raloxifene-resistant BC-stimulated growth has not been widely-reported during the decades 
of treatment in patients with osteoporosis. This is surprising, but perhaps clinicians have not 
been aware of this form of SERM resistance. Nevertheless, our findings here (Supplementary 
Fig. 9A-B PAP1) suggest that E4 or a ShERPA could be deployed, after raloxifene 
discontinuation, to induce tumour regression; through apoptosis in raloxifene-resistant BC. 
Furthermore, ICI could be deployed, as we have shown here that it has a growth inhibitory 
effect (Supplementary Fig. 1F, Supplementary Fig. 2C, and Supplementary Fig. 9D PAP1).      
Second, the actions of TTC-352 were compared and contrasted with those of the well-
characterized partial agonist BPTPE. MD simulations and MM-GBSA calculations for WT 
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ERα in complex with TTC-352, E2, and BPTPE are valuable methodologies to discover key 
ligand-receptor interactions, which aids the pharmacological classification of TTC-352. Most 
importantly, they identify key structural components of oestrogenic therapeutics that ensure 
the appropriate closure of the ERα LBD by H12 in LTED BC. This closure is a prerequisite 
for the activation of ERE-mediated UPR and apoptosis, which is the basis of their anti-
tumour properties.  
The H-bond of TTC-352’s benzothiophene scaffold to Glu353, followed by the H-
bond to His524, are the most stable contacts contributing to the binding mechanism of TTC-
352, which are also the two binding features specific for the oestrogenic activity of E2 (E2’s A 
ring to Glu353) (Fig. 6A-B PAP2). Such strong H-bond between TTC-352 and Glu353, 
induces stability in the LBD and, consequently, to H3. This supports the formation of the H-
bonds between the side-chain of Asp351 (H3) to the backbone of Leu539 and Leu540 (H12), 
which stabilizes H12 in the full-agonist conformation (Fig. 5C PAP2). Such LBD-stabilizing 
network of H-bonds is preserved with TTC-352, but more so with E2, which explains the 
altered potency of TTC-352:ERα compared to E2:ERα. By contrast, BPTPE’s binding 
mechanism is governed by the H-bond of BPTPE’s angular phenolic OH to Thr347, followed 
by the hydrophobic contacts, and a significantly weaker H-bond to Glu353 (Fig. 5E and Fig. 
6C PAP2). Although the H-bond between BPTPE’s angular phenolic group and Thr347 
stabilizes its binding, it disturbs the H-bond network within H3 and the stabilizing H-bonds to 
H12 (i.e., Asp351 to Leu 539 and Leu540). As a result, H12 is prevented from adopting the 
proper orientation specific for the ER full-agonist conformation (Fig. 5F PAP2). This is 
consistent with BPTPE’s reduced recruitment of coactivators (Fig. 4A PAP2), and our 
previous reports of its delayed activation of ERα-induced UPR and apoptosis as well as its 
functional modulation from a partial agonist (3OHTPE) to a full agonist (Z2OHTPE) by the 
removal of the para-phenol substitution (Maximov et al., 2020).   
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Both, Asp351 and H12, play a critical role in modulating the oestrogenic and anti-
oestrogenic intrinsic efficacy of the ligand-ER complex. The natural mutation Asp351Tyr 
was discovered; overexpressed in TAM-stimulated MCF-7 tumours grown in athymic mice 
(Wolf and Jordan, 1994). The molecular pharmacology of the WT ER (Jiang and Jordan, 
1992) and Asp351Tyr ER (Catherino et al., 1995) was established by stable transfection into 
ER-negative MDA-MB-231 BC. Unexpectedly, Asp351Try ER converted the raloxifene:WT 
Asp351 ER complex from anti-oestrogenic to oestrogenic (Levenson et al., 1997). 
Subsequent X-ray crystallography of the raloxifene:ER LBD (Brzozowski et al., 1997), 
demonstrated the critical role of the anti-oestrogenic side chain containing a piperidine ring N 
to shield and neutralize Asp351, which prevented the closure of H12, and the subsequent 
ERE activation. Subsequent interrogation of the structural modulation of raloxifene and its 
interactions with Asp351, demonstrated how Asp351 modulates the oestrogenic and anti-
oestrogenic efficacy of the ligand-ER complex (Liu et al., 2002).     
ESR1 somatic mutations, Y537S and D538G, stabilize ERα in the agonist state, and 
are linked to acquired resistance to endocrine therapies (Fanning et al., 2016). Mutations 
Tyr537Ser and Asp538Gly were most prevalent in BC metastases (Toy et al., 2013b), 
especially AI-resistant BC patients. These mutations improve the closure of H12 over ERα’s 
LBD, through interacting with Asp351, and recruiting coactivators in the absence of 
oestrogen, which increases the oestrogen-like properties of the complex (Toy et al., 2013b).       
ERE DNA pull downs and MS are valuable methodologies to determine if TTC-352 
has an ERα:coactivators’ binding profile of a full or partial agonist, and better understand 
why the TTC-352:ERα:coactivators’ complex in the LTED endocrine-resistant MCF-7:5C is 




In MCF-7:WS8 BC, TTC-352 and BMI-135 are different from BPTPE in terms of 
NCOA1-2 (or SRC1-2) and MED subunit recruitments, with NCOA3 (or SRC-3) not being 
readily-enriched with either ShERPAs compared to E2 and E4 (Fig. 4A PAP2). BPTPE did 
not recruit many of the E2-enriched coactivators, and only a subset of endoxifen-enriched 
coregulators (Fig. 4A PAP2). In MCF-7:5C BC, TTC-352 and BMI-135 recruited NCOA3 
and KMT2D at much lower levels than E2 and E4, with TTC-352 recruiting more MED 
subunits than E2, while BMI-135 displaying shared MED subunit recruitment with E4 (Fig. 
4A PAP2). BPTPE did not have much of coactivator binding (Fig. 4A PAP2).    
TTC-352’s differential recruitment of MED subunit types alongside their differential 
enrichment levels, could explain its ability to cause a higher threshold of stress of ER-
mediated unfolded proteins (Fig. 9 PAP2) followed by earlier apoptosis, compared to that 
with BMI-135 (Fig. 10A PAP2). In MCF-7:5C, NCOA3, KMT2D, and many MEDs 
(especially MED12-16 and MED23) are recruited to ERα with TTC-352, compared to E2, but 
these coactivators are reduced upon the treatment of MCF-7:WS8 with TTC-352 
(Supplementary Table. S5 PAP2). TTC-352’s higher recruitment of major ER coactivators in 
MCF-7:5C, compared to MCF-7:WS8, can explain its ability to cause a high threshold of 
stress of ER-mediated unfolded proteins followed by apoptosis; making it phenotypically 
apoptosis-promoting, versus the growth-promoting MCF-7:WS8 (Fig. 10B PAP2).  The 
altered recruitment patterns of major ER coactivators for transcriptional activation, with 
TTC-352, BMI-135, and E4, in comparison to the levels promoted by E2 or BPTPE, can better 




Figure 18 | Schematic representation of the second paper’s conclusions highlighting major ER 
coactivator-binding differences in MCF-7:5C between E2, E4, ShERPAs, and BPTPE, and with 
ShERPA TTC-352 between WT MCF-7:WS8 and LTED endocrine-resistant MCF-7:5C BC. A) 
E2, E4, ShERPA BMI-135, ShERPA TTC-352, and BPTPE major ER coactivators’ recruitment, and 
anti-tumour molecular mechanism in MCF-7:5C. E2:ERα and E4:ERα complexes mainly recruit 
NCOA3, KMT2D, and many of the same MEDs, and induce a high threshold of stress; through the 
synthesis of unfolded and/ or misfolded proteins, leading to rapid apoptosis. TTC-352 (referred to as 
TT in the illustration) recruited more MED subunits than E2, but less NCOA3 and KMT2D than E2 
and E4, with a similar threshold of stress and timing of apoptosis to E2 and E4. BMI-135 (referred to as 
BM in the illustration) recruited less NCOA3 and KMT2D than E2 and E4, and shared MED subunit 
recruitment with E4, which generated a lower threshold of stress and delayed apoptosis (Abderrahman 
et al., 2020) compared to E2, E4, and TTC-352. BPTPE (referred to as BP in the illustration) did not 
have much of a coactivator-recruitment, which generates a very low threshold of stress and a much 
more delayed course of apoptosis (Abderrahman et al., 2020) compared to E2, E4, TTC-352, and BMI-
135. This differential ligand:ERα:coactivator-reucitment-and-induced EnR stress, sets the therapeutics 
apart, in terms of the timing of activating the UPR, followed by inducing apoptosis. The box (in gray) 
highlights the observed recruitment patterns: thick arrow (in red) represents relatively more 
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recruitment, thin arrow (in burgundy) is relatively less recruitment, thin arrow (in burgundy with 
green border) is shared subunit recruitment, and thin arrow (in blue) is no recruitment. B) TTC-352’s 
paradoxical effect in WT growth-inducing BC MCF-7:WS8 versus LTED apoptosis-inducing BC 
MCF-7:5C. NCOA3, KMT2D, and many MEDs (especially MED12-16 and MED23) are recruited to 
ER, in MCF-7:5C treated with TTC-352 (thick arrow in maroon), compared to E2, but these same 
coactivators are reduced upon the treatment of MCF-7:WS8 with TTC-352 (thin arrow in rose). This 
differential ligand:ERα:coactivator-reucitment-and-induced EnR stress, phenotypically sets the two 
BC models apart.   
Our MD simulations data complements the MS data whereby the dynamics of H12 
orchestrate ER’s coactivator-mediated transcriptional activity. In the agonist complex 
structure, H12 forms one side of a hydrophobic coactivator binding pocket, which allows the 
recruitment of an LXXLL motif present in many transcriptional cofactors (Shiau et al., 2002). 
This is, especially, true with SRC1-3 that possess three LXXLL motifs, two of which bridge 
across the ER dimer (at least for an extended polypeptide containing all three motifs), which 
accounts for the 100-fold higher affinity relative to the single LXXLL-containing peptide 
(Nolte et al., 1998). The overexpression of SRC-3 is observed in over 50% of BCs, and leads 
to constitutive ER-mediated transcriptional activity in the agonist conformation, conferring 
endocrine-resistance in preclinical models and in patients treated with TAM (Osborne et al., 
2003b). E2, E4, TTC-352, and BMI-135 in complex with ERα, yield an agonist conformation 
of the ligand-ER complex (Figs. 5-6 PAP2), and, subsequently, recruit more coactivators 
(Fig. 4A PAP2), opposite to BPTPE. H12 acts as a molecular switch with the contribution of 
those H-Bond networks (Fig. 6 PAP2) and such coactivators (Fig. 4A PAP2).          
Current study demonstrates that the structure-function model of the synthetic 
oestrogen mimic TTC-352 is a less potent full oestrogen agonist compared to E2, allowing 
H12 to seal the LBD, which recruits many E2-enriched coactivators, and induces rapid ERα-
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mediated UPR and apoptosis. This contradicts the model of the benchmark partial agonist 
BPTPE, not allowing H12 to seal the LBD properly, which does not recruit many E2-enriched 
coactivators, and induces delayed ERα-mediated UPR and apoptosis. These data suggest that 
BC patients would potentially benefit more from full agonists like TTC-352 rather than 
partial agonists, because of BPTPE’s delayed UPR-apoptotic effect. A partial agonist with 
delayed apoptosis might create a higher probability of tumour clonal evolution and acquired-
resistance (Rodriguez-Brenes and Wodarz, 2015).  
Overall, the results of current studies support the continuation of future clinical trials 
with the new agents TTC-352 and E4, and, most importantly, provide a structural, 
pharmacological, and mechanistic guide for the future design of effective oestrogenic agents 
to treat advanced BC –that is, BC ERα-targeted full oestrogen agonist molecules whose 
structure facilitates Asp351-to-H12 interaction; ensuring the closure of H12 over the LBD, 
recruiting E2-enriched coactivators, and triggering a rapid UPR and apoptosis, to kill off the 
tumour cells.    
V. Progress and Promise  
Based on the findings of this body of work, the design of a future safer and effective 
new generation of oestrogenic agents, should be geared towards using a full oestrogen agonist 
(i.e., E4 and TTC-352), not a partial oestrogen agonist (i.e., BPTPE) (Figure. 19). This is 
based upon the findings of my thesis that a partial agonist is associated with a delayed ERα-
mediated UPR and apoptosis in LTED BC, compared to full agonists. This, in turn, increases 




Figure 19 | Schematic representation of the structural nuances between the test ligands, and how 
that influence the Asp351-to-H12 interaction, and subsequently coactivator recruitment, and 
UPR and apoptosis induction.   
Second, future oestrogenic agents should be planar (not angular) in their structural 
design, with the preservation of the active phenolic hydroxyl (on the A ring of the steroid 
structure of E2 and E4, or the benzothiophene scaffold of BMI-135 and TTC-352). Such 
active phenolic hydroxyl guarantees the H-bond with Glu353 that allows for the Asp351-to-
H12 interaction. In addition, the preservation of another active phenolic hydroxyl (on the D 
ring of the steroid structures of E2 and E4, or the benzene ring of TTC-352 [compared to its 
absence in BMI-135 and BPTPE]) would guarantee yet another stabilizing H-bond to His524 
that allows for the Asp351-to-H12 interaction. These two H-bonds that ensure the Asp-351-
to-H12 interaction, result in the recruitment of E2-enriched coactivators, and thus the rapid 
induction of the UPR and apoptosis aimed at tumour regression (compared to their delay with 
BMI-135 and BPTPE).  
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Third, future oestrogenic agents should be designed to target the nuclear ERα (not 
membrane ERα), as E4 does. This allows for the avoidance of venous thromboembolism-
related AEs.  
Fourth, future oestrogenic agents (with a structural design similar to E4 or TTC-352), 
can potentially be effective for the treatment of endocrine-resistant MBC patients with both 
WT, and mutant-type ERα. This is based on my papers’ findings upon modeling my test 
ligands with WT and mutant ERα, which would yield an Asp351-to-H12 interaction that 
results in the induction of the UPR and apoptosis in LTED BC. In the case of the mutant-type 
ERα, oestrogenic agents (similar to E4 or TTC-352) would introduce an additional H-bond 
with Glu353 and/ or His524 that facilities the Asp351-to-H12 interaction (other than the H-
bond between 537S/G and Asp351). The presence of the ligand and the associated additional 
stabilizing H-bond network, hypothetically allows for the recruitment of numerous E2-
enriched coactivators. This, in turn, leads to the massive translation of unfolded proteins, and 
the subsequent induction of the UPR and apoptosis in LTED BC. This effect is unlike the 
presence of a single H-bond between 537S/G and Asp351, which although it facilitates the 
Asp351-to-H12 interaction, it doesn’t necessarily allow for the recruitment of many E2-
enriched coactivators and, as a result, would induce a translational-directed growth, instead of 
a translational-directed apoptosis (via the UPR). Overall, such agents could potentially be 
effective in converting the growth-promoting mutant ER BC phenotype into an apoptosis-
promoting mutant ER BC phenotype, other than already being apoptosis-promoting in WT 
ER BC phenotype.  
Lastly, resistance to AIs is associated with ER point mutations, while resistance to 
tamoxifen is associated with SRC3 overexpression. Based on that fact and the fourth point 
above, one could speculate that SRC3-overexpressing, growth-promoting, endocrine-resistant 
BC phenotype could be converted to an SRC3-overexpressing, apoptosis-promoting BC 
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phenotype with the addition of an oestrogenic ligand (such as those of E4 and TTC-352). In 
the case of SRC3-overexpressing BC phenotype (i.e., SRC3 overexpression contributes to its 
oestrogen-independent growth and endocrine-resistance) (Osborne et al., 2003a), a modest 
buildup of the unfolded proteins happens during tumour growth. However, the use of an 
oestrogenic ligand, and the associated additional stabilizing H-bond network, hypothetically 
allows for the recruitment of numerous E2-enriched coactivators that leads to the massive 
translation of unfolded proteins, and the subsequent induction of the UPR and apoptosis in 
LTED BC. The SRC-3 overexpression with tamoxifen treatment, combined with LTED, and 
in the presence of a postmenopausal woman’s oestrogen (i.e., E1), might as well explain the 
survival advantage seen only with tamoxifen (not AIs) for up to 10 years after the initiation of 
tamoxifen treatment, even after the discontinuation of 5 years of tamoxifen treatment (Fisher 
et al., 2004). A closer examination of the Osborne and colleagues study (Osborne et al., 
2003a) shows that the frozen tumour specimens (used for evaluating the role of SRC-3 
overexpression in conferring endocrine resistance), were obtained from 316 BC patients with 
positive axillary lymph nodes at the time of initial surgery. This means that the SRC3-
overexpressing BC phenotype was not LTED, to create the suitable environment for its 
conversion to an apoptosis-promoting BC phenotype, upon the addition of oestrogen. In such 
case, longer oestrogenic deprivation can be achieved with AIs upon the failure of tamoxifen. 
In fact, the standard of care tends to use a combination of 2 years of tamoxifen, followed by 
2-3 years of AIs.    
Overall, E4 and TTC-352 were previously shown to be effective in women with 
endocrine-resistant BC, after the failure of several lines of endocrine treatments (including 




VI. Reflections   
 The strength of this body of work lies in the fact that it uses 11 biologically-different 
patient-derived BC models. The results were also compared within a wide range of ERα 
ligands, including: the potent full agonist E2, the less potent full agonists E1 and E3, the 
benchmark partial agonist triphenylethylene bisphenol (BPTPE), antagonists 4-
hydroxytamoxifen, endoxifen, and raloxifene, and the SERD ICI. Additionally, the test 
ligands were evaluated in a wide range of cell-based assays, including: cell viability assays, 
real-time polymerase chain reaction, luciferase reporter assays, chromatin 
immunoprecipitation, human unfolded protein response (UPR) RT2 PCR profiler arrays, 
immunoblotting, ERE DNA pull downs, mass spectrometry, X-ray crystallography, docking 
and molecular dynamic simulations, live cell imaging, and annexin V staining. Such 
techniques covered the trail of what happens starting from the moment the ligand binds to the 
ER, and ending with the biological endpoint of apoptosis.  
 What could have been done differently, if one possessed more financial resources, is 
the evaluation of the corepressors’ recruitment with the test ligands in WT MCF-7:WS8 and 
apoptotic-type MCF-7:5C, and the evaluation of the dynamic UPR gene regulation over more 
than two time points. The natural progression of my in vitro studies would have been to 
proceed towards in vivo studies, however, this had already been completed by the original 
investigators of E4 and SEMs.    
Breast cancer is projected to double by 2030 than it was in 2011 (Rosenberg et al., 
2015), the majority of which will be ER-positive with a high risk of recurrence Moreover, 
treated ER-positive BC metastases often harbor private ‘driver’ mutations, compared to 
untreated metastases (Hu et al., 2020). This highlights the need to leverage new rapidly-
acting BC therapeutics such as oestrogens, which could become one treatment modality to 
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offer to women with endocrine-resistant MBC, after the failure of their treatments (i.e., 
tamoxifen, AIs, fulvestrant, mTOR inhibitors, and CDK4/6 inhibitors). The recent long-term 
follow-up results of the WHI Trials (Jordan, 2020) reaffirm the clinical potential of novel and 
safe oestrogenic therapy, in significantly reducing BC incidence and mortality, in LTED 
patients. The WHI trials (i.e., 27,347 postmenopausal women, from 40 U.S. centers) 
described oestrogen therapy as the following: “Prior use of CEE alone is the first 
pharmacologic intervention demonstrated to be associated with a statistically significantly 
reduction in deaths from breast cancer.” Furthermore, the clinical trial of E4 (Schmidt, 2020) 
goes to show that while oestrogen therapy can be safe and effective in treating endocrine-
resistant MBC, it can also yield favorable effects on the patients’ well-being (i.e., 
ameliorating the symptoms of oestrogen deficiency, such as: hot flashes, vaginal dryness, 
sleep disturbances, mood changes, bone osteoporotic changes, and arthralgia). This positions 
oestrogen treatment among the few if any of the treatment modalities, which not only treat 
the disease, but also improve the patients’ quality of life. Other than using oestrogenic agents 
to treat advanced or resistant BC, the biology of oestrogen-induced apoptosis can be used as a 
treasure hunting grounds to identify novel anti-cancer targets, which can be targeted to 
potentially treat different cancers.  
 What can be achieved to personalize treatments to our BC patients, based on the 
findings and areas of investigation of my thesis, can be summarized as the following:  
I. The development of assays to measure circulating ESR1 mutations, in patients treated 
with AIs. These levels can serve an independent risk factor for poor outcome after AI 
failure, and to indicate that it could then be appropriate to use an oestrogenic agent to 




II. The development of assays to measure SRC-3 overexpression in BC tumours, in 
patients treated with tamoxifen. These levels can serve as a diagnostic tool, to 
indicate when it’s appropriate to continue with the LTED using AIs instead, and to 
indicate that it could then be appropriate to use an oestrogenic agent to convert the 
SRC-3-overexpresisng growth-promoting BC phenotype to that of apoptosis-
promoting (as long as LTED had taken place).  
III. The development of assays to measure the ratio of circulating oestrogens that are 
indicative of the woman’s dynamic metabolism, in terms of the balance between 
oestrogen synthesis and deactivation. This can help identify which postmenopausal 
women have higher levels of oestrogens that could be causing tumour regression in 
association with any observed BC regression, or significant decreases in BC 
incidence and mortality. 
IV. The development of a mathematical model for the UPR activation and dynamics over 
time, using patient-derived tissues treated with E2. This can help identify the rate and 
anti-cancer kinetics of this biology in real time.      
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ABSTRACT
Long-term estrogen deprivation (LTED) with tamoxifen (TAM) or
aromatase inhibitors leads to endocrine-resistance, whereby
physiologic levels of estrogen kill breast cancer (BC). Estrogen
therapy is effective in treating patients with advanced BC after
resistance to TAM and aromatase inhibitors develops. This
therapeutic effect is attributed to estrogen-induced apoptosis
via the estrogen receptor (ER). Estrogen therapy can have
unpleasant gynecologic and nongynecologic adverse events.
Here, we study estetrol (E4) and a model Selective Human ER
Partial Agonist (ShERPA) BMI-135. Estetrol and ShERPA TTC-
352 are being evaluated in clinical trials. These agents are
proposed as safer estrogenic candidates compared with 17b-
estradiol (E2) for the treatment of endocrine-resistant BC. Cell
viability assays, real-time polymerase chain reaction, lucifer-
ase reporter assays, chromatin immunoprecipitation, docking
and molecular dynamics simulations, human unfolded protein
response (UPR) RT2 PCR profiler arrays, live cell microscopic
imaging and analysis, and annexin V staining assays were
conducted. Our work was done in eight biologically different
human BC cell lines and one human endometrial cancer cell
line, and results were compared with full agonists estrone, E2,
and estriol, a benchmark partial agonist triphenylethylene
bisphenol (BPTPE), and antagonists 4-hydroxytamoxifen and
endoxifen. Our study shows the pharmacology of E4 and BMI-
135 as less-potent full-estrogen agonists as well as their
molecular mechanisms of tumor regression in LTED BC
through triggering a rapid UPR and apoptosis. Our work
concludes that the use of a full agonist to treat BC is
potentially superior to a partial agonist given BPTPE’s delayed
induction of UPR and apoptosis, with a higher probability of
tumor clonal evolution and resistance.
SIGNIFICANCE STATEMENT
Given the unpleasant gynecologic and nongynecologic adverse
effects of estrogen treatment, the development of safer estro-
gens for endocrine-resistant breast cancer (BC) treatment and
hormone replacement therapy remains a priority. The naturally
occurring estrogen estetrol and Selective Human Estrogen-
Receptor Partial Agonists are being evaluated in endocrine-
resistant BC clinical trials. This work provides a comprehensive
evaluation of their pharmacology in numerous endocrine-
resistant BC models and an endometrial cancer model and their
molecularmechanisms of tumor regression through the unfolded
protein response and apoptosis.
Introduction
In 1944, Sir Alexander Haddow used high-dose synthetic
estrogen therapy to treat metastatic breast cancer (MBC)
(Haddow et al., 1944) in patients who were long-term ($5 years
past menopause) estrogen-deprived (LTED) (Haddow, 1970). A
30% response rate was reported. High-dose estrogen therapy
was used for 30 years prior to the introduction of tamoxifen
(TAM) (Jordan, 2003). Tamoxifen was preferred because of
the lower incidence of adverse events (AEs) (Cole et al., 1971;
Ingle et al., 1981). In the 1970s, the translational research
proposal of long-term adjuvant antihormone TAM therapy
was successfully advanced (Jordan et al., 1979; Jordan and
Allen, 1980). This strategy established TAM as the agent of
choice for adjuvant therapy (Early Breast Cancer Trialists’
Collaborative Group, 1998).
Acquired resistance to TAM therapy in vivo initially
involves the growth of breast cancer (BC) populations
within 1 to 2 years that are TAM- and estrogen-dependent
(Gottardis and Jordan, 1988; Gottardis et al., 1989b). Sub-
sequent studies in vivo demonstrated that 5 years of TAM
treatment (mimicking the standard of care period at the
time) leads to new BC populations that grow with TAM but
die with physiologic levels of estrogen (Wolf and Jordan,
1993; Yao et al., 2000). This discovery explained (Jordan,
2008) why high-dose estrogen therapy was only effective
$5 years past menopause in Haddow’s original clinical
studies (Haddow, 1970).
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Physiologic estrogen in LTED BC cells triggers a cellular
stress response named the unfolded protein response (UPR) and
induces apoptosis (Song et al., 2001; Lewis et al., 2005a; Ariazi
et al., 2011). Hosford et al. (2019) confirmed the involvement of
the UPR and apoptosis in patient-derived estrogen-deprived
estrogen receptor (ER)-positive xenografts treated with 17b‐
estradiol (E2). This UPR and apoptosis–paired biology under-
pinning estrogen-induced tumor regression not only explains the
earlier observational clinical science (Haddow, 1970) but also
reaffirms estrogen’s therapeutic potential for the treatment of
endocrine-resistant BC.
Lønning et al. (2001) used high-dose estrogen therapy in
postmenopausal women with advanced endocrine-resistant
BC (median deprivation of 4 years). The conjugated equine
estrogen arm in the Women’s Health Initiative trial and its
long-term follow-up (Anderson et al., 2004; Chlebowski et al.,
2020; Jordan, 2020) unintentionally illustrated the clinical
relevance of estrogen-induced tumor regression (Abderrahman
and Jordan, 2016). The Women’s Health Initiative trial had
more than 75% of the postmenopausal women LTED for
10 years past menopause. When given estrogen replacement
therapy, there were significant decreases in BC incidence and
mortality (Anderson et al., 2004; Roehm, 2015; Chlebowski
et al., 2020). Ellis et al. (2009) demonstrated the antitumor
actions of low-dose estrogen therapy in postmenopausal women
with advanced adjuvant aromatase inhibitor–resistant BC
(deprivation $2 years). Iwase et al. (2013), using ethiny-
lestradiol in patients with MBC (median age 63 years),
had a 56% clinical benefit rate. Chalasani et al. (2014),
using E2 during 3-month exemestane breaks in patients
with MBC, had measurable clinical activity. These clinical
studies reaffirm the earlier laboratory findings that estro-
gen treatment after LTED with TAM in vivo leads to BC
regression (Yao et al., 2000).
These in vivo and in vitro studies and clinical trials
support the clinical benefit of using estrogen alone or in
combination with growth inhibitors and/or apoptosis pro-
moters for the treatment of endocrine-resistant BC. None-
theless, concerns regarding AEs require the development
of safer estrogens.
There are four naturally occurring forms of estrogen (Fig. 1):
estrone (E1), E2, estriol (E3), and estetrol (E4).
Estetrol (Fig. 1), produced by the fetal liver during pregnancy
(Holinka et al., 2008), is proposed as a promising estrogen for
the treatment of advanced BC (Singer et al., 2014; Coelingh
Bennink et al., 2017; Verhoeven et al., 2018; Schmidt et al.,
2020), advanced prostate cancer (Dutman et al., 2017), use
in hormone replacement therapy (Gérard et al., 2015;
Coelingh Bennink et al., 2016; https://clinicaltrials.gov/
ct2/show/NCT02834312), and in contraception (Creinin
et al., 2019). In preclinical models, E4 selectively activates
the nuclear ERa, which plays a prominent role in the
vasculoprotective action of estrogens (Abot et al., 2014). An
ongoing phase I/IIA clinical trial of E4 (Schmidt et al., 2020)
shows the majority of patients experience favorable effects on
wellbeing, and one patient completed both phases with stable
disease after 24 weeks of treatment.
Selective Human ER Partial Agonists (ShERPAs), also
known as selective estrogen mimics (Fig. 1), are novel benzo-
thiophene [raloxifene (Ralox) or arzoxifene] derivatives with
nanomolar potency designed to treat endocrine-resistant BC
(Molloy et al., 2014; Xiong et al., 2016). The ShERPAs BMI-135
and TTC-352 were shown to cause tumor regression in TAM-
resistant BC xenograft models and not to cause significant
estrogen-like uterine growth in these models (Molloy et al.,
2014; Xiong et al., 2016). An ongoing phase I clinical trial of
TTC-352 (O’Regan et al., 2019) shows manageable safety and
early clinical evidence of activity in patients with MBC
progressing on endocrine therapy.
Given the clinical relevance of E4 and ShERPAs, here we
expand the study of their pharmacology in a broad range of BC
and endometrial cancer cell lines and delineate their antitu-
mor molecular mechanisms through triggering the UPR and
apoptosis in select LTED and endocrine-resistant BC models.
Materials and Methods
Cell Culture and Reagents. E1, E2, E3, E4, and 4-hydroxyTAM
(4OHT) were purchased from Sigma-Aldrich (St. Louis, MO). Endox-
ifen was purchased from Santa Cruz Biotechnology (Santa Cruz, CA),
Raloxwas purchased fromSigma-Aldrich, and ICI 182,780 fulvestrant
(ICI) was purchased from Tocris Bioscience (Bristol, UK). Triphenyl-
ethylene bisphenol (BPTPE)was originally synthesized at theOrganic
Synthesis Facility, Fox Chase Cancer Center (Philadelphia, PA)
(Maximov et al., 2010). The ShERPA BMI-135 was a gift from Dr.
Debra Tonetti and Dr. Gregory R.J. Thatcher (University of Chicago,
IL). The protein kinase regulated by RNA-like EnR kinase (PERK)
inhibitor GSK G797800 was purchased from Toronto Research
Chemicals (Toronto, ON, Canada). The inositol-requiring enzyme 1
(IRE1a) Inhibitor MKC-3946 was purchased from Calbiochem (San
Diego, CA). Thioflavin T (ThT) was purchased from Sigma-Aldrich. All
compounds except BMI-135 and E4 were dissolved in ethanol, stored
at220°C, and protected from light. Compounds BMI-135 and E4 were
dissolved in DMSO. Wild-type (WT) estrogen-dependent BC cell line
MCF-7:WS8 (Jiang et al., 1992); mutant p53 estrogen-dependent
BC cell line T47D:A18 (Murphy et al., 1990b); the first in vitro cellular
model recapitulating acquired-TAM resistance developed in athymic
mice in vivo MCF-7:PF (Fan et al., 2014); estrogen-responsive,
ER-positive, progesterone receptor–positive, and human epidermal
growth factor receptor 2–positive luminal B BC cell line BT-474
(Kraus et al., 1987); estrogen-responsive, ER-positive, progesterone
receptor–positive, and androgen receptor–positive luminal A BC cell
line ZR-75-1 (Engel et al., 1978); antihormone-resistant estrogen-
independent BC cell line MCF-7:5C (Lewis et al., 2005b);
antihormone-sensitive estrogen-independent BC cell line MCF-7:2A
(Pink et al., 1995); and antihormone (Ralox)-resistant estrogen-
independent BC cell line MCF-7:RAL (Liu et al., 2003) were cultured
ABBREVIATIONS: AE, adverse event; ATF, activating transcription factor; BC, breast cancer; BPTPE, triphenylethylene bisphenol; ChIP, chromatin
immunoprecipitation; CT, cycle threshold; DBPS, Dulbecco’s phosphate-buffered saline; E1, estrone; E2, 17b-estradiol; E3, estriol; E4, estetrol; EnR,
endoplasmic reticulum; ER, estrogen receptor; ERAD, EnR-associated degradation; ERE, estrogen-responsive element; FITC, fluorescein
isothiocyanate; GREB1, Growth Regulation by Estrogen in Breast Cancer 1; ICI, ICI 182,780 fulvestrant; IRE1a, inositol-requiring enzyme 1; LBD,
ligand-binding domain; LTED, long-term estrogen deprivation; MBC, metastatic BC; MBTPS1, Membrane Bound Transcription Factor Peptidase,
Site 1; MD, molecular dynamics; 4OHT, 4-hydroxyTAM; PCR, polymerase chain reaction; PERK, protein kinase regulated by RNA-like EnR kinase;
PI, propidium iodide; Ralox, raloxifene; RMSD, root-mean-square deviation; RMSF, root-mean-square fluctuation; RT-PCR, real-time PCR; SERM,
Selective Estrogen Receptor Modulator; ShERPA, Selective Human Estrogen Receptor Partial Agonist; SRC-3, steroid receptor coactivator 3; TAM,
tamoxifen; TFF1, trefoil factor 1; ThT, Thioflavin T; TPE, triphenylethylene; UPR, unfolded protein response; WT, wild type.














as previously described. Human endometrial adenocarcinoma cell line
Ishikawa was cultured as previously described (Nishida et al., 1985).
All cell cultures were done in T75 and T175 culture flasks (Thermo
Fisher Scientific, Waltham, MA), passaged twice a week at 1:3 ratio,
and grown in 5% CO2 at 37°C. All cell lines were validated according
to their short tandem repeat profiles at The University of Texas MD
Anderson Cancer Center Characterized Cell Line Core. The short
tandem repeat patterns of all cell lines were consistent with those from
theCharacterizedCell LineCore standard cells (SupplementalTable 1).
Cell Viability and Proliferation Assays. The biologic proper-
ties of test compounds (E1, E2, E3, E4, BMI-135, BPTPE, 4OHT,
endoxifen, raloxifene, and ICI) in cells lines (MCF-7:WS8, T47D:A18,
MCF-7:PF, BT-474, ZR-75-1, MCF-7:5C, MCF-7:2A, andMCF-7:RAL)
were evaluated by assessing the DNA content of the cells as ameasure
of cell viability and proliferation using a DNA fluorescence Quantita-
tion kit (Bio-Rad Laboratories, Hercules, CA) as previously described
(Fan et al., 2013). The EC50 of all test compounds in different human
BC and human endometrial cancer cell lines are summarized in
Table 1. EC50 was calculated using the formula: Y = Bottom + (Top-
Bottom)/(1 + 10^((LogEC50-X)*HillSlope)).
Real-Time Polymerase Chain Reaction. MCF-7:WS8 and
MCF-7:5C cells were seeded into six-well plates at a density of
100,000 cells/well. Cells were treated the next day with test com-
pounds (E2, BMI-135, BPTPE, and endoxifen) for 24 hours. RNA
isolation, cDNA synthesis, and real-time polymerase chain reaction
(RT-PCR) were performed as previously described (Obiorah et al.,
2014). All primers were obtained from Integrated DNA Technologies
Inc. (IDT, Coralville, IA) and validated by melt-curve analysis that
revealed single peaks for all primer pairs. The primer sequences used
for human trefoil factor 1 (TFF1) cDNA amplification were: 59-CAT
CGACGTCCCTCCAGAAGA-39 sense, 59-CTCTGGGACTAATCACCG
TGCTG-39 antisense; human Growth Regulation by Estrogen in
Breast Cancer 1 (GREB1) gene: 59-CAAAGAATAACCTGTTGGCCC-
TGC-39sense, 59-GACATGCCTGCGCTCTCATACTTA-39 antisense; and
the reference gene 36B4: 59-GTGTCCGACAATGGCAGCAT-39 sense, 59-
GACACCCTCCAGGAAGCGA-39 antisense.
TABLE 1
EC50 of test compounds in different human BC and human endometrial cancer cell lines
The EC50 was calculated to indicate potency differences between test compounds used in treating these cell lines over a specific period of time (Figs. 2 and 4), as indicated in
the table.
Cell Line Time Frame Compound E1 E2 E3 E4 BMI-135
MCF-7:5C 1 wk EC50 (2log [M]) 29.19 210.89 210.04 28.73 28.39
MCF-7:5C 2 wk 210.00 - 210.31 29.30 28.98
MCF-7:2A 2 wk 28.99 210.74 29.14 28.50 28.29
MCF-7:RAL 1 wk 211.11 212.99 29.13 210.07 29.97
MCF-7:RAL 2 wk 28.93 211.06 29.04 27.22 29.24
MCF-7:RAL 3 wk 29.53 210.89 29.75 28.38 27.47
MCF-7:PF 1 wk 28.68 210.67 29.43 28.52 28.87
MCF-7:WS8 1 wk 210.01 211.92 210.81 29.80 29.01
T47D:A18 1 wk 29.33 211.25 210.01 28.98 28.87
BT-474 1 wk - 211.31 - - 28.71
ZR-75-1 1 wk - 211.39 - - 28.21
Ishikawa 1 wk - 210.97 - 28.26 28.57
Fig. 1. Chemical structures of naturally occurring estrogens (E1,E2, E3, and E4), SERM raloxifene, synthesized ShERPA BMI-135 based on the
benzothiophene scaffold of raloxifene, partial agonist BPTPE, andSERMendoxifen. The estrogenE2 is themost potent estrogen. However, E1 is generally
12 times less potent than E2, and E3 is generally 80 times less potent than E2.














Transient Transfection and Dual Luciferase Reporter
Assays. Ishikawa cells were seeded into 24-well plates at a density
of 100,000 cells/well. After 24 hours, cells were transfected with 28.8
mg of pERE(5X)TA-ffLuc and 9.6 mg of pTA-srLuc reporter plasmids
using 3 ml of TransIT-LT1 transfection reagent (Mirus Biolabs,
Madison, WI) per 1 mg of plasmid DNA in 52.5 ml of OPTI-MEM
serum-free media (Invitrogen, Carlsbad, CA). Transfection mix con-
taining the transfection complexes was added to cells in growthmedia
to a final concentration of 0.3mg pERE(5X)TA-ffLuc and 0.1mg of pTA-
srLuc reporter plasmids per well. After 18 hours, transfection
reagents were removed, and fresh media were added instead. After
24 hours post-transfection, cells were treated with test compounds
(E2, E4, BMI-135, BPTPE, and endoxifen) for 24 hours. After 24-
hour treatment, cells were washed once with cold Dulbecco’s
phosphate-buffered saline (DPBS) (Invitrogen) and lysed, and the
estrogen-responsive element (ERE) luciferase activity was deter-
mined using Dual-Luciferase Reporter Assay System (Promega,
Madison, WI) according to manufacturer’s instructions. Samples
were quantitated on a Synergy H1 plate reader (BioTek Instru-
ments Inc., Winooski, VT) in white-wall 96-well plates (Nalge Nunc
International, Rochester, NY).
Chromatin Immunoprecipitation Assays. The chromatin im-
munoprecipitation (ChIP) assay was performed as previously de-
scribed (Sengupta et al., 2010; Obiorah et al., 2014). The antibodies
used for the pull-downs were anti-ERa clone F-10Xmousemonoclonal
(2 mg/ml; 5 mg per reaction) (Santa Cruz Biotechnology), anti–steroid
receptor coactivator 3 (SRC-3) clone AX15.3 mouse monoclonal
(1 mg/ml; 5 mg per reaction) (Abcam, Cambridge, UK), and normal
mouse IgG as intraperitoneal negative control (2 mg/ml; 5 mg per
reaction) (Santa Cruz Biotechnology). The DNA fragments were
purified using Qiaquick polymerase chain reaction (PCR) purifica-
tion kit (Qiagen, Germantown, MD). Then, 2 ml of eluted DNA was
used for RT-PCR analysis. The primer sequences used were GREB1
proximal ERE enhancer site amplification: 59-GTGGCAACTGGG
TCATTCTGA-39 sense and 59-CGACCCACAGAAATGAAAAGG-39
antisense (Integrated DNA Technologies). The data are expressed as
percent input of starting chromatin material after subtracting the
percent input pull-down of the intraperitoneal negative control.
Docking of BMI-135 to ERa. The experimental complex struc-
ture of TTC-352:ERawas employed for docking BMI-135:ERa because
BMI-135 could not crystallize with the ER ligand-binding domain
(LBD). The structure was prepared using Maestro software (Schrö-
dinger Release 2019-3; Schrödinger, LLC, New York, NY, 2019)
and Protein Preparation Wizard (Schrödinger Release 2019-3:
Epik, Impact, Prime; Schrödinger, LLC, 2019). Briefly, the work-
flow involves the following steps: addition of hydrogen atoms,
correction of bonds and bond order assignments, deletion of water
molecules beyond 5 Å of a heteroatom, generation of ionization
states at pH 7.4, and, finally, the restrained refinement of the
ligand-receptor complex. The polar amino acids Asp, Glu, Arg, and
Lys were modeled as charged and all Tyr were modeled as neutrals.
The ligand was prepared for simulation using the LigPrep module
(Schrödinger Release 2019-3; Schrödinger, LLC, 2019) in default
settings. The experimental structure of ERa in complex with E2
was resolved with Tyr537 mutated to Ser. Since all biologic
experiments were performed against the WT receptor, we modeled
the experimental structure by mutating Ser537 to Tyr using the
Maestro software. Then, the residues within a range of 5 Å of
Tyr537 were refined while the remaining protein-ligand complex
was kept frozen. The ligand was docked to the active site of WT
ERa using Induced Fit Docking (Schrödinger Release 2019-3:
Glide, Prime; Schrödinger, LLC, 2019) based on Prime and Glide
docking (Sherman et al., 2006a,b). This methodology takes into
account the receptor’s flexibility, allowing the side-chain and
backbone movements in the binding site to better adjust to the
shape and binding mode of the ligand. The grid was centered on
the cocrystallized ligand, and the receptor van der Waals radii of
the heavy atoms were scaled down to 0.5. The residues within 5 Å
of ligand poses were selected to be refined. The extraprecision
option was selected for docking. The top 20–ranked ligand-
receptor structures were retained, and the best docking solution
was selected based on the Induced Fit Docking score and visual
inspection.
Molecular Dynamics Simulations. Molecular dynamics (MD)
simulations for the selected BMI-135:ERa complex were carried out
with Desmond software (Schrödinger Release 2019-3, Schrödinger,
LLC, 2019), utilizing the methodology previously described (Maximov
et al., 2020). Briefly, the SystemBuildermodule of Desmondwas used
to solvate the ligand:receptor complex in a periodic orthorhombic
water box based on the transferable intermolecular potential with 3
points (TIP3P) model. The charge neutrality of the system was
guaranteed by adding sodium and chloride ions. To relax and
equilibrate the system, Desmond’s default relaxation protocol was
employed. Minimization was followed by 50-nanosecond MD pro-
duction run performed in periodic boundary conditions in the
isothermal–isobaric (NPT) ensemble at constant pressure and tem-
perature of 1 atm and 300 K, respectively. The integration time step
and the recording interval of coordinates were set to 2 femtoseconds
and 2 picoseconds, respectively. Trajectory analysis was carried out
using the analysis tool Simulation Integration Diagram of Maestro.
The root-mean-square deviation (RMSD) and root-mean-square fluc-
tuation (RMSF) of the receptor backbone atoms relative to the
reference structure were calculated and compared with the same
metrics computed for the trajectories of ERa bound to E2 and BPTPE,
respectively [previously published (Maximov et al., 2020)]. The
clustering algorithm of Desmond was used to extract the most
representative frames of trajectory in terms of the conformational
space sampling. The trajectory was clustered, the top 10 most-
populated clusters were retained, and the representative structure
of each cluster was extracted. Then, free binding energy calculations
were performed with the Molecular Mechanics/Generalized Born
Surface Area (MM-GBSA) method implemented in Schrödinger
2019-3 to select the best structure for analysis and comparison
with the E2 complex. Moreover, protein-ligand interactions (e.g.,
H-bonds and hydrophobic contacts) were monitored throughout
the simulation. All graphs were prepared using the ggplot pack-
age of R software (R, version 3.2.3; The R Foundation, Vienna,
Austria, 2015), and the figures were generated using PyMol 2.0
(Schrödinger, LLC, 2019).
Human Unfolded Protein Response RT2 PCR Profiler PCR
Arrays (Real-Time Profiler Assay). MCF-7:5C cells were seeded
into six-well plates at a density of 200,000 cells/well for the 48- and 72-
hour time points and 45,000 cells/well for day-7 time point. After
24 hours, cells were treated with test compounds (E2, E4, BMI-135,
and BPTPE). Cells were harvested using Qiazol reagent (Qiagen,
Hilden, Germany), and total RNA was isolated using an miRNeasy
Mini Kit (Qiagen) according to manufacturer’s instructions. During
the RNA purification process, samples were treated with DNase using
the RNase-Free DNase Set (Qiagen) according to manufacturer’s
instructions. The cDNAwas reverse-transcribed using 2 mg of isolated
RNA and theHigh Capacity cDNAReverse TranscriptionKit (Applied
Bioscience, Carlsbad, CA) according to manufacturer’s instructions.
The cDNA was diluted 1:50, and a 2x RT2 SYBR Green Mastermix
(Qiagen) was used to prepare the reactions. The plates were loaded
and run on a QuantStudio 6 Flex Real-Time PCR thermocycler
(Applied Bioscience) according to manufacturer’s instructions. The
Ct values were exported at the end of each run, compiled, and
uploaded to Qiagen’s Data Analysis Center for analysis. For the
volcano plots, the fold change [2^(2DDCT)] in the normalized gene
expression [2^(2DCT)] in the test sample divided the normalized gene
expression [2^(2DCT)] in the control sample. Fold regulation repre-
sents fold-change results in a biologically meaningful way. Fold-
change values greater than one indicate a positive regulation or an
upregulation, and the fold regulation is equal to the fold change. Fold-
change values less than one indicate a negative regulation or down-
regulation, and the fold regulation is the negative inverse of the fold














change. The P values of the volcano plots were calculated using
a Student’s t test of the replicate 2^(2DCT) values for each gene in the
control group and treatment groups.
Live Cell Imaging and Analysis. MCF-7:5C cells were seeded
into 15 m-slide two-well chambered coverslip slides (Ibidi, Mar-
tinsried, Germany) at a density of 300,000 cells/well for the 48-hour
time point and at 200,000 cells/well for the 72-hour time point. After
24 hours, cells were treated with test compounds (E2, E4, BMI-135,
and thapsigargin). On the day of live cell imaging, the green
fluorescent dye ThT (UPR-indicative dye) (Sigma-Aldrich) was
freshly prepared as previously described (Beriault and Werstuck,
2013), and the blue fluorescent live cell nuclear dye Hoechst 33342
(counterstain dye) (Thermo Fisher Scientific) was freshly prepared
at a final concertation of 5 mg/ml. The staining with ThT was for
1 hour, and this was followed by substituting the culture media
(containing test compounds and ThT) with PBS containing Hoechst
33342 for 15 minutes in a CO2 incubator. Fluorescent images of
MCF-7:5C live cells were taken at a 38-millisecond exposure under
a 20/0.7 objective with ZEISS Celldiscoverer 7 (Carl Zeiss AG,
Oberkochen, Germany). Images were converted to 12-bit before
being quantified by the ZEISS Zen Software Module-Image Anal-
ysis. Cells from each image were manually counted to normalize
the fluorescent data per cell. Relative intensity per cell = ThT
intensity/cell count and was generated for each treatment per
image. A mean of the relative intensity per cell (using three images
per treatment) was then calculated to give a final quantification
alongside the S.D. The relative intensity per cell data are repre-
sented in Table 2. The excitation and emission settings were
Hoechst 33342 (Excitation: 348 nm, Emission: 455 nm) and ThT
(Excitation: 433 nm, Emission: 475 nm).
Annexin V–Staining Assays. MCF-7:5C cells were seeded into
10-cm Petri dishes at a density of 800,000 cells/dish for the 72- and 96-
hour time points. MCF-7:2A cells were seeded into 10-cm Petri dishes
at a density of 400,000 cells/dish for day-9 time point and at 100,000
cells/dish for day-13 time point. MCF-7:RAL cells were seeded into 10-
cm Petri dishes at a density of 150,000 cells/dish for day-14, day-17,
and day-21 time points. After 24 hours, cells were treated with test
compounds (E2, E4, BMI-135, BPTPE, 4OHT, endoxifen, raloxifene,
ICI, GSK G797800, and MKC-3946). Harvested cells were suspended
in 1 binding buffer, and 1  105 cells were stained simultaneously
with FITC-labeled annexinV and propidium iodide (PI) for 15minutes
at 37°C using the FITC Annexin V Apoptosis Detection Kit I (BD
Pharmingen, San Diego, CA) according to the manufacturer’s instruc-
tions. The cells were analyzed using a BD Accuri C6 plus flow
cytometer.
Statistical Analyses. All data are mean 6 S.D. of three different
fields for each condition from three independent biologic experiments
performed in technical duplicates. One-way ANOVA was used with
a follow-up Tukey’s test to determine the statistical significance of the
treatments.
Results
Effects of E4 and BMI-135 on Cell Viability and
Proliferation in Numerous BC Models. Cell viability
and proliferation assays were used to investigate the biologic
properties of test compounds. Estetrol and ShERPA BMI-135
display activity similar to E2 but right shifted across eight BC
cell lines that are estrogen-dependent (MCF-7:WS8, T47D:
A18, MCF-7:PF, BT-474, and ZR-75-1), estrogen-independent
(MCF-7:5C, MCF-7:2A, and MCF-7:RAL), endocrine-sensitive
(MCF-7:2A), endocrine-resistant (MCF-7:PF, MCF-7:5C, and
MCF-7:RAL), mutant p53 (T47D:A18), human epidermal
growth factor receptor 2–positive (BT-474), luminal A (ZR-
75-1), and luminal B (BT-474).
The concentration 1 mM for E4 and BMI-135 achieved either
the maximal cellular growth (Fig. 2, A–E; Supplemental Fig. 1,
A–C), or themaximal cellular death (Fig. 2, F–H; Supplemental
Fig. 1, D–F). Both were shown to be less potent full agonists
compared with E2, requiring higher concentrations to produce
the same maximal effect of E2. The EC50 for all test compounds
used in treating these cell lines are summarized in Table 1.
In MCF-7:5C, E4 and BMI-135 almost completely reduced
the amount of viableMCF-7:5C cells after 1 week of treatment
in a dose-dependent manner, with a maximum reduction of
cells by an average of 58% for E4 and 46% for BMI-135 at their
highest concentration of 1026 M (P , 0.05 compared with
vehicle) (Fig. 2F). Reduction in the amount of viableMCF-7:5C
cells by E2 at 10
29 M was by an average of 58% (Fig. 2F). In
MCF-7:2A, E4 and BMI-135 almost completely reduced the
amount of viable MCF-7:2A cells after a 2-week treatment in
a dose-dependent manner, with a maximum reduction of cells
by an average of 57% for E4 and 50% for BMI-135 at their
highest concentration of 1026 M (P , 0.05 compared with
vehicle) (Fig. 2G). Reduction in the amount of viable MCF-7:
2A cells by E2 at 10
29 Mwas by an average of 67% (Fig. 2G). In
MCF-7:RAL, E4 and BMI-135 almost completely reduced the
amount of viableMCF-7:RAL cells after a 3-week treatment in
a dose-dependent manner, with a maximum reduction of cells
by an average of 45% for E4 and 43% for BMI-135 at their
highest concentration of 1026 M (P , 0.05 compared with
vehicle) (Fig. 2H). Reduction in the amount of viable MCF-7:
RAL cells by E2 at 10
29 M was by an average of 45% (Fig. 2H).
Effects of E4 and BMI-135 Are Mediated via
ERa. MCF-7:5C, MCF-7:2A, and MCF-7:RAL representing
LTED estrogen-independent BC were treated with 1 mM E4,
1 mM BMI-135, and a combination of these with 1 mM 4OHT
and 1 mM endoxifen to investigate whether E4 and BMI-135
exert their function via ERa. In MCF-7:5C, full estrogen
agonists should cause cellular death within 1 week, antago-
nists should not (i.e., MCF-7:5C is endocrine-resistant), and
the agonists’ pairing with the antagonists should block the
death effect. Indeed, E2, E4, and BMI-135 killed the cells within
1 week (P , 0.05 compared with vehicle) (Supplemental Fig.
2A), whereas 4OHT and endoxifen did not (P , 0.05 compared
with vehicle) (Supplemental Fig. 2A). The combination of E2,
E4, and BMI-135 with 4OHT and endoxifen blocked the death
effect (Supplemental Fig. 2A).
In MCF-7:2A, full agonists should cause cellular death
within 2 weeks, antagonists should cause growth inhibition
TABLE 2
Quantification of the UPR in live MCF-7:5C cells through measuring ThT
relative intensity/cell
(A) ThT relative intensity/cell (mean and S.D.) with test compounds after 48-hour
treatments. (B) ThT relative intensity/cell (mean and S.D.s) after 72-hour
treatments. This reflects the differential capacity of test compounds in inducing
EnR stress over time. ThT relative intensity/cell per treatment is representative of
three biologic repeats.
(A) Day 2

























(i.e., MCF-7:2A is endocrine-sensitive), and the agonists’
pairing with the antagonists should block the death effect.
Indeed, E2, E4, and BMI-135 killed the cells within 2 weeks
(P , 0.05 compared with vehicle) (Supplemental Fig. 2B),
whereas 4OHT and endoxifen caused growth inhibition (P ,
0.05 compared with vehicle) (Supplemental Fig. 2B). The
combination of E2, E4, and BMI-135 with 4OHT and endoxifen
blocked the death effect (Supplemental Fig. 2B).
In MCF-7:RAL cells, full agonists should cause cellular
death within 2 to 3 weeks in vitro; antagonists, especially
Selective ER Modulator (SERM) raloxifene (positive control),
should cause cellular growth; and the agonists’ pairing with
antagonists should block the death effect. Indeed, E2, E4, and
BMI-135 killed the cells within 3 weeks (P , 0.05 compared
with vehicle) (Supplemental Fig. 2C), whereas the SERMs
4OHT, endoxifen, and especially raloxifene caused cellular
growth (P , 0.05 compared with vehicle) (Supplemental Fig.
2C). The combination of E2, E4, and BMI-135 with 4OHT and
endoxifen blocked the death effect (Supplemental Fig. 2C).
Interestingly, ICI (a selective ER downregulator or “pure
antiestrogen”) caused a decrease in cell DNA amount in MCF-
7:RAL cells after a 3-week treatment (P, 0.05 compared with
vehicle) (Supplemental Figs. 1F and 2C).
Endoxifen, the major biologically active metabolite of TAM,
was used as an antiestrogenic control alongside 4OHT and
neither induced an increase or decrease in viable cells (P ,
0.05 compared with vehicle controls) (Supplemental Fig. 2A).
Only inMCF-7:2A cells did 4OHT and endoxifen cause growth
inhibition (Supplemental Fig. 2B), and in MCF-7:RAL cells,
both caused growth stimulation (Supplemental Fig. 2C), as
predicted.
BMI-135 Induces the Transcriptional Activity of ERa
Similar to E2 in WT MCF-7:WS8 and Apoptotic-Type
MCF-7:5C BC Models. Quantitative RT-PCR was used to
assess the transcriptional activity of ERa onERE genes (TFF1
andGREB1) with test compounds. After 24-hour treatment in
MCF-7:WS8 cells, BMI-135 increased the levels of TFF1 and
GREB1 mRNAs compared with vehicle controls (P , 0.05)
(Fig. 3, A and B). On the other hand, the partial agonist
BPTPE induced a partial increase in the levels of TFF1 and
GREB1mRNAs and less than that of full agonist E2 (P, 0.05)
and BMI-135 (P , 0.05) (Fig. 3, A and B). The minimal
concentration that produced a complete increase in the levels
of TFF1 and GREB1 was at 1026 M for BMI-135 (P , 0.05
compared with vehicle) (Fig. 3, A and B).
After 24-hour treatment in MCF-7:5C cells, BMI-135 in-
creased the levels ofTFF1 andGREB1mRNAs comparedwith
vehicle controls (P, 0.05) (Fig. 3, C andD). On the other hand,
BPTPE induced a partial increase in the levels of TFF1 and
GREB1 mRNAs and less than that of E2 (P , 0.05) and BMI-
135 (P , 0.05) (Fig. 3, C and D). The minimal concentration
that produced a complete increase in the levels of TFF1 and
GREB1 was at 1026 M for BMI-135 (P , 0.05 compared with
vehicle) (Fig. 3, C and D).
The ERE-dependent transcriptional activity with E4 was
done by Abot et al. (2014) and showed an induction similar to
E2, only with a lower potency.
Overall, the induction of the mRNA levels of TFF1 and
GREB1 by BMI-135 in MCF-7:WS8 and MCF-7:5C was
similar to that by full agonist E2, only at a lower potency.
Estetrol and BMI-135 Induce the Transcriptional
Activity of ERa Similar to E2 in Human Endometrial
Cancer Model Ishikawa. Transient transfection and lucif-
erase activity assays were used to determine the transcrip-
tional activity of ERa on estrogen-responsive genes (5xERE)
with test compounds as ERE dual luciferase activity. After
Fig. 2. Cell viability and proliferation assays inmultiple BC cell lines with test compounds. (A) Effects of test compounds alone after 7 days of treatment
(percent DNA of vehicle vs. test compounds’ concertation) in MCF-7:WS8. (B) Effects of test compounds alone after 7 days of treatment in T47D:A18. (C)
Effects of test compounds alone after 7 days of treatment inMCF-7:PF. (D) Effects of test compounds alone after 7 days of treatment in BT-474. (E) Effects
of test compounds alone after 7 days of treatment in ZR-75-1. (F) Effects of test compounds alone after 7 days of treatment inMCF-7:5C. (G) Effects of test
compounds alone after 14 days of treatment in MCF-7:2A. (H) Effects of test compounds alone after 21 days of treatment in MCF-7:RAL. Endox, endoxifen.














24-hour treatment of Ishikawa cells, E4 and BMI-135 in-
creased the levels of 5x-ERE luciferase activity compared
with vehicle controls (P, 0.05) (Fig. 4A). On the other hand,
the partial agonist BPTPE induced a partial increase in the
levels of 5x-ERE luciferase activity and less than that of full
agonist E2, E4, and BMI-135 (P , 0.05) at concentration
range of 1028–1026 M (Fig. 4A). The minimal concentration
that produced a complete increase in the levels of 5x-ERE
luciferase activity was at 1027M for E4 and BMI-135 (P, 0.05
compared with vehicle) (Fig. 4A).
To determine whether the effects of E4 and BMI-135 were
mediated via ERa in Ishikawa cells, transiently transfected
Fig. 3. Transcriptional activity of well characterized estrogen-responsive genes TFF1 (or pS2) andGREB1 inWTMCF-7:WS8 andLTEDMCF-7:5Cwith test
compounds. (A)mRNAexpression ofTFF1 inMCF-7:WS8 cells after 24-hour treatmentwith1nME2and1mMfor other test compounds. (B)mRNAexpression
ofGREB1 inMCF-7:WS8 cells after 24-hour treatmentwith 1nME2 and 1mMfor other test compounds. (C)mRNAexpression ofTFF1 inMCF-7:5C cells after
24-hour treatment with 1 nME2 and 1mMfor other test compounds. (D)mRNA expression ofGREB1 inMCF-7:5C cells after 24-hour treatment with 1 nME2
and 1 mM for other test compounds. Data are mean6 S.D. from three independent experiments performed in triplicate analyzed by one-way ANOVA.
Fig. 4. Transient transfection of the human endometrial cancer cells Ishiskawa with 5x-ERE and dual luciferase activity assay. (A) Dose-response curve
of test compounds vs. 5x-ERE luciferase activity (promoter activity = Firefly luciferase activity/Renilla luciferase activity). (B) 5x-ERE luciferase activity
with indicated test compounds alone vs. in combination with 1 mM endoxifen. Data are mean 6 S.D. from three independent experiments performed in
triplicate analyzed by one-way ANOVA. *P , 0.05: statistical difference between E4 or BMI-135 and BPTPE treatments over 10
28–1026 concentration
range (t test). Veh, vehicle.














Ishikawa cells were treated with test compounds in combina-
tion with antagonist endoxifen for 24 hours, and luciferase
activity assays were conducted (Fig. 4B). The increase in the
levels of 5x-ERE luciferase activity with E4 and BMI-135
was blocked with endoxifen treatment at 1026 M (P , 0.05
compared with vehicle) (Fig. 4B). This confirms that E4 and
BMI-135 exert their function via Ishikawa’s ERa. In addition,
endoxifen alone did not increase the levels of 5x-ERE lucifer-
ase activity in Ishikawa cells, acting as an antagonist in this
uterine model (Fig. 4B).
Overall, the induction of the levels of 5x-ERE luciferase
activity by E4 and BMI-135 in Ishikawa cells was similar to
that by full agonist E2, only at a lower potency (Table 1).
E4 and BMI-135 Recruit ERa and SRC-3 to the
GREB1 Proximal Enhancer Region Similar to E2 in
MCF-7:5C BC Model. ChIP assays were used to assess the
recruitment of ERa and SRC-3 to theGREB1 proximal enhancer
regionwith test compounds. Estetrol and BMI-135 treatments
resulted in a very strong recruitment of ERa to the GREB1
proximal enhancer region similar to E2 and higher than that
with the partial agonist BPTPE (P , 0.05) (Fig. 5A).
However, the recruitments of the coactivator SRC-3 to the
GREB1 proximal enhancer region with E4 and BMI-135 treat-
ments were higher than that with BPTPE (P , 0.05) (Fig. 5B).
SRC-3 recruitmentwith E2 was the highest.With E4, there was
an 18.72% recruitment reduction compared with E2; with BMI-
135, there was a 51.17% recruitment reduction compared with
E2; with BPTPE, there was a 65.47% recruitment reduction
compared with E2; and with endoxifen, there was a 98.14% re-
cruitment reduction compared with E2 (Fig. 5B).
Overall, the recruitment of ERa to the GREB1 proximal
enhancer region with E4 and BMI-135 in MCF-7:5C cells was
similar to that by full agonist E2, and the recruitment of SRC-3
to theGREB1 proximal enhancer region with E4 and BMI-135
in MCF-7:5C cells was higher than that with the partial
agonist BPTPE. Although SRC-3 recruitment with BMI-135
treatment was lower than that with E2 (P , 0.05), it was
higher than that with BPTPE (P , 0.05).
Analysis of E4 and BMI-135’s Binding Mode in
Comparison with Full Agonist E2 and Partial Agonist
BPTPE. To outline the similarities and differences between
BMI-135 and other investigated ligands (e.g., E2, E4, and
BPTPE), their overall conformations and interactions with
residues of the binding site were analyzed (Fig. 6; Supplemental
Fig. 10, B–I). The BMI-135 ligand was docked into the experi-
mental structure of the ERa:TTC-352 complex and adopted the
canonical agonist conformation with helix 12 (H12) positioned
over the binding pocket, sealing the ligand inside. We used the
induced fit docking methodology because it allows flexibility for
certain parts of the receptor (e.g., amino acids of the binding site).
The top-ranked BMI-135–receptor pose and experimental struc-
tures of ERa bound to E2, E4, and BPTPE adopt the agonist
conformation of ERa, with H12 sitting in a groove between H5
andH11 delineated byH3 and the ligands occupying the binding
pocket composed of residues from helices H3, H6, H8, and H11
(Fig. 6, A, C, and E).
The predicted binding mode of BMI-135 shared, to some
extent, the network of interactions specific to E2, E4, and
BPTPE, as shown (Fig. 6, B, D, and F; Supplemental Fig. 10,
F–I). The familiar H-bond network between a phenolic
hydroxyl, Glu353, and Arg394 was common to ligands.
The benzothiophene moiety of BMI-135 was implicated in
p-p stacking interactions with Phe404 and made several
additional contacts with Ala350 (H3), Leu387, Met388,
and Leu391 (H6), similar to A and B rings of E2. The two
substituted phenyl rings were involved in hydrophobic con-
tacts with Leu346 (H3), Ala350 (H3), Ile424 (H8), and Leu525
(H11), and the fluorine substituent was headed toward
Thr347 (H3). The most apparent difference between BMI-
135 and E2 binding modes (also seen for BPTPE) was the
absence of H-bond with the imidazole ring of His524. We
noticed that the side chain of His524 was pushed toward the
outer part of the protein by the bulkier ethinyl group of
BMI-135, which hovered between helices H3, H8, and H11 in
a space delineated by residues Met343 (H3), Val418 (H8),
Met421 (H8), Leu525 (H11), andMet528 (H11) (Supplemental
Fig. 5. ChIP assay inMCF-7:5C cells showing the recruitment of ERa and coactivator SRC-3 to TFF1 ERE promoter. Recruitment of ERa (A) and SRC-3
(B) after 45-minute treatment with indicated ligands; 1 nME2 and 1 mM for the rest of test compounds. Recruitment of ERa and SRC-3 was calculated as
percentage of the total input after subtracting the IgG recruitment. All treatments were performed in triplicate; data represent the average of these
replicates. *P , 0.05: statistical difference between BMI-135 and BPTPE treatments with SRC-3 recruitment. Veh, vehicle.














Fig. 10H). These flexible residuespermitted theaccommodationof
the large etinylbenzoyl moiety in this part of the binding pocket.
A contact unique to BPTPE was the H-bond between the
second phenolic group of the ligand and the OH group of
Thr347 (Fig. 6D), whereas specific to E4 was the involve-
ment of the second OH group of the D ring into an extra
H-bond to His524, adding stability to the ligand in the
binding site (Fig. 6F). In addition, the hydrophobic contacts
and p-p stacking interactions with Phe404 complemented
the binding profile of these ligands (Supplemental Fig. 10,
C, E, G, and I).
MD Simulations Analysis. To investigate the stability of
BMI-135 in the binding site of ERa, the dynamics of the
interactions, and how they compared with the interactions in
the structures of E2 and BPTPE, we performed MD simu-
lations against the top-ranked ERa:BMI-135 complex, as
previously described in Materials and Methods. The recorded
trajectory was analyzed and compared with the trajectories
previously reported (Maximov et al., 2020) for WT ERa bound
to E2 and BPTPE.
Firstly, we explored the conformational stability of the
simulation. To ensure that the model had reached equilib-
rium, RMSDs of the protein backbone atoms, relative to their
position in the first frame, were computed for trajectory. The
RMSD evolution indicated that the system had reached
equilibrium after approximately 5 nanoseconds, similar to
the E2 model (Supplemental Fig. 3A).
Next, to investigate the mobility of the protein and the
dynamics of ligand binding, we monitored the RMSF of the
residues along the trajectory (Supplemental Fig. 3A). Com-
paring the RMSF calculated for backbone atoms with the
previously reported values for the runs of E2 and BPTPE, we
noticed a similar pattern for BMI-135 and E2. There were
several substantial fluctuations, which mainly overlapped
with the flexible domains of the receptor (a significant peak
located between residues 332–338 matches the loop connect-
ing helices H2 andH3). The largest peak in all trajectories was
situated between residues 456 and 469, part of the loop
connecting H9 to H10, and missing in all experimental
structures used in this analysis (Supplemental Fig. 3A). The
high flexibility of this domain and the predicted coordinates
for this loop could explain the observed fluctuation. Overall,
theBMI-135 complex showedmobility domainsmatchingwith
the E2 system mainly positioned in connection loops, flexible
regions of a protein. In addition, based on the previous
analysis of the correlation between RMSF values and
Fig. 6. Representations of ERa-LBD with E2, E4,
BMI-135, and BPTPE. Comparison between the
agonist conformation of ERa-LBD in complex with
E2, superimposed with BMI-135 (A), BPTPE (C), and
E4 (E) in similar conformations of the receptor. The
helices forming the ligand-binding site are labeled
togetherwith helix 12 (H12), which defines the receptor
conformation and those essential for the coactivator
binding groove. The alignment in the binding site
and the contacts between BMI-135 (B), BPTPE (D),
E4 (F), and critical amino acids of the binding
pocket are revealed in comparison with the binding
alignment of E2. For BMI-135 and BPTPE, themost
representative conformations extracted from MD
trajectories are shown, whereas for E2 and E4, the
experimental structures are presented. The ligand:
receptor complexes are colored based on C atoms as
follows: yellow for E2, blue for BMI-135, magenta
for BPTPE, and light green for E4, whereas the N,
O, and S atoms are colored in dark blue, red, and
yellow, respectively. For clarity, the amino acids
involved in critical contacts (i.e., H-bonds and p- p
stacking) are shown as sticks together with those
having contacts with occurrence frequencies during
the MD trajectories larger than 40% of the simula-
tion time. The remaining amino acids of the binding
sites are shown as lines. The H-bonds redepicted as
black dashed lines.














B-factors for E2 and BPTPE, we observed that the high RMSF
values of protein fragments parallel with large B-factors.
Then, we explored the stability of the ligands relative to the
protein and the binding site together with the internal
fluctuations of ligands’ atoms (Supplemental Fig. 3B). The
analysis shows that BMI-135 did not fluctuate significantly
and was stably bound in the active site, similar to E2 and
BPTPE, with average RMSD values of 0.8 6 0.23 and 1.6 6
0.34 Å, respectively (Supplemental Fig. 3B).
Analysis of BMI-135 Ligand-Protein Interactions in
Modeled WT ERa Systems. We analyzed the binding
dynamics of BMI-135 and assessed the stability of the
interactions by monitoring the frequency of occurrence of that
specific interaction throughout the trajectory. Overall, the
computed variations of RMSF, based on the backbone and
side-chain atoms, showed similar trends for E2, BMI-135, and
BPTPE (Supplemental Fig. 10A). The residues involved in
H-bonds with the ligands (e.g., Thr347, Glu353, His524), p-p
stacking, and hydrophobic contacts (e.g., Phe404, Ala350,
Leu387) showed RMSF values that were smaller than average
and fluctuated less, indicating stable contacts. This observa-
tion was also supported by the occurrence frequencies of these
interactions monitored throughout the trajectory (Supplemental
Fig. 11, A–C). A striking difference was noticed for BMI-135,
which displayed the largest peak of side-chain RMSF for Arg394.
This mobility indicated that Arg394 was not involved in a direct
H-bond with the ligand and/or ionic bridges to Glu353, therefore
not stabilizing it.However,H-bondswere sporadicallymonitored
during the simulationbetween the ligandandArg394 via awater
bridge, with frequencies below 15%. Additionally, the bulkier
substituents of BMI-135 displaced the amino acid and forced it
not to adopt orientations proper for the binding.
Similarly to E2, BMI-135 was stabilized by the H-bond to
Glu353 andp-p stacking interactionswithPhe404 but occurred
in lower frequency. The hydrophobic contacts, mainly with
residues Ala 350, Leu384, Leu 387, Met388, Leu391, Leu403,
and Leu525, were stable for both ligands during the simulation
time, however, in lower occurrence frequencies for BMI-135
(Supplemental Fig. 11, A and B). The H-bond to His524, which
was very stable for E2, was lacking for BMI-135 and BPTPE,
but occasional hydrophobic contacts with the ethinyl-benzoyl
moiety of BMI-135 were noticed. BPTPE mainly recapitulated
the interactions mentioned above but with frequencies lower
than those of E2.
A distinctive feature of BPTPE is the H-bonding to Thr347,
which occurred in over 95% of the trajectory (Supplemental
Fig. 11C), indicating a very stable contact, and this was
confirmed by the low RMSF value of the residue (Supplemental
Fig. 10A). However, as previously shown, the H-bond to Thr347
prevented the formation of an H-bond between the side chains of
Asn348 (H3) and Tyr537 (H11) (usually forming a stabilizing
contact in the vicinity of H12) and, together with the phenol
group of BPTPE, triggered a slightly different conformation of
H12 (Maximov et al., 2020). Although the 4-fluoro-phenyl sub-
stituent of BMI-135 was oriented toward Thr347, the interaction
Asn348-Tyr537 was not disturbed and occurred 52% of the
simulation time but to a slightly lesser extent compared with
E2 (i.e., 70%); nonetheless, it is still significant. Another contact
that added stability to the agonist conformation of the receptor
was the interaction between the side chain of His524 and
backbone of Glu419, which was found almost 80% of the time
during the simulation of E2. Surprisingly, this contact was
observed in the trajectory of BMI-135 with a frequency of
72% of the simulation time.
Overall, these data show the confirmation of the BMI-135:
ERa complex to be more similar to that of E2, compared with
that of BPTPE.
E4 and BMI-135 Activate the UPR. Human UPR real-
time profiler assays were used to assess the regulation of UPR
genes with test compounds. Cell viability and proliferation
assays showed a decline in MCF-7:5C cell DNA amount with
E2 and E4 treatments at 72 hours (Fig. 7D). Furthermore, flow
cytometry showed apoptosis at 72 hours (annexin staining
14.8% with E2 and 12.6% with E4 vs. vehicle control 4.5%)
(Fig. 7E). The time point at 48 hours was chosen to investigate
the terminal (or proapoptotic) UPR gene regulation with E2
and E4 treatments in MCF-7:5C cells, which precedes apopto-
sis by 72 hours.
After 48-hour treatment with 1 nME2 and 1 mME4 [i.e., these
concentrations were shown earlier to trigger maximal cellular
death (Fig. 2; Table 1)], the endoplasmic reticulum–associated
degradation (ERAD) genes (downstream IRE1a/XBP1s and
ATF6 p50), HTRA4 (P , 0.001), SYVN1 (P , 0.001), and
HERPUD1 (P , 0.001), were downregulated (Fig. 7, B and C;
Supplemental Fig. 5, A and B). The lipid or cholesterol metab-
olism genes (downstream IRE1a/XBP1s and ATF6 p50),
MBTPS1 (P , 0.001) and SERP1 (P , 0.001), were down-
regulated with E2 treatment, whereas onlyMBTPS1 (P, 0.001)
was downregulated with E4 (Fig. 7, B and C; Supplemental Fig.
5, A and B). The chaperone (chaperones are usually downstream
IRE1a/XBP1s, PERK/P-eIF2a:ATF4, and ATF6 p50) gene SIL1
(P , 0.001) was downregulated with E4 treatment (Fig. 7C;
Supplemental Fig. 5B). By contrast, the genes CEBPB (P ,
0.001) and INHBE (P , 0.001), which reflect high UPR stress,
wereupregulated (Fig. 7, BandC;SupplementalFig. 5,A andB).
The heat map of MCF-7:5C cells with E2 and E4 treatments
at 48 hours displays a general UPR gene downregulation
(situated on the right side of the heat map) compared with
vehicle control (situated on the left) (Fig. 7A). The majority of
the profiler assays’ genes belong to the lipid metabolism,
ERAD, and chaperone gene groups, which are considered
prosurvival mechanisms that help the cells cope with extrinsic
or intrinsic cellular stress (Fig. 9). This general downregula-
tion by 48 hours (Fig. 7, B andC; Supplemental Fig. 5, A andB)
highlights MCF-7:5C cells’ proapoptotic UPR phase and pro-
gramming to undergo apoptosis by 72 hours (Fig. 7E).
Cell viability and proliferation assays showed a decline in
MCF-7:5C cell DNA amount with BMI-135 treatment by
96 hours (Fig. 8D). Furthermore, flow cytometry showed
apoptosis by 96 hours (annexin staining 17.1% with BMI-135
vs. vehicle control 5.7%) (Fig. 8E). The time point of 72 hours
was chosen to investigate the proapoptotic UPR gene regula-
tion with BMI-135 treatment in MCF-7:5C cells, which pre-
ceded apoptosis by 96 hours. Another time point of 48 hours
was chosen to compare and contrast the UPR gene regulation
with that by 72 hours and show how this regulation is dynamic
and culminates over time.
After 48-hour treatmentwith 1mMBMI-135, the ERAD genes
EDEM1 (P , 0.001), HTRA4 (P , 0.001), SYVN1 (P , 0.001),
and HERPUD1 (P , 0.001) were downregulated (Fig. 8C;
Supplemental Fig. 5C). The lipid metabolism genes MBTPS1
(P, 0.001) and SERP1 (P, 0.001)were downregulated (Fig. 8C;
Supplemental Fig. 5C). By contrast, the genes CEBPB (P ,
0.001) and INHBE (P , 0.001) were upregulated (Fig. 8C;














Supplemental Fig. 5C). Interestingly, there was a 9.46-fold (P ,
0.05) downregulation of EIF2AK3 (PERK) (Supplemental Fig.
5C), whichmight play a role inMCF-7:5C cells’ delayed course
of apoptosis with BMI-135 treatment compared with E2 and
E4. After a 72-hour treatment with 1 mM BMI-135, there was
an intensified (or terminal) UPR gene regulation compared
with 48 hours, with an upregulation of CEBPB (P , 0.001),
INHBE (P, 0.001), PPP1R15A (GADD34, P, 0.001), DDIT3
(CHOP, P , 0.001), and ERN1 (IRE1a, P , 0.001). This is
coupled with a downregulation of the ERAD genes, HTRA4
(P, 0.001), SEL1L (P, 0.01), andHERPUD1 (P, 0.001); the
chaperone gene HSPA2 (P , 0.001); and the lipid metabolism
gene MBTPS1 (P , 0.001) (Fig. 8B; Supplemental Fig. 5D).
The heat map of MCF-7:5C cells with BMI-135 treatment at
72 hours (Fig. 8A) displays a general UPR gene downregula-
tion (situated on the right side of the heat map) compared
with vehicle control (situated on the left). This general
downregulation by 72 hours (Fig. 8B; Supplemental Fig.
5D) highlights MCF-7:5C cells’ trajectory to undergo apo-
ptosis by 96 hours (Fig. 8E).
Cell viability and proliferation assays showed a decline in
MCF-7:5C cell DNA amount with BPTPE treatment by day 8
(Supplemental Fig. 4D). Furthermore, flow cytometry
showed apoptosis by day 8 (annexin staining 31.5% with
BPTPE vs. vehicle control 9.4%) (Supplemental Fig. 4E).
The time point of day 7 was chosen to investigate the
proapoptotic UPR gene regulation, which precedes apoptosis
by day 8. Another time point of day 3 was chosen to compare
and contrast the UPR gene regulation with that of day 7
and show how this regulation is dynamic and culminates
over time.
After a 3-day treatment with 1 mM BPTPE, there was
a relatively minor UPR gene activation compared with the one
seen by day 7 (Supplemental Figs. 4, B and C and 5, E and F).
Interestingly, there was a 2.15-fold (P , 0.001) downregula-
tion of EIF2AK3 with 3-day BPTPE treatment (Supplemental
Fig. 5E), which might play a role in MCF-7:5C cells’ delayed
course of apoptosis with BPTPE treatment compared with E2
and E4. This is also observed with BMI-135’s early treatment
time point (Supplemental Fig. 5C). After a 7-day treatment
with BPTPE, there was a downregulation of the ERAD gene
HERPUD1 (P , 0.001), the lipid metabolism genes INSIG2
(P, 0.001) andMBTPS1 (P, 0.001), and the chaperone genes
HSPA2 (P , 0.001) and DNAJB9 (P , 0.001) (Supplemental
Figs. 4B and 5F).
The heat map of MCF-7:5C cells with BPTPE treatment at
day 7 (Supplemental Fig. 4A) displays a general UPR gene
downregulation (situated on the left side of the heat map)
compared with vehicle control (situated on the right). This
general downregulation by day 7 (Supplemental Figs. 4B and
5F) highlights MCF-7:5C cells’ programming to undergo
apoptosis by day 8 (Supplemental Fig. 4E).
The statistically significant regulated UPR genes with test
compounds are stated and grouped at select time points
(Fig. 9) to show the similar terminalUPR regulation preceding
apoptosis.
Fig. 7. Human UPR RT2 PCR profiler PCR arrays, proliferation assays, and annexin V staining in MCF-7:5C cells with 48-hour, 96-hour, and 7-day E2
and E4 treatments. (A) A heatmap providing a visualization of the fold changes in expression between select groups (from left to right; vehicle, E4, and E2,
respectively) for every gene in the array in the context of the array layout. (B) A volcano plot of 48-hour E2 treatment identifying significant gene-
expression changes and displaying statistical significance vs. fold change on the y- and x-axes, respectively. The volcano plot combines a P-value
statistical test with the fold-regulation change-enabling identification of genes with both large and small expression changes that are statistically
significant. (C) A volcano plot of 48-hour E4 treatment. (D) Effects of E2 and E4 alone after 7 days of treatment. (E) Flow cytometry of 72-hour E2 and E4
treatments. (B and C) Green represents downregulated, black unchanged, and red upregulated. Data are mean 6 S.D. from three independent
experiments performed in triplicate analyzed by one-way ANOVA. Veh, vehicle.














E4 and BMI-135 Induce ThT Fluorescence as
a Marker of UPR. ThT has been successfully used for the
detection and quantification of EnR stress and the UPR in
living cells (Beriault andWerstuck, 2013) given that it directly
interacts with the accumulated misfolded protein amyloid
during the UPR (Beriault and Werstuck, 2013).
The “blue” Hoechst 33342 dye was used for counter-
staining as a live cell nuclear dye (channel A), the “green”
ThT dye was used as a UPR-indicative dye (channel B), and
a colocalization of ThT and Hoechst 33342 dyes is shown
(channel C). 17b-Estradiol and E4 were shown to induce
ThT fluorescence by 48 hours, like the induction seen with
positive control thapsigargin, and compared with vehicle
control (Supplemental Fig. 6B). After 48-hour treatment, E4
had the highest ThT relative intensity/cell of 1.244892,
and this was followed by thapsigargin of 0.875072; E2 of
0.741126; and BMI-135 of 0.497225, compared with vehicle
control of 0.27594 (Table 2A).
BMI-135 induced a stronger delayed ThT fluorescence by
72 hours (Fig. 10B; Table 2B) compared with that seen by
48 hours (Supplemental Fig. 6B; Table 2A). The relative
intensity/cell with 48-hour BMI-135 treatment was 0.497225
compared with vehicle control 0.27594 (Table 2A). However,
the relative intensity/cell with 72-hour BMI-135 treatment
was 4.878173 compared with vehicle control of 0.29573
(Table 2B). The relative intensity/cell over time is represented
in Table 2.
E4 and BMI-135 Induce Apoptosis in Multiple
Endocrine-Resistant and Estrogen-Independent BC
Models. Flow cytometry was used to determine whether
the type of stress-induced cell death in MCF-7:5C, MCF-7:
2A, and MCF-7:RAL cells was apoptosis when treated with
1 mM E4 and 1 mM BMI-135.
In MCF-7:5C, 1 mME4 induced apoptosis (annexin staining
12.6% vs. vehicle control 4.5%) similar to the time course of 1
nME2 (annexin staining 14.8%vs. vehicle control 4.5%) (Fig. 7E),
which was by 72 hours. However, MCF-7:5C’s apoptosis with
BMI-135 treatment (annexin staining 17.1% vs. vehicle control
5.7%) was delayed by 96 hours (Fig. 8E representing 96 hours;
Supplemental Fig. 8D representing 72 hours). The antagonist
4OHT (as a negative control) and its pairing with E2, E4, and
BMI-135 did not induce apoptosis by 72 or 96 hours, as predicted
(unpublished data).
In MCF-7:2A, E4 induced apoptosis (annexin staining
6.7% vs. vehicle control 0.8%) similar to the time course
of E2 (annexin staining 8% vs. vehicle control 0.8%)
(Supplemental Fig. 8A), which was by day 9. However,
MCF-7:2A’s apoptosis with BMI-135 treatment (annexin
staining 7.3% vs. vehicle control 2.2%) was delayed by day
13 (Supplemental Fig. 8B representing day 13; Supplemental
Fig. 8C representing day 9). The antagonist 4OHT (as
a negative control) and its pairing with E2, E4, and
BMI-135 did not induce apoptosis by day 9 or 13, as
predicted (unpublished data).
Fig. 8. HumanUPRRT2 PCR profiler PCR arrays, proliferation assays, and annexin V staining inMCF-7:5C cells with 48-hour, 72-hour, 96-hour, and 7-
day BMI-135 treatments. (A) A heat map of 72-hour BMI-135 treatment, providing a visualization of the fold changes in expression between the select
groups (from left to right; vehicle and BMI-135, respectively) for every gene in the array in the context of the array layout. (B) A volcano plot of 72-hour
BMI-135 treatment. (C) A scatter plot of 48-hour BMI-135 treatment comparing the normalized expression of every gene on the array between the two
select groups by plotting them against one another to quickly visualize large gene-expression changes. The central line indicates unchanged gene
expression. The dotted lines indicate the selected fold-regulation threshold. Data points beyond the dotted lines in the upper left and lower right sections
meet the selected fold-regulation threshold. (D) Effects of BMI-135 alone after 7 days of treatment. (E) Flow cytometry of 96-hour BMI-135 treatment. (B
and C) Green represents downregulated, black unchanged, and red upregulated. Data are mean6 S.D. from three independent experiments performed
in triplicate analyzed by one-way ANOVA. Veh, vehicle.














In MCF-7:RAL, E4 induced apoptosis (annexin staining
7.6% vs. vehicle control 5.3%) similar to the time course of
E2 (annexin staining 9% vs. control 5.3%) (Supplemental Fig.
9A), which was by day 14. However, MCF-7:RAL’s apoptosis
with BMI-135 (annexin staining 8% vs. control 0.8%) was
delayed until day 17 (Supplemental Fig. 9B representing day
17; Supplemental Fig. 9C representing day 14). The antago-
nists 4OHT and raloxifene and their pairing with E2, E4, and
BMI-135 did not induce apoptosis by day 14 or 17, as predicted
(Supplemental Fig. 9A). Interestingly, treatment of MCF-7:
RAL cells with ICI for 3 weeks caused a decline in cell DNA
amount (P , 0.05) (Supplemental Fig. 2C); however, this was
not due to apoptosis (Supplemental Fig. 9D). Such observed
effect of ICI in MCF-7:RAL could be attributed to growth
inhibition by preventing cell replication.
Inhibition of PERK Pathway Blocks Apoptosis in
MCF-7:5C with E4 and BMI-135 Treatments. Blocking
the UPR transducer PERK with 10 mM GSK G797800 in
combinationwith 1 nME2 and in combinationwith 1mME4 by
72 hours inhibited apoptosis (annexin staining 7.8% and 7.9%,
respectively, vs. vehicle control 7%) (Supplemental Fig. 7A)
compared with E2- and E4-alone treatments that trigger
apoptosis (Fig. 7E) and compared with the negative control
GSK G797800–alone treatment that does not trigger apoptosis
(annexin staining 5.7% vs. vehicle control 7%) (Supplemental
Fig. 7A).
Blocking PERK with 10 mM GSK G797800 in combina-
tion with 1 mM BMI-135 by 96 hours inhibited apoptosis
(annexin staining 4% vs. vehicle control 5.7%) (Fig. 11A)
compared with BMI-135–alone treatment that triggers
apoptosis (Fig. 11A) and compared with GSK G797800–alone
treatment (annexin staining 5.5% vs. control 5.7%)
(Fig. 11A).
Inhibition of IRE1a:XBP1s Pathway Enhances Apo-
ptosis in MCF-7:5C with E4 and BMI-135 Treatments.
The compound MKC-3946 inhibits IRE1a by inhibiting basal
XBP1 splicing. Blocking the UPR transducer IRE1a with
20 mM MKC-3946 in combination with 1 mM E4 by 72 hours
induces more apoptosis (annexin staining 34.1% vs. control
1.4%) (Supplemental Fig. 7B) compared with E4-alone treat-
ment that triggers apoptosis (annexin staining 18.6% vs.
control 1.4%) (Supplemental Fig. 7B) and compared with
MKC-3946–alone treatment that triggers apoptosis (annexin
staining 8.8% vs. control 1.4%) (Supplemental Fig. 7B).
Blocking IRE1awith 20 mMMKC-3946 in combination with
1 mM BMI-135 by 96 hours induces more apoptosis (annexin
staining 33.3% vs. control 1.4%) (Fig. 11B) compared with
BMI-135–alone treatment (annexin staining 26.5% vs. control
1.4%) (Fig. 11B) and compared with MKC-3946–alone treat-
ment (annexin staining 8.8% vs. control 1.4%) (Fig. 11B).
Discussion
Estetrol is a naturally occurring fetal estrogen, which is
associated with a low risk of drug-drug interactions (CYP450
family) and a neutral impact on risk markers of venous
thromboembolism (Singer et al., 2014; Coelingh Bennink
et al., 2017; Verhoeven et al., 2018). BMI-135 is a member of
a new class of estrogenmimics, which did not cause significant
uterine proliferation (Molloy et al., 2014; Xiong et al., 2016).
Estetrol and the ShERPA TTC-352 are currently being evaluated
in endocrine-resistant MBC clinical trials (O’Regan et al., 2019;
Fig. 9. A schematic representation of the statistically significant UPR genes and their gene groupings with test compounds. The y-axis displays fold
regulation, and the x-axis states theUPRgenes and their groupings, demonstrating a signature proapoptoticUPR regulation at different time points with
test compounds. Green represents downregulation and red upregulation. The ERAD proteins decrease cellular stress by degrading severely misfolded or
unfolded proteins, and chaperones do so by folding the misfolded or unfolded proteins that could be rescued (Hetz, 2012). Lipid metabolism-related
proteins play a critical role in lipidmetabolism and homeostasis to combat cellular stress (Hetz and Saxena, 2017). The downregulation of theseUPR gene
groups (P , 0.05) as well as the upregulation of UPR stress indicators (INHBE and CEBPB) (P , 0.05) form a UPR phase whose regulation is
characterized as terminal/proapoptotic (Maly and Papa, 2014; Grootjans et al., 2016).














Schmidt et al., 2020). Our study, in a wide range of endocrine-
resistant and estrogen-independent BC cell models as well as an
endometrial cancer cell model, shows E4 and BMI-135 to be less
potent full estrogen agonists (Figs. 2–5 and 6, B and F) with the
induction of terminal UPR and apoptosis as their antitumor
mechanism of action (Figs. 7–12; Supplemental Figs. 5, B and D
and 6–9). Although BMI-135 exhibits a slightly delayed UPR-
and-apoptosis biology compared with E2 and E4 (Figs. 7–11;
Supplemental Figs. 6–9), it is still distinct from the much delayed
UPR-and-apoptosis biology of the benchmark partial agonist
BPTPE (Supplemental Fig. 4).
The application of long-term adjuvant endocrine therapy
(Jordan et al., 1979) to treat ER-positive BC is invaluable for
patient care. As a result, women’s lives are extended or saved
(Early Breast Cancer Trialists’ Collaborative Group, 1998;
Goss et al., 2003, 2005). Nonetheless, recurrence of endocrine-
resistant stage IV BC is common (Pisani et al., 2002), hence
the discovery of new therapeutic options remains a clinical
priority.
Cell models (Pink et al., 1995; Liu et al., 2003; Lewis et al.,
2005b; Ariazi et al., 2011; Fan et al., 2014) and athymic mice
models (Gottardis and Jordan, 1988; Gottardis et al., 1989a,b;
Yao et al., 2000) deciphered the evolution of acquired TAM
resistance over years to eventually give rise to a vulnerability
in BC: E2-induced apoptosis (Jordan, 2008; Jordan, 2015).
Although estrogen is approved to treat BC, there is a re-
luctance to use estradiol as a salvage therapy in stage IV BC
because of AEs. As a result, safer estrogenic alternatives are
being considered.
Our goal was to compare and contrast the actions of E4 and
BMI-135 with the well characterized partial agonist BPTPE.
Our earlier pharmacological studies classified ER-binding
ligands into agonists, partial agonists, and antagonists
(Jordan, 1984; Jordan et al., 1984, 1986; Murphy et al.,
1990a) and are essential to decipher the current molecular
mechanisms of E2-induced apoptosis through the ER signal
transduction pathway. These functional cell-based assays
(Lieberman et al., 1983a,b; Jordan and Lieberman, 1984;
Jordan et al., 1986) dovetailed with the subsequent X-ray
crystallography studies of the agonist and antagonist ER
complexes of the LBD (Brzozowski et al., 1997; Shiau et al.,
1998). Our earlier biologic studies described E2-induced
apoptosis (Jordan, 2015). Our current study shows that E4
and BMI-135:ERa complexes initiate and modulate the UPR
(Figs. 7–12; Supplemental Figs. 5–7). This is an ERa-medi-
ated (Supplemental Fig. 2) activation of the unfolded proteins’
synthesis and thus of cellular stress.
The intrinsic activity of the ER complex was evaluated by
comparing and contrasting TFF1 and GREB1 estrogen-regulated
gene activation with E2, BMI-135, BPTPE, and endoxifen
Fig. 10. Detection ofUPR in liveMCF-7:5C cells usingThT fluorescent dye after 72-hour treatments asmeasured by the ZEISSCelldiscoverer 7microscope.
(A) Hoechst 33342 dye single panel (blue). (B) ThT dye single panel (green). (C) A merge or colocalization ThT + Hoechst 33342 dyes panel (blue and green).
Treatments included 0.1% DMSO (vehicle control), 1 mM thapsigargin (positive control; promoting EnR stress by disrupting EnR Ca2 + homeostasis), and 1
mM BMI-135. Scale bar, 50 mM. ThT relative intensity/cell, per treatment, is the mean of three biologic repeats with S.D. (Table 2B). Veh, vehicle.














treatments in WT MCF-7 and LTED MCF-7:5C cells (Fig. 3).
The pharmacology of each ligand as a full agonist (E2, E4, and
BMI-135) or a partial agonist (BPTPE) or an antagonist with
no intrinsic activity (endoxifen) mirrored the pharmacology in
cells (Fig. 2).
Molecular modeling studies demonstrated that E4, BMI-
135, and BPTPE bind to the classic agonist conformation of
ERa, similar to E2 (Fig. 6, A, C, and E). The flexible docking
and MD simulations performed for BMI-135:ERa complex
show the dynamic profile of the system to be similar to E2
(Supplemental Fig. 3A) with the ligand firmly bound to the
active site (Supplemental Fig. 3B). Although BMI-135 is
larger than E2, the same contacts have been observed, with
the notable exception of the H-bond to His524 (Fig. 6B).
These H-bonds and hydrophobic contacts are stable for both
ligands, with slightly larger frequencies of occurrence with
E2 (Supplemental Fig. 11, A and B), which indicates
a stronger binding mode of E2. BPTPE exhibits equivalent
binding contacts to E2 (Fig. 6, C and D) but forms a distinc-
tive robust H-bond with Thr347 (Supplemental Fig. 11C),
which induces the stability of the ligand binding but
increases the mobility of H12 and the loop connecting H11
and H12, which affects the overall stability of the system.
This is most likely responsible for the partial agonist profile
of BPTPE. These data support the molecular classification
of E4 and BMI-135 as full agonists and further explain their
observed biologic behavior.
A comparison of E4, BMI-135, and BPTPE in multiple WT
and LTED BC cell lines (Fig. 2; Supplemental Fig. 1)
demonstrates the partial agonist actions of BPTPE on both
growth (Figs. 2, A–E and 3, A and B; Supplemental Fig. 1, A–C
and F) and E2-induced apoptosis (Figs. 2, F–H and 3, C and D;
Supplemental Fig. 4, D and E). All experiments used
BPTPE as a well characterized partial agonist (Jordan
and Lieberman, 1984), which triggers delayed E2-induced
apoptosis in LTED BC cells compared with E2 (Obiorah
et al., 2014; Obiorah and Jordan, 2014) (Supplemental Fig.
4E). Themechanism is shown here to be through a delay in the
induction of the proapoptotic UPR signaling (Supplemental
Figs. 4, B and C and 5, E and F).
Delayed apoptosis with BPTPE (which contains a free para-
hydroxyl on the phenyl ring) mirrors the delayed apoptosis
with the synthesized angular triphenylethylene (TPE) de-
rivative 3OHTPE (which contains the free para-hydroxyl)
(Maximov et al., 2020). The other synthesized TPE derivative
Z2OHTPE does not contain the free para-hydroxyl and causes
early apoptosis, similar to E2 (Maximov et al., 2020). This free
para-hydroxyl in BPTPE and 3OHTPE is part of the anti-
estrogenic side chain of endoxifen, which prevents the com-
plete closure of ERa’sH12 over the ligand:LBD (Supplemental
Fig. 11C). This delays the coactivators’ recruitment to the ER
to form a transcriptionally active complex (Fig. 5B), which
delays the ligand:ERa–induced transcription and translation
of the unfolded proteins, resulting in delayed apoptosis
(Supplemental Fig. 4).
Although BMI-135 does not exhibit the pharmacology of
BPTPE (Figs. 2–5 and 6, A and B; Table 1), there is still
a slight delay in the induction of the terminal UPR signaling
and apoptosis, which is mediated by the BMI-135:ERa
complex (Figs. 8, B and E and 10B; Supplemental Fig. 5D;
Fig. 11. Flow cytometry inMCF-7:5C cells with BMI-135 plus a PERK inhibitor or an IRE1a inhibitor after 96-hour treatments. (A)MCF-7:5C cells were
treated with 0.1% DMSO (vehicle control), 1 mM BMI-135, 10 mM GSK G797800, and 1 mM BMI-135 + 10 mMGSK G797800 then stained with annexin
V–FITC and propidium iodide and analyzed by flow cytometry. Viable cells (left lower quadrant) are annexin V–FITC2 and PI2; early apoptotic cells
(right lower quadrant) are annexin V–FITC+ and PI2; dead cells (left upper quadrant) are PI+, and late apoptotic cells (right upper quadrant) are
annexin V–FITC+ and PI+. An increased, late apoptotic effect is observed in the right upper quadrant. (B) MCF-7:5C cells were treated with 0.1% DMSO
(vehicle control), 1 mMBMI-135, 20 mMMKC-3946, and 1 mMBMI-135 + 20 mMMKC-3946. Data are mean6 S.D. from three independent experiments
analyzed by one-way ANOVA. (A and B).














Table 2B for the 72-hour time point vs. Fig. 8C; Supplemental
Figs. 5C, 6B, and 8D; Table 2A for the 48-hour time point).
The ChIP assay (Fig. 5) is valuable in understanding the
delayed apoptotic biology with BMI-135 and BPTPE. Earlier
studies (Sengupta et al., 2013; Obiorah et al., 2014) demon-
strated a reduction in the binding of the BPTPE:ERa:SRC-3
complex using the ChIP assay in MCF-7 cells, which is
reproduced here (Fig. 5, A and B). A reduced DNA binding of
the partial agonist complex occurs, which correlates with a re-
duction in the efficacy of the complex to synthesize misfolded or
unfolded proteins, hence with a delay in the induction of the
terminal UPR and apoptosis compared with E2 (Supplemental
Fig. 4). Although BMI-135 recruits equivalent quantities of ERa
(Fig. 5A), there is a reduced recruitment of the coactivator SRC-3
compared with E2 and E4. Nonetheless, BMI-135:ERa’s recruit-
ment of SRC-3 is higher than that with BPTPE (P , 0.05)
(Fig. 5B). This correlates with BMI-135’s slightly delayed in-
duction of the terminal UPR and apoptosis (Fig. 8).
The downregulation of the prosurvival mechanisms, chaper-
ones, ERAD, and lipid metabolism genes (P , 0.05), alongside
the upregulation of marker UPR stress proteins (INHBE
and CEBPB) (P , 0.05) constitute the terminal/proapop-
totic UPR phase and underscore the antitumor mechanism
of E2, E4, BMI-135, and BPTPE (Figs. 7–9 and 12; Supplemental
Figs. 4 and 5).
Apoptosis with E4 and BMI-135 treatments was prevented by
blocking thePERKpathway (Fig. 11A; SupplementalFig. 7A).By
contrast, blocking the IRE1a:XBP1s pathway after E4 and BMI-
135 treatments enhanced apoptosis (Fig. 11B; Supplemental
Fig. 7B). These data demonstrate the modulation of apoptosis
with E4 and BMI-135 through the modulation of UPR’s
subcellular sensors.
The timing of UPR-indicative ThT fluorescence with E4 and
BMI-135 is synchronic with that of their proapoptotic UPR
gene regulation (P, 0.05). The ThT fluorescence and terminal
UPR gene regulation were shown to be by 48 hours with E2
and E4 (before apoptosis by 72 hours), by 72 hours with BMI-
135 (before apoptosis by 96 hours), and by day 7 with BPTPE
(before apoptosis by day 8) (Figs. 7, 8, and 10B; Supplemental
Figs. 4, 5, and 6B; Table 2).
Translational research (Gottardis et al., 1988) identified
a potential link between TAM treatment and the occurrence of
endometrial cancer in patients (Jordan and Assikis, 1995).
Raloxifene does not have an increased risk of endometrial
cancer in clinical trials (Cummings et al., 1999; Vogel et al.,
2006). BMI-135 is a raloxifene derivative (Fig. 1) (Xiong et al.,
2016) and was tested to determine whether the ShERPABMI-
135:ER:coregulators complex is an agonist in the human
endometrial cancer cell line Ishikawa transfected with 5x-
ERE (Fig. 4). BPTPE exhibited a partial agonist activity
(Fig. 4A), but both E4 and BMI-135 exhibited a less potent
full agonist activity compared with E2 (Fig. 4A). This effect is
mediated via the Ishikawa ERa (Fig. 4B). Although BMI-135
was shown not to induce uterine growth in a mouse xenograft
model (Xiong et al., 2016), based on this study’s observations,
it would be wise to require an endometrial screening for
patients with BC receiving E4 or BMI-135.
Raloxifene induces acquired resistance as evidenced by
SERM-stimulated BC cell growth (Liu et al., 2003; Balaburski
et al., 2010) (Fig. 2H; Supplemental Figs. 1F and 2C). Such
Fig. 12. Schematic representation of the study’s concluded
antitumor molecular mechanisms of E4, BMI-135, and
BPTPE in LTED endocrine-resistant BC MCF-7:5C. Este-
trol:ERa complex recruits the most coactivator SRC-3 and
thus induces the most accumulation of unfolded proteins
(highest threshold of stress), followed by BMI-135:ERa
(BMI-135 is referred to as BMI in the illustration) and
BPTPE:ERa (BPTPE is referred to as BP in the illustra-
tion). This differential ligand:ERa:coactivator-induced en-
doplasmic reticulum stress activates the transducers of the
UPR, with a downregulation of chaperons, ERAD, and lipid
metabolism genes and proteins (P , 0.05), which are
considered prosurvival mechanisms. This downregulation
state constitutes the proapoptotic UPR phase, which is
reached quickly with E4, followed by BMI-135 and BPTPE,
and eventually induces apoptosis.














laboratory data have clinical significance because a case report
of an antiestrogen withdrawal effect with raloxifene was
reported (Lemmo, 2016). Raloxifene-resistant BC-stimulated
growth has not been widely reported during the decades of
treatment in patients with osteoporosis. This is surprising, but
perhaps clinicians have not been aware of this form of SERM
resistance. Nevertheless, our findings here (Supplemental Fig.
9, A and B) suggest that E4 or an ShERPA could be deployed
after raloxifene discontinuation to induce tumor regression
through apoptosis in raloxifene-resistant BC. Furthermore, ICI
could be deployed, as we have shown here that it has a growth
inhibitory effect (Supplemental Figs. 1F, 2C, and 9D).
Estrogen receptor-positive BC constitutes more than 70% of
all BCs (Clark et al., 1984). Rosenberg and coworkers (2015)
projected BC cases in the United States to double by 2030
compared with cases in 2011. Themajority will be ER-positive
BC. The development of new agents to treat ER-positive
endocrine-resistant MBC remains a priority. Overall, the
results of our work support the continuation of future clinical
trials with the new agents E4 and ShERPAs.
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ABSTRACT
◥
Patients with long-term estrogen-deprived breast cancer, after
resistance to tamoxifen or aromatase inhibitors develops, can
experience tumor regression when treated with estrogens. Estro-
gen’s antitumor effect is attributed to apoptosis via the estrogen
receptor (ER). Estrogen treatment can have unpleasant gynecologic
and nongynecologic adverse events; thus, the development of safer
estrogenic agents remains a clinical priority. Here, we study syn-
thetic selective estrogenmimics (SEM) BMI-135 and TTC-352, and
the naturally occurring estrogen estetrol (E4), which are proposed as
safer estrogenic agents compared with 17b-estradiol (E2), for the
treatment of endocrine-resistant breast cancer. TTC-352 and E4 are
being evaluated in breast cancer clinical trials. Cell viability assays,
real-time PCR, immunoblotting, ERE DNA pulldowns, mass spec-
trometry, X-ray crystallography, docking and molecular dynamic
simulations, live cell imaging, and Annexin V staining were con-
ducted in 11 biologically different breast cancer models. Results
were compared with the potent full agonist E2, less potent full
agonist E4, the benchmark partial agonist triphenylethylene bisphe-
nol (BPTPE), and antagonists 4-hydroxytamoxifen and endoxifen.
We report ERa’s regulation and coregulators’ binding profiles with
SEMs and E4. We describe TTC-3520s pharmacology as a weak full
agonist and antitumor molecular mechanisms. This study high-
lights TTC-3520s benzothiophene scaffold that yields an H-bond
with Glu353, which allows Asp351-to-helix 12 (H12) interaction,
sealing ERa’s ligand-binding domain, recruiting E2-enriched coac-
tivators, and triggering rapid ERa-induced unfolded protein
response (UPR) and apoptosis, as the basis of its anticancer
properties. BPTPE’s phenolic OH yields an H-Bond with Thr347,
which disrupts Asp351-to-H12 interaction, delaying UPR and
apoptosis and increasing clonal evolution risk.
Introduction
Estrogen therapy can cause tumor regression in patients with breast
cancer, who were long-term estrogen-deprived (LTED) with tamox-
ifen (TAM), which blocks estrogen binding to the breast cancer
estrogen receptor (ER), or aromatase inhibitors (AI), which inhibit
estrogen synthesis via the breast cancer aromatase enzyme system (1).
Long-term adjuvant TAM therapy (2) became the translational strat-
egy of choice for LTED treatment (3), whereby 5-year TAM therapy
leads to a new phase of endocrine resistance, characterized by TAM-
induced breast cancer growth and 17b-estradiol (E2)–induced breast
cancer apoptosis (4). Today, AIs are widely used for LTED in treating
postmenopausal women with ER-positive breast cancer. The Oxford
overview analyses show that at least 50% of breast cancer recurrences
occur more than 5 years after diagnosis (5). This prompted investi-
gators to provide a guide (6) to improve the risk benefit of long-term
adjuvant endocrine therapy in concordance with the patient’s indi-
vidualized risk for early- versus late-distant recurrence.
Estrogen triggers an endoplasmic reticulum (EnR) stress response,
the unfolded protein response (UPR), and induces apoptosis in LTED
breast cancer models (7). Numerous clinical trials (8–12) demonstrat-
ed the benefit of estrogen-induced tumor regression in patients with
LTED breast cancer. However, estrogen therapy can have unpleasant
gynecologic and nongynecologic adverse events. The research and
development of safer estrogenic agents for the treatment of drug-
resistant or metastatic breast cancer (MBC) remains a clinical priority,
especially with breast cancer expected to double by 2030 than it was in
2011 (13), and MBC being associated with significantly higher health
care costs (14). Themajority of breast cancerwill be ER-positive, which
has a high risk of recurrence and residual relapse even with clinically
low-risk disease (T1N0; ref. 15).
Three Selective Human ER Partial Agonists (ShERPAs; including
pilot BMI-135 and clinically tested TTC-352; Fig. 1; ref. 16) are
proposed as safer estrogen mimics for the treatment of endocrine-
resistant breast cancer. In preclinical studies, TTC-352 demonstrated
efficacy and tolerability (17). A clinical trial using TTC-352 in patients
with hormone receptor–positive MBC, who had progressed on at least
two lines of endocrine therapy, shows manageable safety and early
clinical evidence of activity (11).
Estetrol (E4; Fig. 1), a fetal estrogen that activates the nuclear ERa
with a vasculoprotective effect, is proposed as a safer estrogen for the
treatment of endocrine-resistant breast cancer (12), advanced prostate
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cancer, and use for hormone replacement therapy as well as oral
contraception. The combination of E4 and progestin drospirenone is
subject to FDA approval, with the possibility of E4 becoming the first
natural estrogen approved in a contraceptive product in the United
States and the first new estrogen introduced in the United States in
50 years. A clinical trial using E4, to treat advanced breast cancer, shows
that themajority of patients experienced favorable subjective effects on
wellbeing, and 1 patient completed the phase 1/IIA with stable disease
after 24 weeks of treatment (12).
The ER in LTED breast cancer is at the crossroads of mediating the
antitumor actions of therapeutics as well as breast cancer growth
through ERa-activating mutations (18). Investigating ERa’s regula-
tion and DNA-or-ligand-binding profiles with ShERPAs and E4
enhances our understanding of how these therapeutics influence
cancer through ER.
ERa gene ESR1 point mutations in the ligand-binding domain
(LBD) lead to constitutive hormone-independent activation of ER and
are identified in approximately 40% ofMBC (19). These mutations are
especially enriched in patients with breast cancer pretreated with
AIs (20).
The expression level and stability of ER is modulated by estrogens
and antiestrogens. Two regulatory mechanisms that govern the
steady-state of ER messenger RNA (mRNA) and protein levels in
breast cancer cells are documented (21). Model I ER regulation
reflects the rapid downregulation of the steady state of ER mRNA
and protein levels upon estrogen exposure, and is exemplified in
MCF-7:WS8 breast cancer, ovarian carcinoma (PEO4), and the rat
and mouse uterus. Model II ER regulation reflects the upregulation
of the steady-state level of ER mRNA, alongside the maintenance of
the ER protein level upon estrogen exposure, and is exemplified in
T47D:A18 breast cancer. In MCF-7:WS8 and T47D:A18, the anti-
estrogen 4-hydroxytamoxifen (4OHT) has little effect on the ER
mRNA level, but accumulates the ER protein over time (21). The
Selective ER Downregulator ICI 182,780 fulvestrant (ICI) has little
effect on the ER mRNA level in MCF-7:WS8, whereas it causes its
reduction in T47D:A18, and ICI dramatically reduces the ER
protein level in both (21).
ERa’s transcriptional control of diverse downstream gene expres-
sion is dictated by the ability of bound estrogens or antiestrogens (22)
to recruit and assemble primary steroid receptor coactivators [steroid
receptor coactivator-3 (SRC-3), also known as nuclear receptor coac-
tivator-3 (NCOA3), and A1B1], followed by secondary coactivators
[p300/E1A-binding protein p300 (EP300)], in what is known as
minimal receptor–coactivator complex (23). This facilitates chromatin
remodeling and transcriptional activation. A model was proposed for
the assembly mechanism of the quaternary complex: the two ligand-
boundERamonomers each, independently, recruit one SRC-3 protein
through the transactivation domain of ERa, and the two SRC-3s,
subsequently, bind to different regions of one p300 protein viamultiple
contacts (23).
We investigate ShERPAs and E4’s influence on breast cancer
through studying their ERa regulation and coactivators’ binding
profiles in biologically different breast cancer models. Furthermore,
we present the first X-ray crystallography of TTC-352 with themutant
ER, its pharmacology, andmolecular mechanisms of tumor regression
in LTED endocrine-resistant breast cancer.
TTC-352BMI-135
E2
Class I planar estrogens
DES
Class II angular estrogens
BPTPE3OHTPE
Selective estrogen mimics (ShERPAs)
Raloxifene




Chemical structures of planar estrogens, angular estrogens, SERMS, and ShERPAs. Thebox (in green) highlights the benzothiophene scaffold embedded in raloxifene
and arzoxifene structures, of which the ShERPAs' structures were based upon. The continuous box (in yellow) highlights the phenyl ring bearing OH of TPEs:
trihydroxytriphenylethylene (3OHTPE) and BPTPE (46), which makes them angular estrogens/partial agonists. The dashed box (in brown) highlights the
absence of OH on the phenyl ring of the Z-isomer of dihydroxytriphenylethylene (Z2OHTPE), which makes it an angular estrogen/full agonist like E2 and
diethylstilbestrol (DES; ref. 46).
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Materials and Methods
Materials
E2, E4, 4OHT, and raloxifene (Ralox) were purchased from
Sigma-Aldrich. Endoxifen (Endox) was purchased from Santa Cruz
Biotechnology, and ICI from Tocris Bioscience. Triphenylethylene
bisphenol (BPTPE) was originally synthesized at the Organic
Synthesis Facility, Fox Chase Cancer Center (Philadelphia, PA;
ref. 24). The ShERPAs BMI-135 and TTC-352 were a gift from
Drs. Debra A. Tonetti and Gregory R.J. Thatcher (University of
Chicago, IL). The PERK inhibitor GSK G797800 was purchased
from Toronto Research Chemicals. The IRE1a Inhibitor MKC-
3946 was purchased from Calbiochem. Thioflavin T (ThT) was
purchased from Sigma-Aldrich. For Western blotting, anti-ERa (sc-
544), anti-eIF2a (D-3), and anti–b-actin (C-4) were purchased
from Santa Cruz Biotechnology. Anti–phospho-eIF2a (Ser51;
#9721), anti-ATF4 (D4B8), anti-CHOP (L63F7), and anti-cleaved
PARP (Asp214; 19F4) were purchased from Cell Signaling Tech-
nology. Anti-XBP1 (isoforms nonspliced and spliced, ab37152) was
purchased from Abcam. For immunoblotting validations for the
ERE DNA pulldowns, the antibodies used were: anti-MLL4 (Milli-
pore Sigma, ABE1867), anti-NCOA1 (Santa Cruz Biotechnology,
sc-32789), anti-NCOA3 (custom-made in Bert W. O’Malley’s lab-
oratory, Baylor College of Medicine, Houston, TX; ref. 25), anti-
MED6 (Santa Cruz Biotechnology, clone D-2), anti-MED17 (Novus
Biologicals, clone 4D4), and anti-ESR1 (Santa Cruz Biotechnology,
sc-543). For chromatin immunoprecipitation’s (ChIP’s) pulldowns,
the antibodies used were: anti–SRC-3 (clone AX15.3, 1 mg/mL; 5 mg
per reaction; Abcam), and normal mouse IgG as IP negative control
(2 mg/mL; 5 mg per reaction; Santa Cruz Biotechnology).
Cell culture
Wild-type (WT) estrogen-dependent breast cancerMCF-7:WS8 (26);
mutant p53 estrogen-dependent breast cancer T47D:A18 (27); estrogen-
responsive, ER-positive, progesterone receptor (PgR)–positive, and
HER2-positive luminal B breast cancer BT-474 (28); estrogen-
responsive, ER-positive, PgR-positive, and androgen receptor–positive
luminal A breast cancer ZR-75–1 (29); the first in vitro cellular model
recapitulating acquired TAM resistance developed in athymic mice
in vivo MCF-7:PF (30); antihormone-resistant estrogen-independent
breast cancer MCF-7:5C (31); antihormone-sensitive estrogen-
independent breast cancer MCF-7:2A (32); antihormone (raloxifene)-
resistant, estrogen-independent breast cancer MCF-7:RAL (33); TAM-
sensitive, estrogen-independent, ER-positivebreast cancerLCC1 (34, 35);
TAM-resistant and ICI-sensitive, estrogen-independent, ER-positive
breast cancer LCC2 (36); and TAM and ICI cross-resistant, ER-
positive breast cancer LCC9 (37) were cultured as described previously.
Cell viability and proliferation assays
The biological properties of compounds (E2, BMI-135, TTC-352,
BPTPE, 4OHT, endoxifen, and raloxifene) in cells lines were
evaluated by assessing the DNA content of the cells, as a measure
of cell viability, using a DNA fluorescence Quantitation kit (Bio-Rad
Laboratories) as described previously (38). The DNA fingerprinting
pattern of these cell lines is consistent with that reported by the
ATCC. All cell lines were validated according to their short tandem
repeat (STR) profiles at UT MD Anderson Cancer Center Char-
acterized Cell Line Core (CCLC). The STR patterns of all cell lines
were consistent with those from the CCLC standard cells (Supple-
mentary Table S1). The calculated half maximal effective concen-
tration (EC50) for all test compounds, used in treating these cell
lines, is summarized in Supplementary Table S2.
Quantitative real-time RT-PCR
Total RNA was isolated from MCF-7:WS8 and MCF-7:5C cells
usingMagMAX-96 Total RNA Isolation Kit (Applied Biosystems) and
processed using Kingfisher Duo Prime magnetic particle processor
(Thermo Scientific). The cDNA was synthesized using High Capacity
cDNA Reverse transcription kit (Applied Bioscience). Quantitative
real-time PCR assays were performed using Power SYBR Green PCR
Master Mix (Applied Biosystems) and a QuantStudio 6 Flex real-time
PCR System (Applied Biosystems). All primers were synthesized by
Integrated DNA Technologies Inc. All data were normalized using
reference gene 36B4.
Immunoblotting
Cells were treated with different compounds [E2 (1 nmol/L), BMI-
135 (1 mmol/L), TTC-352 (1 mmol/L), E4 (1 mmol/L), BPTPE (1 mmol/
L), 4OHT (1 mmol/L), endoxifen (1 mmol/L), raloxifene (1 mmol/L),
ICI (1 mmol/L), thapsigargin (1 mmol/L), GSK G797800 (10 mmol/L),
and MKC-3946 (20 mmol/L)], for different periods, and harvested in
cell lysis buffer (Cell Signaling Technology) supplemented with Pro-
tease Inhibitor Cocktail Set I and Phosphatase Inhibitor Cocktail Set II
(Calbiochem). Immunoblotting was performed as described previ-
ously (38). Analysis was validated by densitometry using Image J
(National Institutes of Health). Densitometry data are presented in
Supplementary Tables S3 and S4.
ERE DNA pulldowns
MCF-7:WS8 and MCF-7:5C cells were grown in 20 to 30 15-cm
dishes, and nuclear extracts (NE)weremade. The 4x estrogen response
element (ERE) DNA pulldown assays were performed, by first immo-
bilizing four copies of the Xenopus Vitellogennin ERE sequences onto
Dynabeads M280 streptavidin as described previously (39). One
milligram of NE from MCF-7:WS8 or MCF-7:5C cells, and 0.5 mg
recombinant ERa protein (Invitrogen) were added to 4xERE-beads,
with either vehicle controls (ethanol or DMSO), or E2 (100 nmol/L),
BMI-135 (1 mmol/L), TTC-352 (1 mmol/L), E4 (1 mmol/L), BPTPE
(1 mmol/L), and endoxifen (1 mmol/L), for a 1.5-hour incubation at
4C. After performing three washes, the final coregulator-ERa-ERE
DNA complexes were eluted from the beads in 30 mL 2x SDS-sample
buffer for mass spectrometry (MS) as described previously (39). The
detailed methodology is presented in Supplementary Materials.
MS
Label-free LC-MS was performed with quantification, by intensity-
based absolute quantification (iBAQ; ref. 40), and the ERE/ER cor-
egulator–binding reactions were analyzed as described previously (39).
Samples were electrophoresed on 10% NuPAGE gels, 4 broad-region
bands were excised, and the proteins were in-gel digested with trypsin.
For each experiment, the peptides were combined into two pools and
measured on a Thermo Scientific Orbitrap Elite mass spectrometer
coupled to an EASY nLC1200 UHPLC system. The raw data were
searched in Proteome Discoverer suite (PD2.2) with Mascot 2.5
engine. For peptide quantification, the PD 2.2 Peak Area Detector
module was used, and for gene-centric inference and label-free quan-
titation based on the iBAQmethod, the gpGrouper software was used.
All raw MS and gpGrouper result files are deposited into the Proteo-
meXchange Consortium (http://proteomecentral.proteomexchange.
org; ref. 41). Compiled results are provided in Supplementary Table S5.
X-ray crystallography
The 6His-TEV–tagged ER-Y537S LBD mutant was expressed in
E. coli BL21 (DE3) and purified as described previously (42). The LBD
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(5 mg/mL) was incubated with 1 mmol/L TTC-352 and 2.5 mmol/L
GRIP peptide at 4Covernight. The detailedmethodology is presented
in Supplementary Materials. Each structure was validated and depos-
ited in the Protein Data Bank (accession code 7JHD).
Molecular dynamics simulations
Molecular dynamics (MD) simulations were performed for the
following systems: hERaLBD in complex with E2, TTC-352, and
BPTPE, using the Desmond software (Schr€odinger Release 2019–3,
Schr€odinger, LLC, 2019). The detailed methodology is presented in
Supplementary Materials.
Live cell imaging and analysis to detect cellular stress
MCF-7:5C cells were seeded into three 15-m slide 2-well cham-
bered coverslip slides (Ibidi). After 24 hours, cells were treated with
vehicle control [DSMO (0.1%)], positive control thapsigargin
(1 mmol/L), TTC-352 (1 mmol/L), and 4OHT (1 mmol/L). After
72-hour treatment, ThT was prepared as described previously (43)
and used in cotreating the cells for 1 hour. The Hoechst 33342 dye
(Thermo Fisher Scientific) was prepared at a final concentration of
5 mg/mL and used in staining the cells for 15 minutes. Live cell
images were taken at a 38 ms exposure under a 20X/0.7 objective
with ZEISS Celldiscoverer 7 (Carl Zeiss AG). Fluorescent images
were converted to 12-bit before being quantified by the ZEISS
Zen Software Module-Image Analysis. Cells from each image were
manually counted to normalize the fluorescent data per cell.
Relative intensity per cell ¼ ThT intensity/cell count was generated
for each treatment per image. An average of the relative intensity
per cell (using three images per treatment) was then calculated
to give a final quantification. The excitation and emission
settings were: Hoechst 33342 (Ex. 348 nm, Em. 455 nm), and ThT
(Ex. 433 nm, Em. 475 nm).
Annexin V–binding assays to detect apoptosis
AFITCAnnexinVApoptosisDetectionKit I (BDPharmingen)was
used to quantify apoptosis of cells through flow cytometry. In brief,
MCF-7:5C, MCF-7:2A, and MCF-7:RAL cells were seeded in 10-cm
dishes. After 24 hours, the cells were treated with different compounds
[E2 (1 nmol/L), TTC-352 (1 mmol/L), 4OHT (1 mmol/L), raloxifene
(1 mmol/L), GSK G797800 (10 mmol/L), and MKC-3946 (20 mmol/L)]
for different time periods. Cells were suspended in 1x binding buffer,
and 1  105 cells were stained simultaneously with FITC-labeled
Annexin V and propidium iodide (PI) for 15 minutes at room
temperature. The cells were analyzed using a BD Accuri C6 plus flow
cytometer.
ChIP assays
The ChIP assay was performed as described previously (44, 45). The
DNA fragments were purified using Qiaquick PCR purification kit
(Qiagen). Then, 2 mL of eluted DNA was used for RT-PCR analysis.
The primer sequences used are: GREB1 proximal ERE enhancer site
amplification: 50-GTGGCAACTGGGTCATTCTGA-30 sense, 50-
CGACCCACAGAAATGAAAAGG-30 antisense (Integrated DNA
Technologies). The data are expressed as percent input, of starting
chromatin material, after subtracting the percent input pulldown of
the IP-negative control.
Statistical analysis
All reported values are mean  SD. Statistical comparisons were
assessed using two-tailed Student t tests. Results were considered
statistically significant if the P value was less than 0.05.
Results
Effects of TTC-352 on cell viability in multiple breast cancer
models
Cell viability assays were used to test the biological properties of
compounds. TTC-352 exhibits a full agonist action, similar to E2,
across eight breast cancer cell lines that are estrogen-dependent (MCF-
7:WS8, T47D:A18, BT-474, ZR-75–1, and MCF-7:PF), estrogen-
independent (MCF-7:5C, MCF-7:2A, and MCF-7:RAL), endocrine-
sensitive (MCF-7:2A), endocrine-resistant (MCF-7:PF, MCF-7:5C,
and MCF-7:RAL), mutant p53 (T47D:A18), HER2-positive (BT-
474), luminal A (ZR-75–1), and luminal B (BT-474).
The concentration 1 mmol/L for TTC-352 achieved either the
maximal cellular growth (P value < 0.05 compared with vehicle
control; Supplementary Fig. S1A–S1E) or the maximal cellular
death (P < 0.05 compared with vehicle control; Supplementary
Fig. S1F–S1H). TTC-352 was shown to be a less potent full agonist
compared with E2 (Supplementary Fig. S1 and Supplementary
Table S2). The calculated EC50s are summarized in Supplementary
Table S2, and the detailed results are presented in Supplementary
Materials.
TTC-352 induces the transcriptional activity of ER similar to E2
in WT breast cancer MCF-7:WS8 and apoptotic-type breast
cancer MCF-7:5C
qRT-PCR was used to assess the transcriptional activity of ERa on
estrogen-responsive genes (TFF1 and GREB1) with TTC-352. After
24-hour treatment in MCF-7:WS8, TTC-352 significantly (P < 0.05)
increased the levels of TFF1 and GREB1 mRNAs compared with
vehicle controls (Fig. 2A–B). On the other hand, BPTPE induced a
partial increase in the levels of TFF1 andGREB1mRNAs, significantly
(P < 0.05) less than that of E2 and TTC-352 (Fig. 2A–B). The minimal
concentration that produced a complete increase in the levels of TFF1
and GREB1 was at 106 mol/L for TTC-352 (P < 0.05 compared with
vehicle control).
After 24-hour treatment in MCF-7:5C, TTC-352 significantly (P <
0.05) increased the levels of TFF1 and GREB1mRNAs compared with
vehicle controls (Fig. 2C–D). On the other hand, BPTPE induced a
partial increase in the levels of TFF1 andGREB1mRNAs, significantly
(P < 0.05) less than that of E2 and TTC-352 (Fig. 2C–D). The minimal
concentration that produced a complete increase in the levels of TFF1
and GREB1 was at 106 mol/L for TTC-352 (P < 0.05 compared with
vehicle control).
Overall, the induction of the levels of TFF1 and GREB1mRNAs by
TTC-352 in MCF-7:WS8 and MCF-7:5C is similar to that by full
agonist E2, only at a higher concentration.
Effects of TTC-352, BMI-135, and E4 on ERa regulation in
multiple breast cancer models
Western blotting and densitometry were used to assess the
regulation of ERa protein levels with compounds. In MCF-7:WS8,
TTC-352 was able to downregulate the protein levels of ERa after
72-hour treatment, compared with vehicle control, and similar to E2
and E4 (Model I; Fig. 3A and Supplementary Table S3). Whereas
BMI-135 seems to have a different effect by slightly downregulating
ERa’s protein levels by 72 hours, compared with vehicle control
(Supplementary Fig. S2A and Supplementary Table S4). This down-
regulation is less than that with BPTPE; nonetheless, BMI-135 does
not accumulate the receptor compared to 4OHT and endoxifen
(Supplementary Fig. S2A and Supplementary Table S4). This reg-
ulation trend with TTC-352, BMI-135, and E4 in MCF-7:WS8 is
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replicated in MCF-7 ATCC (Supplementary Fig. S2B and Supple-
mentary Table S3).
In T47D:A18, TTC-352 and BMI-135 maintain the protein
levels of ERa (Model II), compared with vehicle control, and similar
to E2 and E4 (Fig. 3B, Supplementary Fig. S2C and Supplementary
Tables S3 and S4). BPTPE, 4OHT, and endoxifen accumulate the
receptor by 72 hours (Supplementary Fig. S2C and Supplementary
Table S4).
In BT474, TTC-352 downregulates the protein levels of ERa by
72 hours, compared with vehicle control, and similar to E2 and E4
(Model I; Fig. 3C; Supplementary Fig. S2E; and Supplementary
Tables S3–S4). Whereas BMI-135 seems to have a similar trend
except that the protein levels by 72 hours are similar to vehicle
control (Supplementary Fig. S2E and Supplementary Table S4). The
protein levels are upregulated by 72 hours with BPTPE, and more so
with endoxifen and 4OHT (Supplementary Fig. S2E and Supple-
mentary Table S4).
In ZR-75–1, TTC-352 slightly downregulates the protein levels of
ERa after 72-hour treatment, compared with vehicle control, and
similar to E2 and E4 (Model I; Fig. 3D; Supplementary Fig. S2D and
Supplementary Tables S3–S4). Whereas BMI-135 seems to have a
different trend whereby by 72 hours the protein levels become similar
to vehicle control (Supplementary Fig. S2D and Supplementary
Table S4). The protein levels are maintained by 72 hours with BPTPE,
4OHT, and endoxifen, compared with vehicle control (Supplementary
Fig. S2D and Supplementary Table S4).
In MCF-7:5C, MCF-7:2A, and MCF-7:RAL, TTC-352, BMI-135,
and E4 downregulate the protein levels of ERa by 72 hours, compared
with vehicle control, and similar to E2 (Model I; Fig. 3E–G and
Supplementary Fig. S3D–S3F). In MCF-7:2A, ER66 and ER77 protein
levels with BMI-135, TTC-352, andE4 are similarly regulated over time
(Model I; Fig. 3F; Supplementary Fig. S3E; ref. 32). In these cell lines,
the protein levels are slightly downregulated with BPTPE, and main-
tained or accumulated with endoxifen, 4OHT, and raloxifene (in
MCF-7:RAL; Supplementary Fig. S3D–S3F).
In LCC1, LCC2, and LCC9, TTC-352, BMI-135, and E4 down-
regulate the protein levels of ERa by 72 hours, compared with vehicle
control, and similar to E2 (Model I; Fig. 3H–J, Supplementary
Fig. S3A–S3C, and Supplementary Table S3). In these cell lines, the
protein levels are downregulated with BPTPE and maintained or
accumulated with endoxifen and 4OHT (Supplementary Fig. S3A–
S3C and Supplementary Table S3).
In 11 breast cancer cell lines, TTC-352 regulated the protein
levels of ERa in a similar manner to E2 (Fig. 3 and Supplementary
Table S3) and different from that with BPTPE (Supplementary
Figs. S2–S3 and Supplementary Table S4), and ICI significantly










































































































































Transcriptional activity of well-characterized estrogen-responsive genes TFF1 and GREB1 in WT MCF-7:WS8 and LTED endocrine-resistant MCF-7:5C with test
compounds. A,mRNA expression of TFF1 (or pS2) in MCF-7:WS8 cells after 24-hour treatment with 1 nmol/L E2, and 1 mmol/L for other test compounds. B,mRNA
expression of GREB1 in MCF-7:WS8 cells after 24-hour treatment with 1 nmol/L E2, and 1 mmol/L for other test compounds. C,mRNA expression of TFF1 in MCF-7:5C
cells after 24-hour treatment with 1 nmol/L E2, and 1 mmol/L for other test compounds. D, mRNA expression of GREB1 in MCF-7:5C cells after 24-hour treatment
with 1 nmol/L E2, and 1 mmol/L for other test compounds.
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Effects of TTC-352, BMI-135, and E4 on coregulator recruitment
to DNA-bound ER in WT breast cancer MCF-7:WS8 and
apoptotic-type breast cancer MCF-7:5C
Cell-free ERE DNA pulldown (39) and LC-MS assays were used
to assess the composition of coregulators recruited to ER bound to
ERE DNA with compounds, using E2 and endoxifen as positive and
negative controls, respectively, for coactivator binding.
InMCF-7:WS8, E2 recruited major coactivators such as NCOA1–3,
the Mediator complex (MED; see subunits in Fig. 4), and Lysine
Methyltransferase 2D (KMT2D orMLL4; Fig. 4A), which is consistent
with prior proteomic publications (39). Endoxifen did not recruit these
coactivators (Fig. 4A). BPTPE did not recruit many of the E2-enriched
coactivators and only a subset of endoxifen-enriched coregulators
(Fig. 4A). Estetrol recruited NCOAs and KMT2D in a similar fashion
to E2, but failed to recruitmanyMED subunits at the level promoted by
E2 (Fig. 4A). TTC-352 and BMI-135 are different from BPTPE in
terms of coactivator recruitment, chiefly recruiting NCOA1–2 and
MED subunits, with NCOA3 not readily enriched compared with E2
and E4 (Fig. 4A).
In MCF-7:5C, E2 recruited NCOA2–3, KMT2D, and the MED
subunits, with slightly different distribution of affinities, whereas
endoxifen repelled them, as expected for this Selective ER Modulator
(SERM), and BPTPE did not have much of a coactivator binding
(Fig. 4A). Estetrol recruited similar levels ofNCOA3 andKMT2D, and
many of the same MED subunits (Fig. 4A). TTC-352 and BMI-135
recruited NCOA3 and KMT2D at much lower levels than E2 and E4
(Fig. 4A). Interestingly, TTC-352 recruited more MED subunits than
E2, whereas BMI-135 displayed sharedMED subunit recruitment with
E4 (Fig. 4A).
The recruitment of KMT2D, NCOA1, NCOA3, and MED17, in
MCF-7:WS8 andMCF-7:5C, was further validated by immunoblotting
(Fig. 4B and Supplementary Fig. S9).
Comparative analysis of the X-ray structures of hERaLBD in
complex with ligands E2, TTC-352, and BPTPE
The experimental X-ray structure (Fig. 5G–I) of hERaLBD in
complex with TTC-352 shows the ligand binding to the agonist
conformation of ERa [i.e., helix 12 (H12) is docked over the active
site, in a grove between helices H5 andH11, leaning onH3, and closing
the ligand inside the hydrophobic binding pocket; Fig. 5A]. The
superposition with hERaLBD in complex with E2 indicates minor
differences between these two structures, with an average root mean
square deviation (RMSD) of 0.55 Å; calculated based on Ca atoms.
However, a difference has been noticed in the positioning of H12, with
it being slightly displaced in the TTC-352:ERa structure by an average
RMSD of 0.85Å, compared with the E2:ERa structure (Fig. 5A). The
bindingmode of TTC-352 to the active site shares similar features with
that of E2. The benzothiophene moiety of TTC-352 overlaps well with
the A and B rings of E2, being involved in p–p stacking interactions
with Phe404, and forming the H-bond network between the hydroxyl
group and the side-chains of residues Glu353, Arg394, and a crystal-
lization water molecule. The phenoxy ring occupies the same region
of the binding pocket as the D ring of E2, but it is buried slightly deeper
in the active site, and oriented parallel with the imidazole ring of
His524, favoring the formation of the H-bond with the hydroxyl
group, like E2 (Fig. 5B).
The analysis of the X-ray structure of hERaLBD in complex with
BPTPE reveals good overlapping with the E2:ERa structure with an
average RMSD of 1.28 Å (Fig. 5D). Regarding the ligand-binding
mode, BPTPE’s alignment in the active site is comparable with E2 and
TTC-352 (Fig. 5E), preserving the same interactions with the excep-
tion of few noteworthy changes. First, the absence of the H-bond to
His524, the residue’s side-chain, is flipped out of the binding site, and
the space freed is partially occupied by the phenyl ring of BPTPE. This
observation could explain the displacement of BPTPEby 0.7Å towards
H11, compared with TTC-352. Second, the presence of an H-bond
between the phenoxy ring of BPTPE and Thr347 (Fig. 5E–F). This
contact leads to an alternative orientation of Thr347, with the methyl
group pointing toward Tyr537, which results in a different confor-
mation, and the displacement of Tyr537 relative to its position,
compared with TTC-352:ERa or E2:ERa (Fig. 5C and F). This
repositioning at the base of H12, together with the reorientation of
Leu540 due to the large phenoxy ring of BPTPE, alters the H-bond
pattern in the vicinity. As a result, the H-bonds between Asp351 (H3)
and the backbone of Leu539 and Leu540 (H12), which normally
stabilize the orientation of H12 in the agonist conformation with
E2:ERa (Fig. 5C), are absent with BPTPE (Fig. 5F), but are present
with TTC-352 (Fig. 5C).
MD simulations were performed to investigate the dynamics of
hERaLBD and of ligand binding, specifically, the interactions respon-
sible for binding, to highlight the differences that could discriminate
between the ligands and explain their observed biological behaviors in
tumor cells. The influence of the ligands onH12 conformationwas also
investigated, by monitoring the key interactions that are known to
stabilize H12 in the agonist conformation (Fig. 5C and F).
MCF-7:WS8












































































ERa protein levels in multiple breast cancer cell lines after 24-, 48-, and 72-hour
treatments with test compounds. A, ERa protein levels in MCF-7:WS8. B, ERa
protein levels in T47D:A18. C, ERa protein levels in BT-474.D, ERa protein levels
in ZR-75–1. E, ERa protein levels in MCF-7:5C. F, ERa protein levels in MCF-7:2A.
G, ERa protein levels in MCF-7:RAL.H, ERa protein levels in LCC1. I, ERa protein
levels in LCC2. J, ERa protein levels in LCC9. Densitometry data are presented in
Supplementary Table S3.
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Evaluation of the trajectory stability from MD simulations
Note that 165 ns MD simulations were performed for all systems.
The RMSDs of the protein backbone atoms, relative to their position in
the first frame, were monitored to evaluate the equilibration and
stability of the simulations. The RMSD evolution for all simulations,
together with the stability of H12 and amino acids of the binding sites,
is displayed (Supplementary Fig. S4A–S4C) and detailed in Supple-
mentary Materials. Briefly, the data indicate that all systems reached
equilibrium and that the trajectories were stable (Supplementary
Fig. S4A). Similar trends were observed for the systems of TTC-352
and E2, whereas BPTPE showed more conformational changes in the
segment corresponding to H12 (Supplementary Fig. S4B). No signif-
icant conformational changes were detected in the active site of all
structures (Supplementary Fig. S4C).
To gain insights into the local flexibility of the receptor chain, root
mean square fluctuation was monitored along the trajectories of all
complexes (Supplementary Fig. S4D–S4F), with detailed results pre-
sented in Supplementary Materials. In summary, the data suggest that
the large fluorophenyl moiety of TTC-352 induces more flexibility in
the loop between H11 and H12, than the phenoxy ring of BPTPE.
However, this is not translating into larger flexibility of H12, mainly
because of the stabilizing effect of the H-bonds between Asp351, and
the backbone of Leu539 and Leu540 with TTC-352, but not with
BPTPE (Fig. 5C and F). Moreover, in the system of BPTPE, increas-
ingly large fluctuations have been detected at the terminal residues of
H12. This indicates more mobility in this region of the helix, which
destabilizes and hinders the proper closing of H12 over the binding
pocket, leading to the inability of BPTPE complex to reach the full-
agonist conformation of the receptor.
Analysis of E2, TTC-352, and BPTPE binding modes from MD
simulations
The interactionmaps of the ligands with key residues of the binding
site, together with the occurrences for specific contacts, are displayed
(Fig. 6), and the detailed results are presented in Supplementary
Materials. TheMD simulations confirmed that theH-bonds to Glu353
and His524 are highly stable for TTC-352 and E2 (Fig. 6A–B). As
reported previously (46), the H-bond to Thr347 is the most stable
interaction for BPTPE, beingmaintained during the entire simulation,
which indicates a strong bond, whereas the H-bond to Glu353 shows a
significantly decreased frequency, which indicates a weaker bond
(Fig. 6C).
Analysis of the binding-free energy decomposition for E2,
TTC-352, and BPTPE
To gain a deeper understanding of the ligand–receptor interactions
and highlight the subtle differences that could discriminate between
these ligands, we performed ligand-binding energy calculations using
theMM-GBSAmethod for the simulated systems. The contribution of
each residue to the binding process was analyzed, by decomposing the
binding energy into ligand-residue pairs, with the results displayed
(Supplementary Fig. S5) and detailed in Supplementary Materials.
The data show that the H-bonding to Glu353 is the driving force of
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Proteomics of major ER coregulators in MCF-7:WS8 and MCF-7:5C breast cancer with test ligands, and immunoblots of KMT2D, NCOA1 and 3, and MED17 to validate
MS data.A,Proteomics ofmajor coregulators differentially recruited toDNA-bound recombinant ER inMCF-7:WS8 andMCF-7:5C cells, treatedwith E2 (100 nmol/L),
E4 (1mmol/L), TTC-352 (1mmol/L), BMI-135 (1mmol/L), BPTPE (1mmol/L), andendoxifen (1mmol/L). Ethanol orDMSO served as the vehicle control.EREDNApulldown
cell-free reactionswere performed, andMS data are depicted as a heatmap for coregulator enrichment (light to dark red color) or repulsion (light to dark blue color).
The values represent quantificationwith label-free iBAQmethod, normalized to ESR1 amount, and are shown (as estimated% relative to ESR1). Official gene symbols
are shown (on the leftmost column). NCOA1–3, KMT2D, and MEDs were defined previously as E2-enriched coactivators (25, 39). B, Immunoblotting to validate MS
data of KMT2D, NCOA1 and 3, andMED17, recruited inMCF-7:WS8 andMCF-7:5CNE toDNA-bound ER (ESR1), when treatedwith E2 (100 nmol/L), E4 (1mmol/L), TTC-
352 (1 mmol/L), and BMI-135 (1 mmol/L). Protein size standards are shown (on the left side as kDa), and 3% input is shown (on the left side; representing 3% ofWS8 or
5C NE that was added to each 4xERE DNA bead).
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agonist binding. The H-bond between BPTPE and Glu353 is weaker,
and the binding of BPTPE is governed by the H-bond to Thr347
(Fig. 6C). This leads to instability in this region of H3, which could
have an impact on the conformation of Asp351 that is found in close
proximity and could explain why the H-bonds to Leu539 and Leu540
are missing for BPTPE:ERa. In addition, the strong interaction with
Thr347 stabilizes the ligand in the active site, but perturbs the local
environment and disrupts the H-bond between Tyr537 and Asn348.
Finally, the stability of H12 and proper closing specific for the agonist
conformation are affected in the structure of BPTPE:ERa.
TTC-352 induces ThT fluorescence as a marker of UPR
Thioflavin T was used to detect and quantify the EnR stress or UPR
in living cells, as it interacts directly with the accumulated misfolded
protein amyloid during the UPR (43). The “blue” Hoechst 33342
fluorescent dyewas used as a nuclear counterstaining dye inMCF-7:5C
living cells (Fig. 7, channel A), the “green” ThT fluorescent dye was
used as a UPR-indicative dye (channel B), and a colocalization of ThT
and Hoechst 33342 dyes is shown (channel C).
TTC-352 induced ThT fluorescence by 72 hours compared with
vehicle control, and somewhat similar to the induction seen with
positive control thapsigargin (i.e., triggers EnR stress by disrupting
EnR Ca2þ homeostasis; Fig. 7B). The ThT relative intensity/cell for
thapsigargin was 3.320555, and 2.025762 for TTC-352, compared with
0.4725 for vehicle control.
TTC-352 triggers apoptosis in multiple estrogen-independent
and endocrine-resistant breast cancer models
Flow cytometry was used to assess if the type of stress-induced cell
death was actually apoptosis, when treated with 1 mmol/L TTC-352. In
Figure 5.
Representation of ERa-LBD with E2, TTC-352, and BPTPE. Comparison of the WT structures of E2 (yellow), TTC-352 (blue), and BPTPE (green) bound to hERa. The
superposition of the X-ray structures of hERaLBD:E2 with hERaLBD:TTC-352 (A), and of hERaLBD:E2 with hERaLBD:BPTPE (D). The closer views of the active sites
show the binding modes of E2 (yellow), in comparison with TTC-352 (blue; B) and BPTPE (green; E), together with the H-bond contacts between H3 and H12 for E2,
TTC-352 (C), and BPTPE (F). The superposition of the mutant Tyr537Ser X-ray structures of hERaLBD in complex with E2 (orange) and TTC-352 (teal; G), together
with the binding site alignment of the ligands (H), and a close view of the H-bond interactions between Asp351 and Ser537 (I). Amino acid residues involved in direct
interactions (i.e., H-bonds and hydrophobic contacts) are labeled and shown in sticks, together with the amino acids directly involved in H-bonds with H12. In the
overall structures, H12 is labeled together with the helices that form the ligand-binding site (i.e., H3, H6, H8, H11) and part of the coactivator site (i.e., H5, H9, H10). The
H-bonds are displayed (dashed lines) in yellow, blue, and green in the structures of E2, TTC-352, and BPTPE, respectively.
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MCF-7:5C, TTC-352 induces apoptosis (Annexin staining 22.9% vs.
vehicle control 6.9%;Fig. 8A), similar to the time course of 1 nmol/L E2
(Annexin staining 23.4% vs. control 6.7%; Supplementary Fig. S7A),
which is in 3 days.
InMCF-7:2A, TTC-352 induces apoptosis (Annexin staining 21.2%
vs. control 2.7%), similar to the time course of E2 (Annexin staining
20.4% vs. control 2.7%; Supplementary Fig. S7B), which is in 9 days.
In MCF-7:RAL, TTC-352 induces apoptosis (Annexin staining
8.4% vs. control 1.5%), similar to the time course of E2 (Annexin
staining 9.1% vs. control 1.5%; Supplementary Fig. S7C), which is in
14 days.
Inhibition of PERK UPR pathway blocks apoptosis in MCF-7:5C
with TTC-352 treatment
Blocking the UPR transducer PERK with 10 mmol/L GSK G797800
in combination with 1 mmol/L TTC-352 by 72 hours inhibited
apoptosis (Annexin staining 6.9% vs. control 6.9%;Fig. 8A), compared
with TTC-352 alone treatment (Fig. 8A; Annexin staining 22.9% vs.
vehicle control 6.9%), and compared with 10 mmol/L GSK G797800
alone treatment (Annexin staining 8.3% vs. control 6.9%; Fig. 8A).
PERK downstream targets p-eIF2a, ATF4, and CHOP as well as
apoptosis target cleavedPARPare upregulated after 72-hour treatment
with TTC-352, whereas the addition of GSK 797800 inhibits this UPR/
apoptosis effect (Fig. 8B).
Inhibition of IRE1a:XBP1s UPR pathway enhances apoptosis in
MCF-7:5C with TTC-352 treatment
Inhibiting the UPR transducer IRE1a, by inhibiting basal XBP1
splicing, with 20 mmol/L MKC-3946 in combination with 1 mmol/L
TTC-352 by 72 hours, enhanced apoptosis (Annexin staining 35.5%vs.
vehicle control 1.4%; Fig. 8C), compared with TTC-352 alone treat-
ment (Annexin staining 27.9% vs. vehicle control 1.4%; Fig. 8C), and
compared with 20 mmol/L MKC-3946 alone treatment (Annexin
staining 8.8% vs. vehicle control 1.4%; Fig. 8C).
Figure 6.
2D ligand–ERa interaction maps highlighting key interactions between the ligands and ERa's amino acids during the simulations. These maps were generated from
the recorded trajectories and the occurrences of the key contributing interactions between E2 (A), TTC-352 (B), BPTPE (C), and the amino acids in the binding site of
ERa, as shown.
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Detection of EnR stress in live MCF-
7:5C cells using ThT dye. A, Hoechst
33342 dye single panel (blue). B, ThT
dye single panel (green). C, A colo-
calization panel of ThT and Hoechst
33342 dyes (blue and green).
Treatments included vehicle con-
trol [DMSO (0.1%)], positive control
thapsigargin (1 mmol/L), and TTC-
352 (1 mmol/L). After 72-hour treat-
ment, cells were cotreated with ThT
(5 mmol/L) for 1 hour. The previous
culture media were then swiped
with Hoechst 33342 dye (5 mg/mL)
in warm PBS for 15 minutes. Live
cell imaging was done by the ZEISS




















































Flow cytometry andWestern blotting inMCF-7:5C cells treatedwith TTC-352 and its combinationwith a PERK inhibitor and an IRE1a inhibitor.A,MCF-7:5C cellswere
treated with vehicle control [DMSO (0.1%)], GSK G797800 (10 mmol/L), TTC-352 (1 mmol/L), and TTC-352 plus GSK G797800, for 3 days, and then stained with
Annexin V–FITC and PI, and analyzed by flow cytometry. Viable cells (left bottom quadrant) are Annexin V–FITC and PI; early apoptotic cells (right bottom
quadrant) are Annexin V–FITCþ and PI; dead cells (left top quadrant) are PIþ; and late apoptotic cells (right top quadrant) are Annexin V–FITCþ and PIþ. An
increased, late apoptotic effect is observed in the right topquadrant.B,p-eIF2a, total eIF2a, ATF4, CHOP, and cleavedPARPprotein levels, inMCF-7:5C, after 72-hour
treatments with vehicle control DMSO (0.1%), UPRþve control thapsigargin (1 mmol/L), TTC-352 (1 mmol/L), and TTC-352 (1 mmol/L) plus GSK 797800 (10 mmol/L).
C,MCF-7:5C cells were treated with vehicle control [DMSO (0.1%)], MKC-3946 (20 mmol/L), TTC-352 (1 mmol/L), and TTC-352 plus MKC-3946, and analyzed by flow
cytometry. D, XBP1s, and XBP1 protein levels, in MCF-7:5C, after 72-hour treatments with vehicle control DMSO (0.1%), TTC-352 (1 mmol/L), and TTC-352 (1 mmol/L)
plus MKC-3946 (20 mmol/L). A and C, , P < 0.001.
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IRE1a downstream target XBP1 (or spliced XBP1) is upregulated
after 72-hour treatment with TTC-352, whereas the addition of MKC-
3946 inhibits this splicing effect (Fig. 8D).
Transcriptional–translational, UPR, and apoptotic effects of
TTC-352 are mediated via ERa
TTC-352was shown to function via ERa. The combination of TTC-
352 and 4OHT blocked SRC-3 recruitment compared with TTC-352
alone treatment (Fig. 9A); inhibited ERE activation compared with
TTC-352 alone treatment (Fig. 9B); blocked the antiproliferative
effects of TTC-352 alone treatment (Supplementary Fig. S8A–S8C);
inhibited the UPR PERK pathway activation (Fig. 9C–D); and pre-
vented apoptosis (Fig. 9C and E–G).
Discussion
TTC-352 is a member of a new class of estrogenmimics (Fig. 1; 16),
which is currently being evaluated in endocrine-resistantMBC clinical
trials (11). Thiswork reports: (i) theX-ray crystallography of TTC-352:
mutant ER with clinical implications given that many patients with
MBC harbor ER mutations (Fig. 5G–I; refs. 19, 20, 47); (ii) the
molecular mechanisms of TTC-3520s breast cancer regression in
patients with LTED (Figs. 7–10); and (iii) the key interactions at the
molecular and atomic levels of the benchmark partial agonist BPTPE:
WT ER, involving Asp351 andH12 (Figs. 5 and 6), which explains the
delayed ERa-induced UPR and apoptosis (48) compared with TTC-
352 (Fig. 8).
Earlier pharmacologic studies classified ER-binding ligands into
agonists, partial agonists, and antagonists (49), and complimented the
subsequent X-ray crystallography studies of the agonist and antagonist
ER complexes of the LBD (22, 50). Earlier biological studies described
E2-induced apoptosis (51). Current study concludes that TTC-352 is a
less potent full estrogen agonist in numerous biologically different
breast cancer models (Figs. 2–6 and 9; Supplementary Fig. S1; and
Supplementary Table S2), with a rapid apoptotic effect (through the
UPR) in estrogen-independent and endocrine-resistant breast cancer
models (Figs. 7–10 and Supplementary Fig. S7B–S7C).
This research area is of particular importance given that breast
cancer is projected to double by 2030 than it was in 2011 (13). The
majority will be ER-positive with a high risk of recurrence, even with
clinically low-risk disease (T1N0; ref. 15). Moreover, treated metas-
tases often harbor private “driver”mutations, compared with untreat-
ed metastases (52). In the case of ER-positive HER2-negative breast
cancer, metastases treated with endocrine therapy acquire somatic
single-nucleotide variants (47). This highlights the need to evaluate
and develop new rapidly-acting breast cancer therapeutics such as
estrogens. The recent long-term follow-up results of the Women’s

















































































































Mediation of the transcriptional–translational, UPR, and apoptotic effects of TTC-352 via ERa.A, Recruitment of SRC-3, in MCF-7:5C cells, after 45-minute treatment
with indicated ligands (1 mmol/L). Recruitment of SRC-3was calculated as percentage of the total input after subtracting the IgG recruitment. B,mRNA expression of
GREB1, in MCF-7:5C cells, after 24-hour treatment with ligands (1 mmol/L). C, p-eIF2a, total eIF2a, ATF4, CHOP, and cleaved PARP protein levels, in MCF-7:5C, after
72-hour treatmentswith vehicle control DMSO (0.1%), TTC-352 (1 mmol/L), and TTC-352 (1 mmol/L) plus 4OHT (1 mmol/L).D,Detection of UPR, in live MCF-7:5C cells,
using ThT dye, after 72-hour treatments with vehicle control DMSO (0.1%), TTC-352 (1 mmol/L), and TTC-352 (1 mmol/L) plus 4OHT (1 mmol/L). Scale bar, 50 mm.
E,MCF-7:5C cells were treatedwith vehicle control DMSO (0.1%), TTC-352 (1 mmol/L), and TTC-352 (1 mmol/L) plus 4OHT (1 mmol/L) for 3 days, and analyzed by flow
cytometry. F, MCF-7:2A cells were treated with vehicle control DMSO (0.1%), TTC-352 (1 mmol/L), and TTC-352 (1 mmol/L) plus 4OHT (1 mmol/L) for 9 days, and
analyzed by flowcytometry.G,MCF-7:RAL cellswere treatedwith vehicle control DMSO (0.1%), TTC-352 (1mmol/L), and TTC-352 (1mmol/L) plus 4OHT (1mmol/L) for
14 days, and analyzed by flow cytometry. E–G,  , P < 0.001.
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and safe estrogenic therapy in significantly reducing breast cancer
incidence and mortality in patients with LTED.
MD simulations and MM-GBSA calculations for WT ERa in
complex with TTC-352, E2, and BPTPE are valuable methodologies
to discover key ligand–receptor interactions, which aid the pharma-
cologic classification of TTC-352. Most importantly, they identify key
structural components of estrogenic therapeutics that ensure the
appropriate closure of the ERa LBD by H12 in LTED breast cancer.
This closure is a prerequisite for the activation of ERE-mediated UPR
and apoptosis, which is the basis of their antitumor properties.
The H-bonds of TTC-3520s benzothiophene scaffold to Glu353,
followed by the H-bond to His524, are the most stable contacts
contributing to the binding mechanism of TTC-352, which are also
the two binding features specific for the estrogenic activity of E2 (E2’s A
ring to Glu353; Fig. 6A–B). Such strong H-bond between TTC-352
andGlu353 induces stability in the LBD and, consequently, toH3. This
supports the formation of the H-bonds between the side-chain of
Asp351 (H3) to the backbone of Leu539 and Leu540 (H12), which
stabilizes H12 in the full-agonist conformation (Fig. 5C). Such LBD-
stabilizing network of H-bonds is preserved with TTC-352, but more
so with E2, which explains the altered potency of TTC-352:ERa
compared with E2:ERa. By contrast, BPTPE’s binding mechanism is
governed by the H-bond of BPTPE’s angular phenolic OH to Thr347,
followed by the hydrophobic contacts, and a significantly weaker H-
bond to Glu353 (Figs. 5E and 6C). Although the H-bond between
BPTPE’s angular phenolic group and Thr347 stabilizes its binding,
it disturbs the H-bond network within H3 and the stabilizing H-bonds
to H12 (i.e., Asp351 to Leu 539 and Leu540). As a result, H12 is
prevented from adopting the proper orientation specific for the ER
full-agonist conformation (Fig. 5F). This is consistent with BPTPE’s
reduced recruitment of coactivators (Fig. 4A), and our previous
reports (48) of its delayed activation of ERa-induced UPR and
apoptosis as well as its functional modulation from a partial agonist
(3OHTPE) to a full agonist (Z2OHTPE) by the removal of the para-
phenol substitution (46).
Both, Asp351 and H12, play a critical role in modulating the
estrogenic and antiestrogenic intrinsic efficacy of the ligand–ER
















































Schematic representation of the study's conclusions highlighting major ER coactivator-binding differences in MCF-7:5C between E2, E4, ShERPAs, and BPTPE, and
with ShERPA TTC-352 between WT MCF-7:WS8 and LTED endocrine-resistant MCF-7:5C breast cancer. A, E2, E4, ShERPA BMI-135, ShERPA TTC-352, and BPTPE
major ER coactivators' recruitment, and antitumormolecularmechanism inMCF-7:5C. E2:ERa and E4:ERa complexesmainly recruit NCOA3, KMT2D, andmany of the
sameMEDs, and induce a high threshold of stress, through the synthesis of unfolded and/ormisfolded proteins, leading to rapid apoptosis. TTC-352 (referred to as TT
in the illustration) recruitedmoreMED subunits than E2, but lessNCOA3 andKMT2D than E2 and E4,with a similar threshold of stress and timing of apoptosis to E2 and
E4. BMI-135 (referred to as BM in the illustration) recruited less NCOA3 and KMT2D than E2 and E4, and shared MED subunit recruitment with E4, which generated a
lower threshold of stress and delayed apoptosis (48) compared with E2, E4, and TTC-352. BPTPE (referred to as BP in the illustration) did not have much of a
coactivator recruitment, which generates a very low threshold of stress and amuchmore delayed course of apoptosis (48) comparedwith E2, E4, TTC-352, and BMI-
135. This differential ligand:ERa:coactivator-recruitment-and-induced EnR stress sets the therapeutics apart, in terms of the timing of activating theUPR, followed by
inducing apoptosis. The box (in gray) highlights the observed recruitment patterns: thick arrow (red) represents relatively more recruitment, thin arrow (burgundy)
is relatively less recruitment, thin arrow (burgundywith green border) is shared subunit recruitment, and thin arrow (blue) is no recruitment.B,TTC-3520s paradoxical
effect in WT growth-inducing breast cancer MCF-7:WS8 versus LTED apoptosis-inducing breast cancer MCF-7:5C. NCOA3, KMT2D, and many MEDs (especially
MED12–16 and MED23) are recruited to ER, in MCF-7:5C treated with TTC-352 (thick arrow in maroon), compared with E2, but these same coactivators are reduced
upon the treatment of MCF-7:WS8 with TTC-352 (thin arrow in rose). This differential ligand:ERa:coactivator-recruitment-and-induced EnR stress phenotypically
sets the two breast cancer models apart.
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overexpressed in TAM-stimulated MCF-7 tumors grown in athymic
mice (55). The molecular pharmacology of the WT ER (56) and
Asp351Tyr ER (57) was established by stable transfection into ER-
negative MDA-MB-231 breast cancer. Unexpectedly, Asp351Try ER
converted the raloxifene:WT Asp351 ER complex from antiestrogenic
to estrogenic (58). Subsequent X-ray crystallography of the raloxifene:
ER LBD (22) demonstrated the critical role of the antiestrogenic side-
chain containing a piperidine ring N to shield and neutralize Asp351,
which prevented the closure of H12 and the subsequent ERE activa-
tion. Subsequent interrogation of the structural modulation of ralox-
ifene and its interactions with Asp351 demonstrated how Asp351
modulates the estrogenic and antiestrogenic efficacy of the ligand–ER
complex (59).
ESR1 somatic mutations, Y537S and D538G, stabilize ERa in the
agonist state and are linked to acquired resistance to endocrine
therapies (60). Mutations Tyr537Ser and Asp538Gly were most prev-
alent in breast cancer metastases (47), especially patients with AI-
resistant breast cancer. These mutations improve the closure of H12
over ERa’s LBD, through interacting with Asp351 and recruiting
coactivators in the absence of estrogen, which increases the estrogen-
like properties of the complex (47).
ERE DNA pulldowns and MS are valuable methodologies to
determine if TTC-352 has an ERa:coactivators’ binding profile of a
full or partial agonist, and better understand why the TTC-352:ERa:
coactivators’ complex in the LTED endocrine-resistant MCF-7:5C is
phenotypically apoptosis-promoting, whereas such complex in WT
MCF-7 is phenotypically growth-promoting.
In MCF-7:WS8 breast cancer, TTC-352 and BMI-135 are dif-
ferent from BPTPE in terms of NCOA1–2 (or SRC-1–2) and MED
subunit recruitments, with NCOA3 (or SRC-3) not being readily
enriched with either ShERPAs compared with E2 and E4 (Fig. 4A).
BPTPE did not recruit many of the E2-enriched coactivators and
only a subset of endoxifen-enriched coregulators (Fig. 4A). In
MCF-7:5C breast cancer, TTC-352 and BMI-135 recruited NCOA3
and KMT2D at much lower levels than E2 and E4, with TTC-352
recruiting more MED subunits than E2, while BMI-135 displaying
shared MED subunit recruitment with E4 (Fig. 4A). BPTPE did not
have much of coactivator binding (Fig. 4A).
TTC-3520s differential recruitment ofMED subunit types alongside
their differential enrichment levels could explain its ability to cause a
higher threshold of stress of ER-mediated unfolded proteins followed
by earlier apoptosis, compared with that with BMI-135 (Fig. 10A). In
MCF-7:5C, NCOA3, KMT2D, and many MEDs (especially MED12–
16 and MED23) are recruited to ERa with TTC-352, compared with
E2, but these coactivators are reduced upon the treatment of MCF-7:
WS8 with TTC-352 (Supplementary Table S5). TTC-3520s higher
recruitment of major ER coactivators in MCF-7:5C, compared with
MCF-7:WS8, can explain its ability to cause a high threshold of stress of
ER-mediated unfolded proteins followed by apoptosis, making it
phenotypically apoptosis-promoting versus the growth-promoting
MCF-7:WS8 (Fig. 10B). The altered recruitment patterns of major
ER coactivators for transcriptional activation, with TTC-352, BMI-
135, and E4, in comparison with the levels promoted by E2 or BPTPE,
can better explain the observed differences in their potency and ERa-
mediated UPR.
Our MD simulations data complement the MS data whereby the
dynamics of H12 orchestrate ER’s coactivator-mediated transcription-
al activity. In the agonist complex structure, H12 forms one side of a
hydrophobic coactivator-binding pocket, which allows the recruit-
ment of an LXXLL motif present in many transcriptional cofac-
tors (61). This is, especially, true with SRC-1–3 that possess three
LXXLLmotifs, two of which bridge across the ER dimer (at least for an
extended polypeptide containing all three motifs), which accounts for
the 100-fold higher affinity relative to the single LXXLL-containing
peptide (62). The overexpression of SRC-3 is observed in over 50% of
breast cancers and leads to constitutive ER-mediated transcriptional
activity in the agonist confirmation, conferring endocrine resistance in
preclinical models and in patients treated with TAM (63). E2, E4, TTC-
352, and BMI-135 in complex with ERa yield an agonist confirmation
of the ligand–ERcomplex (Figs. 5–6; ref. 48) and, subsequently, recruit
more coactivators (Fig. 4A), opposite to BPTPE. H12 acts as a
molecular switch with the contribution of those H-Bond networks
(Fig. 6) and such coactivators (Fig. 4A).
We demonstrate that the structure-function model of the synthetic
estrogen mimic TTC-352 is a less potent full estrogen agonist com-
pared with E2, allowing H12 to seal the LBD, which recruits many E2-
enriched coactivators and induces rapid ERa-mediated UPR and
apoptosis. This contradicts themodel of the benchmark partial agonist
BPTPE, not allowing H12 to seal the LBD properly, which does not
recruit many E2-enriched coactivators, and induces delayed ERa-
mediated UPR and apoptosis. These data suggest that patients with
breast cancer would potentially benefit more from full agonists like
TTC-352 rather than partial agonists, because of BPTPE’s delayed
UPR-apoptotic effect. A partial agonist with delayed apoptosis might
create a higher probability of tumor clonal evolution and acquired
resistance (64).
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